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A B S T R A C T
Background
Early accurate detection of all skin cancer types is essential to guide appropriate management and to improve morbidity and survival.
Melanoma and cutaneous squamous cell carcinoma (cSCC) are high-risk skin cancers which have the potential to metastasise and
ultimately lead to death, whereas basal cell carcinoma (BCC) is usually localised with potential to infiltrate and damage surrounding
tissue. Anxiety around missing early curable cases needs to be balanced against inappropriate referral and unnecessary excision of benign
lesions. Computer-assisted diagnosis (CAD) systems use artificial intelligence to analyse lesion data and arrive at a diagnosis of skin
cancer. When used in unreferred settings (’primary care’), CAD may assist general practitioners (GPs) or other clinicians to more
appropriately triage high-risk lesions to secondary care. Used alongside clinical and dermoscopic suspicion of malignancy, CAD may
reduce unnecessary excisions without missing melanoma cases.
Objectives
To determine the accuracy of CAD systems for diagnosing cutaneous invasive melanoma and atypical intraepidermal melanocytic
variants, BCC or cSCC in adults, and to compare its accuracy with that of dermoscopy.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central Register of
ControlledTrials (CENTRAL);MEDLINE; Embase; CINAHL;CPCI; Zetoc; ScienceCitation Index;USNational Institutes ofHealth
Ongoing Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization International
Clinical Trials Registry Platform. We studied reference lists and published systematic review articles.
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Selection criteria
Studies of any design that evaluated CAD alone, or in comparison with dermoscopy, in adults with lesions suspicious for melanoma or
BCC or cSCC, and compared with a reference standard of either histological confirmation or clinical follow-up.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form (based on
QUADAS-2). We contacted authors of included studies where information related to the target condition or diagnostic threshold were
missing. We estimated summary sensitivities and specificities separately by type of CAD system, using the bivariate hierarchical model.
We compared CAD with dermoscopy using (a) all available CAD data (indirect comparisons), and (b) studies providing paired data
for both tests (direct comparisons). We tested the contribution of human decision-making to the accuracy of CAD diagnoses in a
sensitivity analysis by removing studies that gave CAD results to clinicians to guide diagnostic decision-making.
Main results
We included 42 studies, 24 evaluating digital dermoscopy-based CAD systems (Derm-CAD) in 23 study cohorts with 9602 lesions
(1220 melanomas, at least 83 BCCs, 9 cSCCs), providing 32 datasets for Derm-CAD and seven for dermoscopy. Eighteen studies
evaluated spectroscopy-based CAD (Spectro-CAD) in 16 study cohorts with 6336 lesions (934 melanomas, 163 BCC, 49 cSCCs),
providing 32 datasets for Spectro-CAD and six for dermoscopy. These consisted of 15 studies using multispectral imaging (MSI), two
studies using electrical impedance spectroscopy (EIS) and one study using diffuse-reflectance spectroscopy. Studies were incompletely
reported and at unclear to high risk of bias across all domains. Included studies inadequately address the review question, due to an
abundance of low-quality studies, poor reporting, and recruitment of highly selected groups of participants.
Across all CAD systems, we found considerable variation in the hardware and software technologies used, the types of classification
algorithm employed, methods used to train the algorithms, and which lesion morphological features were extracted and analysed across
all CAD systems, and even between studies evaluating CAD systems. Meta-analysis found CAD systems had high sensitivity for correct
identification of cutaneous invasive melanoma and atypical intraepidermal melanocytic variants in highly selected populations, but
with low and very variable specificity, particularly for Spectro-CAD systems. Pooled data from 22 studies estimated the sensitivity of
Derm-CAD for the detection of melanoma as 90.1% (95% confidence interval (CI) 84.0% to 94.0%) and specificity as 74.3% (95%
CI 63.6% to 82.7%). Pooled data from eight studies estimated the sensitivity of multispectral imaging CAD (MSI-CAD) as 92.9%
(95% CI 83.7% to 97.1%) and specificity as 43.6% (95% CI 24.8% to 64.5%). When applied to a hypothetical population of 1000
lesions at themean observed melanoma prevalence of 20%, Derm-CADwould miss 20 melanomas and would lead to 206 false-positive
results for melanoma. MSI-CAD would miss 14 melanomas and would lead to 451 false diagnoses for melanoma. Preliminary findings
suggest CAD systems are at least as sensitive as assessment of dermoscopic images for the diagnosis of invasive melanoma and atypical
intraepidermal melanocytic variants. We are unable to make summary statements about the use of CAD in unreferred populations, or
its accuracy in detecting keratinocyte cancers, or its use in any setting as a diagnostic aid, because of the paucity of studies.
Authors’ conclusions
In highly selected patient populations all CAD types demonstrate high sensitivity, and could prove useful as a back-up for specialist
diagnosis to assist in minimising the risk of missing melanomas. However, the evidence base is currently too poor to understand
whether CAD system outputs translate to different clinical decision-making in practice. Insufficient data are available on the use of
CAD in community settings, or for the detection of keratinocyte cancers. The evidence base for individual systems is too limited
to draw conclusions on which might be preferred for practice. Prospective comparative studies are required that evaluate the use of
already evaluated CAD systems as diagnostic aids, by comparison to face-to-face dermoscopy, and in participant populations that are
representative of those in which the test would be used in practice.
P L A I N L A N G U A G E S U M M A R Y
What is the diagnostic accuracy of computer-assisted diagnosis techniques for the detection of skin cancer in adults?
Why is improving the diagnosis of skin cancer important?
There are a number of different types of skin cancer, including melanoma, squamous cell carcinoma (SCC) and basal cell carcinoma
(BCC). Melanoma is one of themost dangerous forms. If it is not recognised early treatment can be delayed and this risks themelanoma
spreading to other organs in the body and may eventually lead to death. Cutaneous squamous cell carcinoma (cSCC) and BCC are
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considered less dangerous, as they are localised (less likely to spread to other parts of the body compared to melanoma). However, cSCC
can spread to other parts of the body and BCC can cause disfigurement if not recognised early. Diagnosing a skin cancer when it is not
actually present (a false-positive result) might result in unnecessary surgery and other investigations and can cause stress and anxiety to
the patient. Missing a diagnosis of skin cancer may result in the wrong treatment being used or lead to a delay in effective treatment.
What is the aim of the review?
The aim of this Cochrane Review was to find out how accurate computer-assisted diagnosis (CAD) is for diagnosing melanoma, BCC
or cSCC. The review also compared the accuracy of two different types of CAD, and compared the accuracy of CAD with diagnosis by
a doctor using a handheld illuminated microscope (a dermatoscope or ‘dermoscopy’). We included 42 studies to answer these questions.
What was studied in the review?
A number of tools are available to skin cancer specialists which allow a more detailed examination of the skin compared to examination
by the naked eye alone. Currently a dermatoscope which magnifies the skin lesion (a mole or area of skin with an unusual appearance
in comparison with the surrounding skin) using a bright light source is used by most skin cancer specialists. CAD tests are computer
systems that analyse information about skin lesions obtained from a dermatoscope or other techniques that use light to describe the
features of a skin lesion (spectroscopy) to produce a result indicating whether skin cancer is likely to be present. We included CAD
systems that get their information from dermoscopic images of lesions (Derm-CAD), or that use data from spectroscopy. Most of the
spectroscopy studies used data frommultispectral imaging (MSI-CAD) and are the main focus here.When a skin cancer specialist finds
a lesion is suspicious using visual examination with or without additional dermoscopy, results from CAD systems can be used alone to
make a diagnosis of skin cancer (CAD-based diagnosis), or can be used by doctors in addition to their visual inspection examination
of a skin lesion to help them reach a diagnosis (CAD-aided diagnosis). Researchers examined how useful CAD systems are to help
diagnose skin cancers in addition to visual inspection and dermoscopy.
What are the main results of the review?
The review included 42 studies looking at CAD systems for the diagnosis of melanoma. There was not enough evidence to determine
the accuracy of CAD systems for the diagnosis of BCC (3 studies) or cSCC (1 study).
Derm-CAD results for diagnosis of melanoma
The main results for Derm-CAD are based on 22 studies including 8992 lesions.
Applied to a group of 1000 skin lesions, of which 200 (20%) are given a final diagnosis* of melanoma, the results suggest that:
- An estimated 386 people will have a Derm-CAD result suggesting that a melanoma is present, and of these 206 (53%) will not
actually have a melanoma (false-positive result)
- Of the 614 people with a Derm-CAD result indicating that no melanoma is present, 20 (3%) will in fact actually have a melanoma
(false-negative result)
There was no evidence to suggest that dermoscopy or Derm-CAD was different in its ability to detect or rule out melanoma.
MSI-CAD results for diagnosis of melanoma
The main results for MSI-CAD are based on eight studies including 2401 lesions. In a group of 1000 people, of whom 200 (20%)
actually do have melanoma*, then:
- An estimated 637 people will have anMSI-CAD result suggesting that a melanoma is present, and of these 451 (71%) will not actually
have a melanoma (false-positive result)
- Of the 363 people with an MSI-CAD result indicating that no melanoma is present, 14 (4%) will in fact have a melanoma (false-
negative result)
MSI-CAD detects more melanomas, but possibly produces more false-positive results (an increase in unnecessary surgery).
How reliable are the results of the studies of this review?
Incomplete reporting of studies made it difficult for us to judge how reliable they were. Many studies had important limitations. Some
studies only included particular types of skin lesions or excluded lesions that were considered difficult to diagnose. Importantly, most
of the studies only included skin lesions with a biopsy result, which means that only a sample of lesions that would be seen by a doctor
in practice were included. These characteristics may result in CAD systems appearing more or less accurate than they actually are.
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Who do the results of this review apply to?
Studies were largely conducted in Europe (29, 69%) and North America (8, 19%). Mean age (reported in 6/42 studies) ranged from
32 to 49 years for melanoma. The percentage of people with a final diagnosis of melanoma ranged from 1% to 52%. It was not always
possible to tell whether suspicion of skin cancer in study participants was based on clinical examination alone, or both clinical and
dermoscopic examinations. Almost all studies were done in people with skin lesions who were seen at specialist clinics rather than by
doctors in primary care.
What are the implications of this review?
CAD systems appear to be accurate for identification of melanomas in skin lesions that have already been selected for excision on the
basis of clinical examination (visual inspection and dermoscopy). It is possible that some CAD systems identify more melanomas than
doctors using dermoscopy images. However, CAD systems also produced far more false-positive diagnoses than dermoscopy, and could
lead to considerable increases in unnecessary surgery. The performance of CAD systems for detecting BCC and cSCC skin cancers is
unclear. More studies are needed to evaluate the use of CAD by doctors for the diagnosis of skin cancer in comparison to face-to-face
diagnosis using dermoscopy, both in primary care and in specialist skin cancer clinics.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies, biopsy, clinical follow up, or specialist clinician diagnosis were the reference standards (means of establishing the final
diagnosis).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Question: What is the diagnostic accuracy of computer-assisted diagnosis for the detection of: i) cutaneous invasive melanoma and atypical intraepidermal
melanocyticvariants, ii) BCC, or iii) cSCC in adults?
Population: Adults with lesions suspicious for skin cancer, including:
• Any lesion referred for specialist invest igat ion due to suspicion of skin cancer, and
• Any lesion excised due to suspicion of skin cancer
Index test: Computer-assisted diagnosis (CAD)
Comparator test: Dermoscopy
Target condition: Cutaneous invasive melanoma and atypical intraepidermal melanocyt ic variants, or basal cell carcinoma (BCC), or cutaneous squamous cell
carcinoma (cSCC)
Reference standard: Histology with or without long-term follow-up
Action: If accurate, posit ive results of CAD will ident if y skin cancers that could otherwise be missed, while negat ive results will stop pat ients having
unnecessary excision of skin lesions
Quantity of evidence
Number of studies 42a Total lesions with test
results
13,445 Total with target con-
dition
2452
Limitations
Risk of bias: Patient select ion methods were poorly reported, with some concern (34/ 42) due to use of case-control designs, exclusion of dif f icult-to-diagnose
types of lesion, and inadequate report ing to assess risks of bias. CAD was generally evaluated in independent populat ions (35/ 42). Some concern
as it was not clear that the reference standard was interpreted blind to the CAD results in 19/ 42 studies. Dif ferent ial verif icat ion was used in 6/ 42
studies, part icipants were excluded in 10/ 42, primarily due to technical dif f icult ies with CAD. Tim ing of tests was not mentioned in 28/ 42
Applicability of evi-
dence to question:
High concern for poor clinical applicability of included studies. Almost all studies recruited narrowly-def ined populat ions (41/ 42) or mult iple
lesions per part icipant (14/ 42) or both, and may not be representat ive of populat ions eligible for CAD. Studies provided lit t le information regarding
the thresholds used for presence of malignancy (16/ 42) and of ten evaluated unestablished thresholds (23/ 42). Studies perform ing training of
algorithms provided scarce information on the range of condit ions included in training sets. Lit t le information was given about the expert ise of the
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histopathologist
FINDINGS: All analyses are undertaken on subgroups of the studies
All included studies considered the detection of melanoma, three of which also looked at the detection of BCC and one at the detection of cSCC. There are therefore
insufficient data to make summary statements about the accuracy of CAD for the detection of BCC or cSCC. All results below consider the detection of the primary target
condition: cutaneous invasive melanoma and atypical intraepidermal melanocytic variants.
Test: Digital dermoscopy-based CAD (all systems)
Quantity of evidence Number of studies 22 Total lesions with test
results
8992 Total with melanoma 1063
Sensitivity (95% CI):
Specificity (95% CI):
90.1% (84.0% to 94.0%)
74.3% (63.6% to 82.7%)
Numbers observed in a cohort of 1000 people being testedb
Consistency Sensit ivity est imates
consistent. Some het-
erogeneity in specif icity
between studies
Consequences Prevalence
7% 20% 40%
True positives Receive necessary ex-
cision
63 180 360
False positives Receive unnecessary
excision
239 206 154
False negatives Do not receive required
excision
7 20 40
True negatives Appropriately do not
receive excision
691 594 446
PPV 21% 46% 70%
NPV 99% 97% 92%
Test: Multispectral imaging-based CAD (all systems)
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Quantity of evidence Number of studies 8 Total lesions with test
results
2401 Total with melanoma 286
Sensitivity (95% CI):
Specificity (95% CI):
92.9% (83.7% to 97.1%)
43.6% (24.8% to 64.5%)
Numbers observed in a cohort of 1000 people being tested
Consistency Sensit ivity est imates
consistent. High het-
erogeneity in specif icity
between studies
Consequences Prevalence
7% 20% 40%
True positives Receive necessary ex-
cision
65 186 372
False positives Receive unnecessary
excision
525 451 338
False negatives Do not receive required
excision
5 14 28
True negatives Appropriately do not
receive excision
405 349 262
PPV 12% 29% 52%
NPV 99% 96% 90%
aSix studies with overlapping lesions (Seidenari 1998 and Seidenari 1999; Tomatis 2003 and Bono 2002; Monheit 2011 and
Hauschild 2014).
bNumbers est imated at 25th, 50th (median) and 75%percent iles of invasive melanoma and atypical intraepidermal melanocyt ic
variants prevalence, observed across 42 studies report ing evaluat ions of CAD.
BCC - Basal cell carcinoma; CAD - computer-assisted diagnosis; CI - conf idence interval; cSCC - cutaneous squamous cell
carcinoma; NPV - negat ive predict ive value; PPV - posit ive predict ive value
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B A C K G R O U N D
This review is one of a series of Cochrane Diagnostic Test Accu-
racy (DTA) Reviews on the diagnosis and staging of melanoma
and keratinocyte skin cancers conducted for the National Insti-
tute for Health Research (NIHR) Cochrane Systematic Reviews
Programme. Appendix 1 shows the content and structure of the
programme. Table 1 provides a glossary of terms used, and a table
of acronyms used is provided in Appendix 2.
Target condition being diagnosed
There are three main forms of skin cancer. Melanoma is the most
widely known amongst the general population, yet the common-
est skin cancers in white populations are those arising from ker-
atinocytes: basal cell carcinoma (BCC) and cutaneous squamous
cell carcinoma (cSCC) (Gordon 2013; Madan 2010). In 2003,
the World Health Organization estimated that between two and
three million ‘non-melanoma’ skin cancers (of which BCC and
cSCC are estimated to account for around 80% and 16% of cases,
respectively) and 132,000 melanoma skin cancers occur globally
each year (WHO 2003).
In this DTA review there are three target conditions of interest:
(a) melanoma; (b) basal cell carcinoma (BCC); and (c) cutaneous
squamous cell carcinoma (cSCC).
Melanoma
Melanoma arises from uncontrolled proliferation of melanocytes,
i.e. the epidermal cells that produce pigment or melanin. Cu-
taneous melanoma refers to any skin lesion with malignant
melanocytes present in the dermis, and includes superficial spread-
ing, nodular, acral lentiginous, and lentigo maligna melanoma
variants (see Figure 1). Melanoma in situ refers to malignant
melanocytes that are contained within the epidermis and have not
invaded the dermis, but are at risk of progression to melanoma
if left untreated. Lentigo maligna, a subtype of melanoma in situ
in chronically sun-damaged skin, denotes another form of prolif-
eration of abnormal melanocytes. Lentigo maligna can progress
to invasive melanoma if its growth breaches the dermo-epidermal
junction during a vertical growth phase (when it is a ’lentigo ma-
ligna melanoma’). However its malignant transformation is both
lower and slower than for melanoma in situ (Kasprzak 2015).
Melanoma in situ and lentigo maligna are both atypical intraepi-
dermal melanocytic variants. Melanoma is one of the most serious
forms of skin cancer, with the potential to metastasise to other
parts of the body through the lymphatic system and bloodstream.
It accounts for only a small proportion of skin cancer cases but
is responsible for up to 75% of deaths from this disease (Boring
1994; Cancer Research UK 2017).
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Figure 1. Sample photographs of superficial spreading melanoma (left) and nodular melanoma (right).
Copyright © 2010 Dr Rubeta Matin: reproduced with permission.
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The incidence ofmelanoma rose to over 200,000 newly-diagnosed
cases worldwide in 2012 (Erdmann 2013; Ferlay 2015), with an
estimated 55,000 deaths (Ferlay 2015). The highest incidence is
observed in Australia with 13,134 new cases of melanoma of the
skin in 2014 (ACIM 2017) and in New Zealand with 2341 reg-
istered cases in 2010 (HPA and MelNet NZ 2014). For 2014 in
the USA, the predicted incidence was 73,870 per annum and the
predicted number of deaths was 9940 (Siegel 2015). The highest
rates in Europe are seen in north-western Europe and the Scandi-
navian countries, with a highest incidence reported in Switzerland:
25.8 per 100,000 in 2012. Rates in England have tripled from 4.6
and 6.0 per 100,000 in men and women, respectively, in 1990, to
18.6 and 19.6 per 100,000 in 2012 (EUCAN 2012). Indeed, in
the UK, melanoma has one of the fastest-rising incidence rates of
any cancer, and has the biggest projected increase in incidence be-
tween 2007 and 2030 (Mistry 2011). In the decade leading up to
2013, age-standardised incidence increased by 46%, with 14,500
new cases in 2013 and 2459 deaths in 2014 (Cancer Research
UK 2017). Rates are higher in women than in men, but the rate
of incidence in men is increasing faster than in women (Arnold
2014).The rising incidence of melanoma is thought to be primar-
ily related to an increase in recreational sun exposure and tanning
bed use and an increasingly ageing population with higher lifetime
recreational ultraviolet (UV) exposure, in conjunction with pos-
sible earlier detection (Belbasis 2016; Linos 2009). Putative risk
factors are reviewed in detail elsewhere (Belbasis 2016).
A database of over 40,000 US patients from 1998 onwards which
assisted the development of the 8th American Joint Committee
on Cancer (AJCC) Staging System indicated a five-year survival of
97% to 99% for stage I melanoma, dropping to between 32% and
93% in stage III disease, depending on tumour thickness, the pres-
ence of ulceration and the number of involvednodes (Gershenwald
2017). While these are substantial increases relative to survival in
1975 (Cho 2014), mortality rates have remained static during the
same period. This observation, coupled with increasing incidence
of localised disease, suggests that improvements in survival may
be due to earlier detection and heightened vigilance (Cho 2014).
New targeted therapies for advanced (stage IV), melanoma (e.g.
BRAF inhibitors), have improved survival, and immunotherapies
are evolving such that long-term survival is being documented
(Pasquali 2018; Rozeman 2017). No new data regarding the sur-
vival prospects for patients with stage IV disease were analysed for
the AJCC 8 staging guidelines due to lack of contemporary data
(Gershenwald 2017).
Basal cell carcinoma
BCC can arise from multiple stem cell populations, including
from the bulge and interfollicular epidermis (Grachtchouk 2011).
BCC growth is usually localised, but it can infiltrate and damage
surrounding tissue, sometimes causing considerable destruction
and disfigurement, particularly when located on the face (Figure
2). The four main subtypes of BCC are superficial, nodular, mor-
phoeic (infiltrative) and pigmented. Lesions typically present as
slow-growing, asymptomatic papules, plaques, or nodules which
bleed or form ulcers that do not heal (Firnhaber 2012). The diag-
nosis is often made incidentally rather than by people presenting
with symptoms (Gordon 2013).
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Figure 2. Sample photographs of BCC (left) and cSCC (right). Copyright © 2012 Dr Rubeta Matin:
reproduced with permission.
BCC most commonly occurs on sun-exposed sites on the head
and neck (McCormack 1997) and are more common in men and
in people over the age of 40. A rising incidence of BCC in younger
people has been attributed to increased recreational sun exposure
(Bath-Hextall 2007a; Gordon 2013;Musah 2013). Other risk fac-
tors include Fitzpatrick skin types I and II (Fitzpatrick 1975; Lear
1997; Maia 1995), previous skin cancer history, immunosuppres-
sion, arsenic exposure, and genetic predisposition such as in basal
cell naevus (Gorlin) syndrome (Gorlin 2004; Zak-Prelich 2004).
Annual incidence is increasing worldwide; Europe has experienced
an average increase of 5.5% a year over the last four decades, the
USA 2% a year, while estimates for the UK show that incidence
appears to be increasing more steeply at a rate of an additional 6
per 100,000 persons a year (Lomas 2012). The rising incidence
has been attributed to an ageing population, changes in the dis-
tribution of known risk factors, particularly ultraviolet radiation,
and improved detection due to the increased awareness amongst
both practitioners and the general population (Verkouteren 2017).
Hoorens 2016 points to evidence for a gradual increase in the size
of BCCs over time, with delays in diagnosis ranging from 19 to
25 months.
According to National Institute for Health and Care Excellence
(NICE) guidance (NICE 2010), low-risk BCCs that may be con-
sidered for excision are nodular lesions occurring in people older
than 24 years who are not immunosuppressed and do not have
Gorlin syndrome. Furthermore, low-risk lesions should be located
below the clavicle, should be small (less than 1 cm) with well-
defined margins, not recurrent following incomplete excision and
are not difficult to reach surgically or in highly visible locations
(NICE 2010). Superficial BCCs are also typically low risk and
may be amenable to medical treatments such as photodynamic
therapy or topical chemotherapy (Kelleners-Smeets 2017). Assign-
ing BCCs as low or high risk influences the management options
(Batra 2002; Randle 1996).
Advanced locally-destructive BCC can arise from longstanding
untreated lesions or from a recurrence of aggressive basal cell car-
cinoma after primary treatment (Lear 2012). Very rarely, BCC
metastasises to regional and distant sites resulting in death, espe-
cially cases of large neglected lesions in those who are immunosup-
pressed or those with Gorlin syndrome (McCusker 2014). Rates
of metastasis are reported at 0.0028% to 0.55% (Lo 1991), with
very poor survival rates. It is recognised that baso-squamous car-
cinoma (more like a high-risk cSCC in behaviour and not con-
sidered a true BCC) is likely to have accounted for many cases of
apparent metastases of BCC, hence the spuriously high reported
incidence in some studies of up to 0.55%, which is not seen in
clinical practice (Garcia 2009).
Squamous cell carcinoma of the skin
Primary cSCC arises from the keratinocytes in the epidermis or
its appendages. People with cSCC often present with an ulcer or
firm (indurated) papule, plaque, or nodule (Griffin 2016), often
with an adherent crust (Madan 2010). cSCC can arise in the ab-
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sence of a precursor lesion or it can develop from pre-existing ac-
tinic keratosis (dysplastic epidermis) or Bowen’s disease (consid-
ered by some to be cSCC in situ). The estimated annual risk of
progression is from less than 1% to 20% (Alam 2001), and 5%
for lesions developing from pre-existing dysplasia (Kao 1986). It
remains locally invasive for a variable length of time, but has the
potential to spread to the regional lymph nodes or through the
bloodstream to distant sites, especially in immunosuppressed in-
dividuals (Lansbury 2010). High-risk lesions are those arising on
the lip or ear, recurrent cSCC, lesions arising on non-exposed sites,
scars or chronic ulcers, tumours larger than 20 mm in diameter
or which have a histological depth of invasion greater than 4 mm
or poor differentiation status on histopathological examination
(Motley 2009).
Chronic ultraviolet light exposure through recreation or occupa-
tion is strongly linked to cSCC occurrence (Alam 2001). It is
particularly common in people with fair skin and in less com-
mon genetic disorders of pigmentation, such as albinism, xero-
derma pigmentosum, and recessive dystrophic epidermolysis bul-
losa (RDEB) (Alam 2001). Other recognised risk factors include
immunosuppression; chronic wounds; arsenic or radiation expo-
sure; certain drug treatments, such as voriconazole and BRAFmu-
tation inhibitors; and previous skin cancer history (Baldursson
1993; Chowdri 1996; Dabski 1986; Fasching 1989; Lister 1997;
Maloney 1996; O’Gorman 2014). In solid organ transplant re-
cipients, cSCC is the most common form of skin cancer; the risk
of developing cSCC has been estimated at 65 to 253 times that of
the general population (Hartevelt 1990; Jensen 1999; Lansbury
2010). Overall, local and metastatic recurrence of cSCC at five
years is estimated at 8% and 5% respectively. The five-year sur-
vival rate of metastatic cSCC of the head and neck is around 60%
(Moeckelmann 2018).
Treatment
For primary melanoma, the mainstay of definitive treatment is
wide local surgical excision of the lesion, to remove both the tu-
mour and any malignant cells that might have spread into the sur-
rounding skin (Garbe 2016; Marsden 2010; NICE 2015; SIGN
2017; Sladden 2009). Recommended lateral surgical margins vary
according to tumour thickness (Garbe 2016) and stage of disease
at presentation (NICE 2015).
Treatment options for BCC and cSCC include surgery, other
destructive techniques such as cryotherapy or electrodesiccation
and topical chemotherapy. A Cochrane Review of 27 randomised
controlled trials (RCTs) of interventions for BCC found very
little good-quality evidence for any of the interventions used
(Bath-Hextall 2007b).Complete surgical excision of primaryBCC
has a reported five-year recurrence rate of less than 2% (Griffiths
2005; Walker 2006), leading to significantly fewer recurrences
than treatment with radiotherapy (Bath-Hextall 2007b). After ap-
parent clear histopathological margins (serial vertical sections) af-
ter standard excision biopsy with 4mm surgical peripheral margins
taken there is a five-year reported recurrence rate of around 4%
(Drucker 2017). Mohs micrographic surgery, whereby horizontal
sections of the tumour are microscopically examined intraopera-
tively and re-excision is undertaken until the margins are tumour-
free, can be considered for high-risk lesions where standard wider
excision margins of surrounding healthy skin might lead to con-
siderable functional impairment (Bath-Hextall 2007b; Lansbury
2010; Motley 2009; Stratigos 2015). Bath-Hextall and colleagues
(Bath-Hextall 2007b) found a single trial comparing Mohs mi-
crographic surgery with a 3mm standard excision in BCC (Smeets
2004); the update of this study showed non-significantly lower re-
currence at 10 years with Mohs micrographic surgery (4.4% com-
pared to 12.2% after surgical excision, P = 0.10) (Van Loo 2014).
The main treatments for high-risk BCC are wide local excision,
Mohs micrographic surgery and radiotherapy. For low-risk or su-
perficial subtypes of BCC, or for small and or multiple BCCs at
low-risk sites (Marsden 2010), destructive techniques other than
excisional surgery may be used (e.g. electrodesiccation and curet-
tage or cryotherapy (Alam 2001; Bath-Hextall 2007b)). Alterna-
tively, non-surgical (or non-destructive) treatments may be con-
sidered (Bath-Hextall 2007a; Drew 2017; Kim 2014), including
topical chemotherapy such as imiquimod (Williams 2017), 5-flu-
orouracil (Arits 2013), ingenol mebutate (Nart 2015) and pho-
todynamic therapy (Bath-Hextall 2007b; Roozeboom 2016). Al-
though non-surgical techniques are increasingly used, they do not
allow histological confirmation of tumour clearance, and their use
is dependent on accurate characterisation of the histological sub-
type and depth of tumour. The 2007 systematic review of BCC
interventions found limited evidence from very small RCTs for
these approaches (Bath-Hextall 2007b), which have only partially
been addressed by subsequent studies (Bath-Hextall 2014; Kim
2014; Roozeboom 2012). Most BCC trials have compared inter-
ventions within the same treatment class, and few have compared
medical versus surgical treatments (Kim 2014).
Vismodegib, a first-in-class Hedgehog signalling pathway in-
hibitor, is now available for the treatment of metastatic or lo-
cally-advanced BCC based on the pivotal study ERIVANCEBCC
(Sekulic 2012). It is licensed for use in patients where surgery or ra-
diotherapy is inappropriate, e.g. for treating locally-advanced peri-
ocular and orbital BCCs with orbital salvage of patients who oth-
erwise would have required exenteration (Wong 2017). However,
NICE has recently recommended against the use of vismodegib,
based on cost effectiveness and uncertainty of evidence (NICE
2017).
A systematic review of interventions for primary cSCC found only
one RCT eligible for inclusion (Lansbury 2010). Current practice
therefore relies on evidence fromobservational studies, as reviewed
in Lansbury 2013, for example. Surgical excision with predeter-
mined margins is usually the first-line treatment (Motley 2009;
Stratigos 2015). Estimates of recurrence after Mohs micrographic
surgery, surgical excision, or radiotherapy, which are likely to have
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been evaluated in higher-risk populations, have shown pooled re-
currence rates of 3%, 5.4% and 6.4% respectively, with overlap-
ping confidence intervals; the review authors advise caution when
comparing results across treatments (Lansbury 2013).
Index test(s)
Computer-assisted diagnosis (CAD) describes a range of artificial
intelligence-based techniques that automate the diagnosis of skin
cancer by using a computer to analyse lesion images, anddetermine
the likelihood of malignancy, or the need for excision. Each CAD
system has a data collection component, which collects imaging or
non-visual data (e.g. electrical impedancemeasurements) from the
suspicious lesion and feeds it to the data processing component,
which then performs a series of analyses to arrive at a diagnostic
classification.
Images are acquired using a number of different techniques, al-
though most commonly by digital dermoscopy (Derm-CAD)
which creates digital subsurface images of the skin using a com-
puter coupled with a dermatoscope, videocamera and digital tele-
vision (Rajpara 2009; Esteva 2017). Commercially-available sys-
tems include the DB-MIPS® (DB-Dermo MIPS) (Biomips En-
gineering SRL, Sienna Italy), MicroDERM (Visiomed AG, Ger-
many), SolarScan (Polartechnics Ltd, Australia) and MoleExpert
(DermoScan GmbH, Germany), all of which are hand-held digi-
tal or video dermatoscopes that communicate with CAD analysis
software (see Figure 3).
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Figure 3. Examples of commercially available CAD systems using digital dermoscopy (A), electrical
impedance spectroscopy (B) and multispectral imaging (C and D). Reproduced with permission of the
manufacturers. Copyright © 2018 MedX Corp, Canada; DermoScanGmbH, Germany; SciBase III, Sweden:
reproduced with permission.
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Other systems use spectroscopy (Spectro-CAD), whereby infor-
mation on cell characteristics (such as cell shape or size) is gath-
ered by measuring how electromagnetic waves pass through skin
lesions. This information is most commonly acquired using mul-
tispectral imaging (MSI-CAD) that enables computer-generated
graphic representations of lesionmorphology to be produced from
detecting light reflected at several wavelengths across the lesion.
By far themost common of these is diffuse reflectance spectropho-
tometry imaging (DRSi), which uses light that diffusely penetrates
the skin to a depth of 2 to 2.5 mm beneath the surface to pro-
duce light reflectance images at a number of specific wavelengths
across the visible near-infrared light spectrum (approximately 400
to 1000 nm) to capture variations in light attenuation and scat-
tering from melanin, collagen and blood vessel structures.
DRSi developed from diffuse reflectance spectroscopy, a non-vi-
sual spectroscopic technique which uses optical reflectance to dis-
tinguish between lesion types based on spectral shape and cali-
brated level of reflected light for wavelengths continuously varying
from the ultraviolet (320 nm) to the near-infrared (1100 nm) with
a high spectral resolution (4 nm) (e.g. Marchesini 1992; Wallace
2000b). Commercially available DRSi computer-assisted diagno-
sis systems include the SIAscope™(MedXHealthCorp, Canada),
a hand-held unit that communicates with CAD analysis software
(Figure 3). TheMelaFind® system (Strata Skin Sciences (formerly
Mela Sciences Inc), Horsham, PA, USA) was Food and Drug Ad-
ministration (FDA)-approved; however, it no longer appears to be
commercially available.
The Nevisense™ system (SciBase III, Sweden; Figure 3) is also
commercially available, but is based on electrical impedance spec-
troscopy (EIS), a non-optical method which seeks to provide in-
formation on cellular features by measuring the feedback from an
electrical current once it has passed through the intended tissue.
With Nevisense™, an alternating applied voltage (electrical cur-
rent) is passed by a probe through a skin lesion and the current that
is bounced back is measured by the same probe, which measures
a combination of tissue resistance and capacitance. At high fre-
quencies, conduction occurs easily through all tissue components,
including cells, but at low frequencies current tends to flow only
through the extracellular space. The spectral shape is therefore sen-
sitive to cellular components and dimensions, internal structure
and cellular arrangements. The Nevisense™ EIS systemmeasures
at four multiple depths and at 35 frequencies logarithmically dis-
tributed from 1.0 kHz to 2.5MHz using a 5 x 5mm area electrode
covered in tiny pins that penetrate into the stratum corneum.
Other non-visual sources of lesion data include Raman spec-
troscopy, in which a laser is used to excite vibrations in molecules
which then impart wavelength shifts to some of the scattered light
waves, creating spectral patterns that are related to the molecular
structure of lesions (Maglogiannis 2009), and fluorescence spec-
troscopy which uses a laser to excite electrons, causing molecules
to absorb and then re-emit light in spectral patterns that are also
related to the molecular structure of lesions (Rallan 2004).
All CAD systems use machine learning, where a classification al-
gorithm learns features of groups of lesions (i.e. diagnostic types)
by exposure to a ‘training set’ of lesions of known histological di-
agnosis. This process creates a model which is designed to distin-
guish between these lesion types in future observations. Examples
of machine learning algorithms include discriminant analysis, de-
cision trees, neural networks, fuzzy logic, nearest k-neighbours, lo-
gistic regression and support vector machines (SVMs), and all use
different mathematical equations to set out how observed features
relate to a given diagnosis (Maglogiannis 2009; Masood 2013).
Model outputs also vary, in part according to the type of data used
to acquire lesion information, and can take the form of binary out-
puts indicating the presence of malignancy versus benignity (e.g.
the Melafind® system), risk scores which can be used at varying
thresholds (e.g. the DANAOS system used by MicroDerm), or
graphical representations of the CAD pattern analysis which high-
light areas of concern within a lesion (e.g. the SIAgraphs produced
by SIAscope™). Artificial intelligence systems using continuous
learning algorithms, where computer systems continuously de-
velop their classification algorithm as each new case is examined,
and do not stop learning at the end of a training period, are not
addressed in this review.
Clinical pathway
The diagnosis of skin lesions occurs in primary-, secondary-, and
tertiary-care settings by both generalist and specialist healthcare
providers. In the UK, people with concerns about a new or chang-
ing lesion will present to their general practitioner (GP) rather
than directly to a specialist in secondary care. A GP with clinical
concerns usually refers a patient to a specialist in secondary care
- usually a dermatologist, but sometimes to a surgical specialist
such as a plastic surgeon or an ophthalmic surgeon. Suspicious
skin lesions may also be identified in a referral setting, for example
by a general surgeon, and referred for a consultation with a skin
cancer specialist (Figure 4). Skin cancers identified by other spe-
cialist surgeons (such as an ear, nose, and throat (ENT) special-
ist or maxillofacial surgeon) will usually be diagnosed and treated
without further referral.
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Figure 4. Current clinical pathway for people with skin lesions.
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Current UK guidelines recommend that all suspicious pigmented
lesions presenting in primary care should be assessed by taking a
clinical history and visual inspection (VI) using the seven-point
checklist (MacKie 1990); lesions suspected to be melanoma or
cSCC should be referred for appropriate specialist assessment
within two weeks (Chao 2013; Marsden 2010; NICE 2015). Evi-
dence is emerging, however, to suggest that excision of melanoma
by GPs is not associated with increased risk compared with out-
comes in secondary care (Murchie 2017). In the UK, low-risk
BCCs are usually recommended for routine referral, with urgent
referral for those in whom a delay could have a significant impact
on outcomes, for example due to large lesion size or critical site
(NICE 2015). Appropriately-qualified generalist care providers
increasingly undertake management of low-risk BCC in the UK,
such as by excision of low-risk lesions (NICE 2010). Similar guid-
ance is in place in Australia (CCAAC Network 2008).
For referred lesions, the specialist clinician will use history-taking,
visual inspection of the lesion (in conjunction with other skin
lesions), palpation of the lesion and associated lymph nodes in
conjunction with dermoscopic examination to inform a clinical
decision. If melanoma is suspected, then urgent 2 mm excision
biopsy is recommended (Lederman 1985; Lees 1991); for cSCC
predetermined surgical margin excision or a diagnostic biopsy may
be considered. BCC and pre-malignant lesions potentially eligible
for nonsurgical treatment may undergo a diagnostic biopsy before
initiation of therapy if there is diagnostic uncertainty. Equivocal
melanocytic lesions for which a definitive clinical diagnosis cannot
be reachedmay undergo surveillance to identify any lesion changes
that would indicate excision biopsy or reassurance, and discharge
for those lesions that remain stable over a period of time.
Theoretically, teledermatology consultations may aid appropriate
triage of lesions into urgent referral; non-urgent secondary-care
referral (e.g. for suspected basal cell carcinoma); or where available,
referral to an intermediate care setting, e.g. clinics run by GPs
with a special interest in dermatology. The distinction between
setting and examiner qualifications and experience is important,
as specialist clinicians might work in primary-care settings (for
example, in the UK, GPs with a special interest in dermatology
and skin surgery who have undergone appropriate training), and
generalists might practice in secondary-care settings (for example,
plastic surgeons who do not specialise in skin cancer). The level
of skill and experience in skin cancer diagnosis will vary for both
generalist and specialist care providers and will also impact on test
accuracy.
Prior test(s)
Although smartphone applications and community-based teled-
ermatology services can increasingly be directly accessed by people
who have concerns about a skin lesion (Chuchu 2018b), visual
inspection of a suspicious lesion by a clinician is usually the first
in a series of tests to diagnose skin cancer. In the UK this usually
takes place in primary care, but in many countries people with
suspicious lesions can present directly to a specialist setting.
A range of technologies has emerged to aid skin cancer diagnosis,
both to ensure that malignancies (especially melanoma) are not
missed, and at the same timeminimising unnecessary surgical pro-
cedures. Dermoscopy using a hand-held microscope has become
themostwidely used tool for clinicians to improve diagnostic accu-
racy of pigmented lesions, in particular for melanoma (Argenziano
1998; Argenziano 2012; Haenssle 2010; Kittler 2002), although
it is less well established for the diagnosis of BCC or cSCC. Der-
moscopy is frequently combined with visual inspection of a lesion
in secondary-care settings, and is also increasingly used in primary
care, particularly in countries such as Australia (Youl 2007).The
diagnostic accuracy, and comparative accuracy, of visual inspection
and dermoscopy have been evaluated in a further three reviews in
this series (Dinnes 2018a; Dinnes 2018b; Dinnes 2018c).
Consideration of the degree of prior testing that study participants
have undergone is key to interpretation of test accuracy indices, as
these are known to vary according to the disease spectrum (or case-
mix) of included participants (Lachs 1992; Leeflang 2013; Moons
1997; Usher-Smith 2016). Spectrum effects are often observed
when tests that are developed further down the referral pathway
have lower sensitivity and higher specificity when applied in set-
tings with participants with limited prior testing (Usher-Smith
2016). Studies of individuals with suspicious lesions at the initial
clinical presentation stage (’test-naïve’) are likely to have a wider
range of different diagnoses and include a higher proportion of
people with benign diagnoses compared with studies of partici-
pants who have been referred for a specialist opinion on the basis
of visual inspection (with or without dermoscopy) by a generalist
practitioner. Furthermore, studies in more specialist settings may
focus on equivocal or difficult-to-diagnose lesions rather than le-
sions with a more general level of clinical suspicion. However, this
direction of effect is not consistent across tests and diseases, the
mechanisms in action often being more complex than prevalence
alone, and can be difficult to identify (Leeflang 2013). A simple
categorisation of studies according to primary, secondary or spe-
cialist setting therefore may not always adequately reflect these key
differences in disease spectrum that can affect test performance.
Role of index test(s)
Skin cancer diagnosis, whether by visual inspection alone or with
the use of dermoscopy is undertaken iteratively, using both implicit
pattern recognition (non-analytical reasoning) and more explicit
‘rules’ based on conscious analytical reasoning (Norman 2009), the
balance of which will vary according to experience and familiarity
with the diagnostic question. In the hands of experienced derma-
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tologists, dermoscopy has been shown to enhance the accuracy of
skin cancer detection (especially melanoma) when compared to
unaided visual examination (Dinnes 2018b; Dinnes 2018c). The
subjectivity involved in interpreting lesion morphology is thought
to underlie the decrease in accuracy that occurs when the dermato-
scope is used by less experienced clinicians (Binder 1995).
The addition of computer-based diagnosis to these investigations
has potential to increase the detection of melanomas by reducing
the clinicians’ reliance on subjective information, which is neces-
sarily interpreted using their experience of past cases. The addi-
tive value of CAD systems is also likely to vary with differences
in setting, prior testing and selection of participants, as previously
discussed (Prior test(s)). CAD systems could therefore fulfil three
different roles in clinical practice: (1) to help GPs, or other clini-
cians working in unreferred settings, to appropriately triage lesions
for referral; (2) as part of a remote diagnostic service; or (3) as an
expert-level second opinion to specialists in referral settings. All
three roles would rely on CAD being as sensitive for the diagnosis
of melanoma as experienced dermatologists. On the other hand,
the specificity required for CAD to add value differs for each of
these three situations, as discussed below.
If sensitive enough, use of CAD in primary care could allow
more appropriate triage of higher-risk lesions to secondary care
by increasing the early detection of potentially malignant lesions.
However, although a relatively lower specificity (higher false-pos-
itive rate) may be acceptable in a primary-care setting, limiting
false-positive diagnoses would create health service benefits by
avoiding unnecessary referral, and alleviating patient anxiety more
promptly. Similarly, the remote use of CAD could inform the
need for referral, by sending images or other diagnostic data to
specialist clinics, or even to commercial organisations, for remote
interpretation, much as teledermatology is already used. In this
circumstance, a relatively high specificity would be required in or-
der to avoid unacceptable increases in rates of referral to specialist
centres.
Finally, when used in referral settings as a complement to in-person
diagnosis by a specialist, even if CAD could be shown to pick up
difficult-to-diagnose melanomas that might be missed on visual
inspection or dermoscopy, the specificity of the systemwould need
to be very high so as not to inordinately increase the burden of
skin surgery. False-positive diagnoses not only cause unnecessary
scarring from a biopsy or excision procedure, but also increase
patient anxiety whilst they await the definitive histological results
and increase healthcare costs as the number needed to remove
to yield one melanoma diagnosis increases. Pigmented lesions are
common, so the resource implication for even a small increase in
the threshold to excise lesions in populations where melanoma
rates are increasing, will avoid a considerable healthcare burden to
both patient and healthcare provider, as long as lesions that are not
excised turn out to be benign. The use of CAD to detectmelanoma
in specialist clinics would only be advantageous if it could be
shown to detect skin cancers that would otherwise be missed, or
to decrease unnecessary surgical intervention (i.e. removal of false-
positive lesions) with no loss of sensitivity.
Delay in diagnosis of a BCC as a result of a false-negative test is not
as serious as formelanoma, because BCCs are usually slow-growing
and very unlikely to metastasise. Nevertheless, delayed diagnosis
can result in larger and more complex surgical procedures with
consequent greater morbidity. Very sensitive diagnostic tests for
BCC, however, may compromise on lower specificity, leading to a
higher false-positive rate and an increased burden of skin surgery
such that a balance between sensitivity and specificity is needed.
The greatest potential advantage of CAD in the management of
BCC is likely to lie in its ability to perform rapid, non-invasive
assessments of multiple lesions (common in BCC patients (Lear
1997)).
The situation for cSCC is more similar to melanoma, in that the
consequences of falsely reassuring a person that they do not have
skin cancer can be serious and potentially fatal, given that removal
of an early cSCC is usually curative. Thus, a good diagnostic test
for cSCC should demonstrate high sensitivity and a corresponding
high negative predictive value. A test that can also reduce false-
positive clinical diagnoses without missing true cases of cSCC has
patient and resource benefits.
Alternative test(s)
A number of other tests which may have a role in the diagno-
sis of skin cancer in a specialist setting have been reviewed as
part of our series of systematic reviews, including reflectance con-
focal microscopy (RCM) (Dinnes 2018d Dinnes 2018e), opti-
cal coherence tomography (OCT) (Ferrante di Ruffano 2018a),
high-frequency ultrasound (Dinnes 2018f) and exfoliative cytol-
ogy (Ferrante di Ruffano 2018b). Other tests with a role in ear-
lier settings include teledermatology (Chuchu 2018a) and smart-
phone applications (Chuchu 2018b). Reviews on the accuracy of
gene expression testing and volatile organic compounds could not
be performed as planned, due to an absence of relevant studies.
Evidence permitting, we will compare the accuracy of available
tests in an overview review, exploiting within-study comparisons
of tests and allowing the analysis and comparison of commonly
used diagnostic strategies where tests may be used singly or in
combination.
We also considered and excluded a number of tests from this re-
view, such as tests used for screening (e.g. total body photogra-
phy of those with large numbers of typical or atypical naevi) or
monitoring (e.g. CAD systems used to monitor the progression of
suspicious skin lesions).
Lastly, we did not assess the accuracy of histopathological con-
firmation following lesion excision, because it is the established
reference standard for melanoma diagnosis and will be one of the
standards against which the index tests are evaluated in these re-
views.
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Rationale
Our series of reviews of diagnostic tests used to assist clinical diag-
nosis of skin cancer aims to identify the most accurate approaches
to diagnosis and provide clinical and policy decision-makers with
the highest possible standard of evidence on which to base diag-
nostic and treatment decisions.With increasing rates ofmelanoma
and basal cell carcinoma and a trend to adopt dermoscopy and
other high-resolution image analysis in primary care, the anxi-
ety around missing early malignant lesions needs to be balanced
against the risk of too many unnecessary referrals, and to avoid
sending too many people with benign lesions for a specialist opin-
ion. It is questionable whether all skin cancers identified by so-
phisticated techniques, even in specialist settings, help to reduce
morbidity and mortality. It is also a concern that newer technolo-
gies incur the risk of increasing false-positive diagnoses. It is also
possible that the use of some technologies, e.g. widespread use of
dermoscopy in primary care with little or no training, could ac-
tually result in harm by missing melanomas if they are used as re-
placement technologies for traditional history-taking and clinical
examination of the entire skin. Many branches of medicine have
noted the danger of such “gizmo idolatry” amongst doctors (Leff
2008).
The central premise underlying CAD is that it uses quantitative,
objective and expert-level assessments of lesion features, which
lessen the need for specialist training and lengthy experience in
test use. Given the reliance on specialist training and experience
to make accurate skin cancer diagnosis using dermoscopy, CAD
diagnosis has the potential to improve the health of patients by
widening access to specialist diagnostic capabilities in primary and
secondary care. If it is sensitive enough, introducing CAD could
increase the early detection of skin cancers, which for melanoma
and cSCC in particular, is critical to improving outcomes. As with
any technology requiring significant investment, a full understand-
ing should be acquired of the benefits including patient accept-
ability and cost effectiveness compared with usual practice before
such an approach can be recommended; establishing the accuracy
of diagnosis and referral accuracy is one of the key components.
We identified four published systematic reviews focusing on the ac-
curacy of CAD, two synthesising the performance of Derm-CAD
systems (Ali 2012; Rajpara 2009), and two reviewing both Derm-
CAD and Spectro-CAD systems (Rosado 2003; Vestergaard
2008). All are limited by out-of-date search periods (Ali 2012 up
to 2011, Rajpara 2009 and Vestergaard 2008 up to 2007, Rosado
2003 up to 2002), which is a key concern in the rapidly advancing
field of machine learning. Another concern for Ali 2012, Rajpara
2009 and Rosado 2003 is their inclusion of studies which are inel-
igible for this Cochrane Review due to the absence of an indepen-
dent validation set, a methodological feature likely to inflate the
apparent accuracy of predictive models (Altman 2009). Rosado
2003 also selected datasets on the basis of highest performance,
andpooled accuracy estimates forDerm-CADwith Spectro-CAD,
which we consider to be two different diagnostic tests. There is
therefore a need for an up-to-date and rigorous review of the accu-
racy of dermoscopy-based CAD and of spectroscopy-based CAD
which explicitly considers the following key characteristics.
Because CADmodels are created by analysing patterns in archived
datasets, the degree to which they are likely to make accurate clas-
sifications of new observations in real-life clinical situations relies
on the generalisability of the training sets used to develop them
(Horsch 2011). Training sets that contain few lesions, or a re-
stricted range of the different diagnoses encountered in clinical
practice, are likely to produce models that misclassify new obser-
vations due to inadequate learning. Other important attributes
thought to influence diagnostic ability are the segmentation pro-
cess (how the lesion’s border is detected by the computer), which
features are selected for analysis (akin to the selection of features
for analysis in the algorithms used in epiluminescence microscopy
(ELM) dermoscopy, e.g. ABCD or seven-point), the algorithm
used, and the type of information produced by the CAD system
(e.g. binary outputs indicating presence of malignancy, or visual
images of lesions such as macro- or microscopic photographs or
graphical representations of highlighting suspect structures).
This review follows a generic protocol which covers the full series
of Cochrane DTAReviews for the diagnosis of melanoma (Dinnes
2015a) and for the diagnosis of keratinocyte cancers (Dinnes
2015b). The Background and Methods sections of this review
therefore use some text that was originally published in these pro-
tocols (Dinnes 2015a; Dinnes 2015b) and text that overlaps some
of our other reviews (Dinnes 2018a; Dinnes 2018b; Ferrante di
Ruffano 2018a).
O B J E C T I V E S
To determine the accuracy of CAD systems for diagnosing cuta-
neous invasivemelanoma and atypical intraepidermalmelanocytic
variants in adults, and to compare the accuracy of CAD systems
with that of clinician diagnosis using dermoscopy.
To determine the accuracy of CAD systems for diagnosing BCC
in adults, and to compare the accuracy of CAD systems with that
of clinician diagnosis using dermoscopy.
To determine the accuracy of CAD systems for diagnosing cSCC
in adults, and to compare the accuracy of CAD systems with that
of clinician diagnosis using dermoscopy.
Secondary objectives
• To determine the accuracy of CAD systems for diagnosing
invasive melanoma alone in adults, and to compare the accuracy
of CAD systems with that of clinician diagnosis using
dermoscopy
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• To determine the accuracy of CAD systems for identifying
any lesion requiring excision (due to any skin cancer or high-
grade dysplasia) in adults, and to compare the accuracy of CAD
systems with that of clinician diagnosis using dermoscopy
For each of the primary target conditions:
• To compare the diagnostic accuracy of CAD systems to
clinician diagnosis using dermoscopy, where both tests have been
evaluated in the same studies (direct comparisons);
• To determine the diagnostic accuracy of individual CAD
systems;
• To compare the accuracy of CAD-based diagnosis to CAD-
assisted diagnosis (CAD results used by clinicians as a diagnostic
aid)
• Where CAD systems are used as a diagnostic aid, to
determine the effect of observer experience on diagnostic
accuracy.
Investigation of sources of heterogeneity
We set out to investigate a range of potential sources of hetero-
geneity across our series of reviews, as outlined in our generic pro-
tocols (Dinnes 2015a; Dinnes 2015b) and described in Appendix
3; however, we could not do this because of the available data on
each individual test reviewed.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included test accuracy studies that assessed the result of the
index test against that of a reference standard, including the fol-
lowing:
• Studies where all participants received a single index test
and a reference standard;
• Studies where all participants received more than one index
test and reference standard;
• Studies where participants were allocated (by any method)
to receive different index tests or combinations of index tests and
all receive a reference standard (between-person comparative
studies (BPC));
• Studies that recruited series of participants unselected by
true disease status (referred to as case series for the purposes of
this review);
• Diagnostic case-control studies that separately recruited
diseased and non-diseased groups (see Rutjes 2005); however, we
did not include studies that compared results for malignant
lesions to those for healthy skin (i.e. with no lesion present);
• Both prospective and retrospective studies;
• Studies where previously-acquired clinical or dermoscopic
images were retrieved and prospectively interpreted for study
purposes.
We excluded studies fromwhich we could not extract or derive 2 x
2 contingency data of the number of true positives, false positives,
false negatives and true negatives, or if studies included fewer than
five skin cancer cases or fewer than five benign lesions. The size
threshold of five is arbitrary, however such small studies are un-
likely to add precision to estimate of accuracy.
Studies available only as conference abstracts were excluded; how-
ever, attempts were made to identify full papers for potentially
relevant conference abstracts (Searching other resources).
Participants
We included studies in adults with pigmented or non-pigmented
skin lesions considered to be suspicious for melanoma or an atypi-
cal intraepidermal melanocytic variant or a keratinocyte skin can-
cer (BCC or cSCC). Studies examining adults at high risk of devel-
oping skin cancer, including those with a family history or previ-
ous history of skin cancer, atypical or dysplastic naevus syndrome,
or genetic cancer syndromes were also eligible for inclusion.
We excluded studies that recruited only participants with malig-
nant diagnoses.
We excluded studies conducted in children or which clearly re-
ported inclusion of more than 50% of participants aged 16 and
under.
Index tests
Studies reporting accuracy data for tests using automated diag-
nosis were eligible for inclusion, whether diagnosis was produced
independently by the CAD system (system-based diagnosis), or
by a clinician using a CAD system as a diagnostic aid (computer-
assisted diagnosis). CAD systems using any type of data capture
were eligible, including imaging and non-imaging modalities. We
included all machine learning algorithms.
We included studies developing new algorithms or methods of di-
agnosis (i.e. derivation studies) if they evaluated the new approach
using a separate ’test set’ of participants or images.
We excluded studies if they:
• Evaluated a new statistical model or algorithm in the same
participants or images as those used to train the model (i.e.
absence of an independent test set);
• Used cross-validation approaches such as ’leave-one-out’
cross-validation (Efron 1983); or
• Evaluated the accuracy of the presence or absence of
individual lesion characteristics or morphological features, with
no overall diagnosis of malignancy.
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Although primary-care clinicians can in practice be specialists in
skin cancer, we considered primary-care physicians as generalist
practitioners and dermatologists as specialists. Within each group,
we extracted any reporting of special interest or accreditation in
skin cancer.
Target conditions
We defined the primary target conditions as the detection of:
• Any form of invasive cutaneous melanoma, or atypical
intraepidermal melanocytic variants (i.e. including melanoma in
situ, or lentigo maligna, which has a risk of progression to
invasive melanoma)
• BCC
• cSCC
We considered two additional target conditions in secondary anal-
yses, namely the detection of:
• Any form of invasive cutaneous melanoma alone
• Any skin lesion requiring excision: all forms of skin cancer
listed above, as well as melanoma in situ, lentigo maligna, and
lesions with severe melanocytic dysplasia.
Reference standards
The ideal reference standard is histopathological diagnosis in all eli-
gible lesions. A qualified pathologist or dermatopathologist should
perform histopathology. Ideally, reporting should be standardised,
detailing a minimum dataset to include the histopathological fea-
tures of melanoma to determine the American Joint Committee
on Cancer (AJCC) Staging System (e.g. Slater 2014). We did not
apply this as a necessary inclusion criterion, but extracted any per-
tinent information.
Partial verification (applying the reference test only to a subset of
those undergoing the index test) was of concern, given that lesion
excision or biopsy is unlikely to be carried out for all benign-ap-
pearing lesions within a representative population sample. To re-
flect what happens in reality, we therefore accepted clinical follow-
up of benign-appearing lesions as an eligible reference standard,
whilst recognising the risk of variable verification bias (as misclas-
sification rates of histopathology and follow-up will differ).
Additional eligible reference standards included cancer registry
follow-up and ’expert opinion’ with no histology or clinical fol-
low-up. Cancer registry follow-up is considered less desirable than
active clinical follow-up, as follow-up is not carried out within
the control of the study investigators. Furthermore, if participant-
based analyses as opposed to lesion-based analyses are presented,
it may be difficult to determine whether the detection of a ma-
lignant lesion during follow-up is the same lesion that originally
tested negative on the index test.
We considered all of the above to be eligible reference standards,
with the following caveats:
• All study participants with a final diagnosis of the target
skin cancer disorder must have a histological diagnosis, either
subsequent to the application of the index test or after a period
of clinical follow-up
• At least 50% of all participants with benign lesions must
have either a histological diagnosis or clinical follow-up to
confirm benignity.
Search methods for identification of studies
Electronic searches
The Information Specialist (SB) carried out a comprehensive
search for published and unpublished studies. A single large liter-
ature search was conducted to cover all topics in the programme
grant (see Appendix 1 for a summary of reviews included in the
programme grant). This allowed for the screening of search results
for potentially relevant papers for all reviews at the same time.
A search combining disease related terms with terms related to
the test names, using both text words and subject headings was
formulated. The search strategy was designed to capture studies
evaluating tests for the diagnosis or staging of skin cancer. As the
majority of records were related to the searches for tests for stag-
ing of disease, a filter using terms related to cancer staging and
to accuracy indices was applied to the staging test search, to try
to eliminate irrelevant studies, for example, those using imaging
tests to assess treatment effectiveness. A sample of 300 records that
would be missed by applying this filter was screened and the filter
adjusted to include potentially relevant studies. When piloted on
MEDLINE, inclusion of the filter for the staging tests reduced the
overall numbers by around 6000. The final search strategy, incor-
porating the filter, was subsequently applied to all bibliographic
databases as listed below (Appendix 4). The final search result was
cross-checked against the list of studies included in five systematic
reviews; our search identified all but one of the studies, and this
study was not indexed onMEDLINE. The Information Specialist
(SB) devised the search strategy, with input from the Information
Specialist from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August
2016 for relevant published studies:
• MEDLINE via OVID (from 1946);
• MEDLINE In-Process & Other Non-Indexed Citations via
OVID;
• Embase via OVID (from 1980).
We searched the following bibliographic databases to 30 August
2016 for relevant published studies:
• Cochrane Central Register of Controlled Trials
(CENTRAL) Issue 7, 2016, in the Cochrane Library;
• Cochrane Database of Systematic Reviews (CDSR) Issue 8,
2016 in the Cochrane Library;
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• Cochrane Database of Abstracts of Reviews of Effects
(DARE) Issue 2, 2015;
• CRD Health Technology Assessment (HTA) database Issue
3, 2016;
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (via EBSCO from 1960).
We searched the followingdatabases for relevant unpublished stud-
ies using a strategy based on the MEDLINE search:
• CPCI (Conference Proceedings Citation Index), via Web of
Science™ (from 1990; searched 28 August 2016);
• SCI Science Citation Index Expanded™ via Web of
Science™ (from 1900, using the ’Proceedings and Meetings
Abstracts’ Limit function; searched 29 August 2016).
We searched the following trials registers using search terms
’melanoma’, ’squamous cell’, ’basal cell’ and ’skin cancer’ combined
with ’diagnosis’:
• Zetoc (from 1993; searched 28 August 2016)
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov); searched 29 August 2016
• NIHR Clinical Research Network Portfolio Database (
www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/); searched 29 August 2016;
• The World Health Organization International Clinical
Trials Registry Platform ( apps.who.int/trialsearch/); searched 29
August 2016.
We aimed to identify all relevant studies, regardless of language
or publication status (published, unpublished, in press, or in
progress). We applied no date limits.
Searching other resources
We have screened relevant systematic reviews identified by the
searches for their included primary studies, and included any
missed by our searches. We have checked the reference lists of all
included papers, and subject experts within the author team have
reviewed the final list of included studies. We did not conduct any
electronic citation searching.
Data collection and analysis
Selection of studies
At least one review author (JDi or NC) screened titles and ab-
stracts, with any queries discussed and resolved by consensus. A
pilot screen of 539MEDLINE references showed good agreement
(89% with a kappa of 0.77) between screeners. We included pri-
mary test accuracy studies and test accuracy reviews (for scan-
ning of reference lists) of any test used to investigate suspected
melanoma, BCC, or cSCC at initial screening. Inclusion criteria
(Appendix 5) were applied independently by both a clinical re-
viewer (fromone of a teamof 12 clinician reviewers) and amethod-
ologist reviewer (JDi, NC or LFR) to all full-text articles, resolving
disagreements by consensus or by a third party (JDe, CD, HW,
and RM). We contacted authors of eligible studies when insuffi-
cient data were presented to allow for the construction of 2 x 2
contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer
(JDi, NC or LFR) independently extracted data for details of the
study design, participants, index test(s) or test combinations and
criteria for index test positivity, reference standards, and data re-
quired to populate a 2 x 2 diagnostic contingency table for each
index test, using a piloted data extraction form. We extracted data
at all available index test thresholds, resolving disagreements by
consensus or by a third party (JDe, CD, HW, and RM).
We contacted authors of included studies where information re-
lated to final lesion diagnoses or diagnostic threshold was missing.
In particular, invasive cSCC (included as disease-positive for one
of our secondary objectives) is not always differentiated from in
situ variants such as Bowens disease (which we did not consider as
disease-positive for any of our definitions of the target condition).
We contacted authors of conference abstracts published from2013
to 2015, to ask whether full data were available. We marked con-
ference abstracts as ’pending’, and will revisit them in a future re-
view update.
Dealing with multiple publications and companion papers
Where we found multiple reports of a primary study, we max-
imised yield of information by collating all available data. Where
there were inconsistencies in reporting or overlapping study pop-
ulations, we contacted study authors for clarification in the first
instance. If this contact with authors was unsuccessful, we used
the most complete and up-to-date data source where possible.
Assessment of methodological quality
We assessed risks of bias and applicability of included studies using
the QUADAS-2 checklist (Whiting 2011), tailored to the review
topic (see Appendix 6). We piloted the modified QUADAS-2 tool
on a small number of included full-text articles. One clinical (as
detailed above) and onemethodologist reviewer (JDi, NC or LFR)
independently assessed quality for the remaining studies, resolving
any disagreement by consensus or by a third party where necessary
(JDe, CD, HW, and RM).
Statistical analysis and data synthesis
Our unit of analysis was the lesion rather than the person. This
is because (i) in skin cancer initial treatment is directed to the
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lesion rather than systemically (thus it is important to be able to
correctly identify cancerous lesions for each person), and (ii) it
is the most common way in which the primary studies reported
data. Although there is a theoretical possibility of correlations of
test errors when the same person contributes data for multiple
lesions, most studies include very few people with multiple lesions
and any potential impact on findings is likely to be very small,
particularly in comparison with other concerns for risk of bias
and applicability. For each analysis, we included only one dataset
per study to avoid multiple counting of lesions. Where multiple
CAD models or algorithms were assessed in an individual study,
we selected one at random, using a random-number generator.
Where studies evaluated CAD as a diagnostic aid by clinicians
with varying degrees of experience, we chose the dataset reporting
the highest degree of clinical experience.We made these selections
without reference to the corresponding accuracy data.
We estimated accuracy of dermoscopy separately according to
whether the diagnosis recorded was based on a face-to-face (in-
person) encounter or based on remote (image-based) assessment.
Where multiple algorithms were assessed in an individual study,
we selected dermoscopy datasets on the following preferential ba-
sis:
• ‘No algorithm’ reported; data presented for clinician’s
overall diagnosis or management decision
• Pattern analysis or pattern recognition
• ABCD algorithm (or derivatives of )
• Seven-point checklist (also referred to as Glasgow/Mackie
checklist)
• Menzies algorithm
• Three-point checklist
As for CAD, we preferred dermoscopy datasets reporting the high-
est degree of clinical experience over studies reporting multiple
results using clinicians of varying experience.
We pooled CAD study data for systems using similar methods
of data acquisition; thus we considered all studies using digital
dermoscopy-based CAD (Derm-CAD) to be similar and pooled
them.However, spectroscopy-basedCAD (Spectro-CAD) systems
analyse different data types and so were only pooled in these
subgroups: multispectral imaging studies (MSI-CAD), electrical
impedance spectroscopy (EIS-CAD), and diffuse reflectance spec-
troscopy (DRS-CAD). For each index test, algorithm or check-
list under consideration, we plotted estimates of sensitivity and
specificity on coupled forest plots and in receiver operating char-
acteristic (ROC) space. CAD thresholds are created by complex
statistical algorithms, and a threshold is difficult to define. We
therefore assumed results were binary for the purpose of pooling
results across similar CAD systems. We estimated summary op-
erating points (summary sensitivities and specificities) with 95%
confidence and prediction regions using the bivariate model (Chu
2006; Reitsma 2005). Where inadequate data were available for
the analysis to converge, we simplified the model, first by assum-
ing no correlation between estimates of sensitivity and specificity
and secondly by setting variance terms to zero if there was little or
no heterogeneity on SROC plots (Takwoingi 2015).
We extracted data on the accuracy of dermoscopy from all in-
cluded studies that performed both CAD and dermoscopy in the
same participants. We performed test comparisons using two an-
alytic strategies. First, we performed indirect comparisons by us-
ing all studies of the two tests. Then we made direct comparisons
of CAD and dermoscopy by including only comparative studies
that assessed the accuracy of both tests in the same study popu-
lation to enable a robust comparison (Takwoingi 2013). To min-
imise the risk of bias in the direct comparison, we excluded stud-
ies that performed either CAD or dermoscopy on a subsample
of the total analysed population. In the comparative meta-anal-
yses of indirect and direct comparisons, we compared summary
points by using a bivariate meta-regression model that included
test type as a covariate. We included covariate terms for sensitivity
and specificity. We assessed model fit using likelihood ratio tests
to compare nested models. We computed estimates of absolute
differences in sensitivity and specificity using the bivariate model
parameters, and obtained 95% confidence intervals using the delta
method. We obtained P values for the absolute differences using
Wald tests. We fitted univariate random-effects logistic regression
models incorporating test type as a covariate when there were few
studies or a bivariate meta-regression analysis did not converge.
When the number of studies was insufficient for meta-analysis,
we examined individual study results and calculated 95% CIs us-
ing theNewcombe-Wilson method without continuity correction
(Newcombe 1998).
For illustration of the meta-analytic findings in the ’Summary of
findings’ table, we computed the numbers of true positives, false
positives, false negatives and true negatives, using the summary es-
timates of sensitivity and specificity together with the lower quar-
tile, median and upper quartile of the prevalence observed in the
studies included in the meta-analysis.
We fitted bivariate models using the xtmelogit command in
STATA 15.
Investigations of heterogeneity
We examined heterogeneity between studies by visually inspecting
the forest plots of sensitivity and specificity and summary ROC
plots. Due to limited data availability, we were unable to formally
investigate heterogeneity using meta-regression.
Sensitivity analyses
The primary analysis included both CAD-based diagnoses and
CAD-aided diagnoses. We conducted sensitivity analyses exclud-
ing studies of CAD-aided diagnoses.
Assessment of reporting bias
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Because of uncertainty about the determinants of publication bias
for diagnostic accuracy studies and the inadequacy of tests for de-
tecting funnel plot asymmetry (Deeks 2005), we did not perform
tests to detect publication bias.
R E S U L T S
Results of the search
We identified 34,517 unique references, and screened them for
inclusion.Of these, we reviewed1051 full-text papers for eligibility
for any one of the suite of reviews of tests to assist in the diagnosis
of melanoma or keratinocyte skin cancer. Of the 1051 full-text
papers assessed, we excluded 848 from all reviews in our series (see
Figure 5 PRISMA flow diagram of search and eligibility results).
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Figure 5. PRISMA flow diagram.
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Of the 225 studies tagged as potentially eligible for this review of
CAD (164 for Derm-CAD, 61 for Spectro-CAD), we include 42
publications (24 Derm-CAD and 18 Spectro-CAD). Exclusions
were mainly due to the absence of a ‘test’ set of lesions used to
evaluate CAD’s performance independently of the computer algo-
rithm’s development (Derm-CAD n = 76, Spectro-CAD n = 17);
inability to construct a 2 x 2 contingency table based on the data
presented (Derm-CAD n = 24, Spectro-CAD n = 8); the use of in-
eligible index tests (Derm-CAD n = 18, Spectro-CAD n = 5) (for
example: computers used to measure lesions but not to diagnose
them, e.g. Seidenari 2012); or not meeting our requirements for
an eligible reference standard (Derm-CAD n = 13, Spectro-CAD
n = 9). Other reasons for exclusion included ineligible definition
of the target condition (Derm-CAD n = 10, Spectro-CAD n =
3) and CAD systems based on evaluating the presence of a single
lesion characteristic (Derm-CAD n = 17) (for example, a CAD
system analysing the colour balance of a lesion). We provide a list
of the 183 publications excluded from this review, with reasons
for exclusion in Characteristics of excluded studies, with a list of
all studies excluded from the full series of reviews available as a
separate pdf (please contact skin.cochrane.org for a copy of the
pdf ).
We contacted the authors of 10 publications to acquire additional
detail on published 2 x 2 data for the accuracy of CAD, with re-
sponses for four publications received to date. These did not re-
sult in the inclusion of any additional studies, but did permit the
inclusion of one additional dataset in an already-included study
(Mollersen 2015). One response highlighted an alternative pub-
lication that was independently ascertained by the project search,
and was included (Serrao 2006); two replies were unable to pro-
vide the information requested for two study publications, both
of which we subsequently excluded due to incomplete 2 x 2 data.
We failed to contact authors of six publications, resulting in the
exclusion of those six studies from the review. In addition to these
10 attempted contacts, authors of one other publication (Walter
2012) were contacted as part of another review in this series, i.e.
the accuracy of visual inspection for the diagnosis of melanoma
(Dinnes 2018a), to provided clarification on methods used; the
author response enabled us to include it.
The 42 included studies reported on 39 cohorts of lesions, provid-
ing 63 datasets with 13,445 lesions and 2452 malignancies. Most
of the studies (n = 24, 57%) contributed data on the diagnos-
tic accuracy of digital dermoscopy-based CAD systems (Derm-
CAD), of which seven also compared the diagnostic accuracy of
Derm-CADwith dermoscopic diagnosis. The remaining 18 stud-
ies contributed data on the diagnostic accuracy of spectroscopy-
based CAD (Spectro-CAD), of which five provided comparative
accuracy data with dermoscopy. A cross-tabulation of studies by
CAD type, reported comparisons and target conditions is available
in Table 2.
Studies were case series (n = 27, 64%), case-control (n = 10, 24%),
randomised controlled trial (n = 1, 2%), or of unclear design (n
= 4, 10%). Lesion selection was most commonly retrospective (n
= 22, 52%) or prospective (n = 15, 36%), and was unclear in five
studies (12%). Studies included only pigmented (n = 29, 69%) or
melanocytic lesions (n = 6, 14%), only suspected melanomas (n
= 4, 10%), or any lesions suspected of malignancy (n = 2, 5%).
Participant characteristics such as age and gender were reported
by 15 of the 42 studies.
Methodological quality of included studies
Most of the included studies were of methodological concern, pri-
marily due to lack of applicability to the current review question,
but also due to a high or unclear risk of bias in their design. Since
therewere nomajor differences in quality byCADtype,we provide
an overview of the quality and applicability of all included studies
regardless of CAD type. The methodological quality of studies ac-
cording to CAD type (Derm-CAD or spectroscopy-based CAD)
is summarised in Figure 6 and Figure 7.
Figure 6. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies
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Figure 7. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study
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We judged the risk of participant selection bias to be high in
17 studies (40%), due to the selection of lesions according to
their final diagnosis (case-control studies: n = 10, 24%), and/or
to the inappropriate exclusion of lesions with particular prognos-
tic characteristics (n = 8, 19%), such as high-grade dysplastic le-
sions (Ferris 2015) or small/large lesions (Malvehy 2014;Monheit
2011). Study eligibility criteria and participant exclusionswere not
reported clearly enough to ascertain the risk of selection bias in 17
studies (40%); this meant that we could not determine whether
consecutive or random samples of lesions were recruited (n = 22,
52%), whether participants had been selected according to their
final diagnoses (use of ’case-control’ selection, n = 5, 12%), or
whether participant exclusions were appropriate (n = 22, 52%).
A single study (Sgouros 2014) was of low concern for the appli-
cability of its participant sample to the current review question: it
included unexcised lesions and did not recruit participants with
multiple lesions. All others (n = 41, 98%) were of high concern
due to the use of restricted participant groups and settings (n =
40, 95%), with study populations limited to lesions selected for
excision based on the clinical or dermoscopic diagnosis or selected
retrospectively from histopathology databases (n = 36, 84%). Six
studies did not restrict inclusion to excised lesions, but in three
of these the non-excised lesions could not be extracted due to
the absence of clinical follow-up in at least 50% of benign cases
(Boldrick 2007; Bono 1996; Sgouros 2014). Fourteen studies were
also of concern due to their recruitment of participants with mul-
tiple lesions (including over 5% more lesions than participants).
One of these (Dreiseitl 2009) provided participant-based 2 x 2
data as well as lesion-based data for the accuracy of a Derm-CAD
system. These two analyses of the same population highlight the
distortion that can occur in study populations that include multi-
ple lesions per participant: lesion-based sensitivity was lower than
participant-based sensitivity (74% versus 89%), but lesion-based
specificity was far higher (84% versus 48%) due to the inclusion
of many disease-negative lesions per participant.
Twenty-two (52%) studies did not report the number of partici-
pants included (precluding assessment of the inclusion of multiple
lesions). Of the 18 studies including model derivation, six (33%)
used a wide range of skin conditions to train the classification algo-
rithm. Two (11%) used an inadequately narrow range (absence of
non-dysplastic benign conditions), while the remaining 10 (56%)
provided inadequate detail of diagnoses included in the training
set.
Over half the studies were at high (n = 14, 33%) or unclear (n =
10, 24%) risk of bias due to the methods used to undertake the
index test. Most studies (n = 40, 95%) blinded CAD results to the
reference standard diagnosis, although almost half (n = 20, 48%)
failed to clearly prespecify the diagnostic threshold, of which 13
(30%) were threshold-finding studies that provided accuracy data
for the best threshold possible once index test results had been
examined. Most studies (n = 35, 83%) evaluated CAD in an in-
dependent population from that used to train the classification
algorithm, either by external validation (n = 23, 55%) or internal
validation (randomised division of a single study group into train-
ing and test sets: n = 12, 29%). An additional six studies (14%)
used internal validation, but failed to specify whether division of
the study group was made randomly (i.e. not selected according to
diagnosis), while one study was at risk of bias by selecting which
diagnoses to place in the training and test sets (Tomatis 2003).
Of the 18 studies that included CAD model derivation (train-
ing of the classification algorithm), eight (44%) accounted for
model overfitting by using a Support Vector Machine algorithm
(Gilmore 2010;Mohr 2013; Stanganelli 2005), performing a jack-
knife calculation (Binder 1994; Burroni 2004), or anothermethod
(Rubegni 2002a; Tomatis 2003; Tomatis 2005). One study spec-
ified that model optimisation was not incorporated (Garcia Uribe
2012) and nine (50%) did not discuss overfitting. Most studies (n
= 32, 76%) were of high concern for the applicability of the index
test, due to their evaluation of an unestablished threshold (n = 23),
lack of detail about the diagnostic threshold used (n = 16), and/or
the use of non-expert clinicians (n = 2) in studies evaluating CAD
as a diagnostic aid (n = 7).
Almost all studies reported use of an acceptable reference standard
(n = 37, 88%), and around half (n = 19, 45%) clearly reported
blinding of the reference standard to the CAD result. For the
applicability of the reference standard, four reported using expert
diagnosis for some lesions (high concern) and 26 (62%) were
unclear as to whether histopathology had been interpreted by an
experienced histopathologist or dermatopathologist.
Reporting of study flow and timing was generally poor, with an
unclear risk of bias in 28 studies (67%), largely due to ambiguity
about the interval between the application of the index test and
reference standard (excision for histology or first follow-up visit)
(n = 28). Thirteen studies (30%) were at a high risk of bias be-
cause they used different reference standards according to diag-
nosis (differential verification) (n = 6) and/or did not include all
participants in the analysis (n = 10), primarily due to technical
difficulties with the CAD system (n = 6).
Eleven of the 15 studies comparing CAD with dermoscopy were
at high (n = 2) or unclear (n = 9) risk of bias. Six reported blinding
between tests, two reported no blinding and seven were unclear.
Half (n = 8) did not clearly report the interval between tests.
Findings
The 24 studies evaluating a Derm-CAD system reported 23 co-
horts of lesions providing 32 CAD datasets with 9602 lesions in-
cluding 1313 malignancies of which 1220 were melanomas, at
least 83 BCCs (number not specified in one study,Menzies 1996),
and nine cSCCs. We cannot estimate the total number of study
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participants with suspicious lesions, due to lack of reporting in
study publications (reported in only 10 studies (with 2400 par-
ticipants)). Two publications provided data for one cohort of le-
sions (Seidenari 1998; Seidenari 1999); we included the larger
of the two studies (Seidenari 1999) in the primary analysis with
data from Seidenari 1998 contributing only to the direct com-
parison of Derm-CAD with dermoscopy. We evaluated a total
of 16 different systems (listed in Table 3), three by multiple in-
dependent studies: Microderm (Barzegari 2005; Boldrick 2007;
Serrao 2006), DB-MIPS (also called DB-Dermo MIPS) (Bauer
2000; Burroni 2004; Rubegni 2002a; Seidenari 1998; Seidenari
1999; Stanganelli 2005;Wollina 2007), and Skin View (Cascinelli
1992; Cristofolini 1997). The 16 systems differ in the type of
dermoscopy used to acquire images, the storage devices used, fea-
tures analysed and statistical classifier used (summarised in Table
3). The approach to computer-assisted support also differed, with
21 studies (88%) evaluating a stand-alone automated diagnosis
(‘system-based diagnosis’), and three studies using Derm-CAD as
a diagnostic aid to assist clinical decision-making.
The 18 publications evaluating a Spectro-CAD system reported
16 cohorts of lesions contributing 32 datasets with 6336 le-
sions including 1084 malignancies of which 934 weremelanomas,
163 BCCs and 49 cSCCs. We cannot estimate the total num-
ber of study participants with suspicious lesions, due to lack of
reporting in study publications (reported in only eight studies
totaling 4484 participants). Four publications provided data for
two patient cohorts (Bono 2002; Tomatis 2003 and Hauschild
2014; Monheit 2011); we included the larger studies (Monheit
2011; Tomatis 2003) in the primary analysis, with data from
Bono 2002 (same population as Tomatis 2003) and Hauschild
2014 (same population as Monheit 2011) contributing only
to the direct comparison of Spectro-CAD with dermoscopy.
These 18 studies reported on five different multispectral sys-
tems using DRSi: SpectroShade (Ascierto 2010; Tomatis 2005),
Melafind (Friedman 2008; Gutkowicz Krusin 1997; Hauschild
2014; Monheit 2011; Wells 2012; Winkelmann 2016), SIAscope
(Glud 2009; Terstappen 2013), and ‘Telespectrophotometric Sys-
tem’ (Bono 1996; Tomatis 2003). One study evaluated a non-
imaging diffuse reflectance spectroscopy system: OIDRS (Garcia
Uribe 2012), which used analysis of data from incidentally-re-
flected diffuse light. Nevisense was the only system to use elec-
trical impedance spectroscopy (EIS), and was evaluated in two
large prospective studies; these had overlapping recruitment pe-
riods and study centres, so we cannot rule out the possibility of
overlap in analysed participants (Malvehy 2014; Mohr 2013). As
for the Derm-CAD systems, the Spectro-CAD systems differ in
terms of the image acquisition and storage devices used, features
analysed, statistical classifier used, and the approach to computer-
assisted support (i.e. whether used as a stand-alone automated di-
agnosis, or as information to assist a clinician’s diagnostic decision)
(Table 4).
Study results are summarised below according to target condition,
with forest plots of available study data provided in Figures 8 to
23. Results of meta-analysis are provided in Table 5 and Table 6.
Target condition: invasive melanoma and atypical
intraepidermal melanocytic variants
The diagnostic accuracy of CAD assessment for the detection of
invasive cutaneous melanoma or atypical intraepidermal variants
was reported by 36 studies with a total of 14,451 lesions including
1889 melanomas. Of these, 23 studies evaluated a Derm-CAD
system (total 9082 lesions with 1094 melanomas) and 13 studies
evaluated a Spectro-CAD system (total 5369 lesions with 795
melanomas).
Derm-CAD
Twenty-two studies were included in a meta-analysis to esti-
mate the accuracy of dermoscopy-based CAD systems in referral
settings, regardless of the system manufacturer, algorithm used,
or whether CAD was used as a stand-alone automated diagno-
sis or as a diagnostic aid (Barzegari 2005; Bauer 2000; Binder
1994; Binder 1998; Blum 2004a; Boldrick 2007; Burroni 2004;
Cascinelli 1992; Cristofolini 1997; Dreiseitl 2009; Ferris 2015;
Gilmore 2010; Maglogiannis 2015; Menzies 2005; Mollersen
2015; Piccolo 2002; Piccolo 2014; Rubegni 2002a; Seidenari
1999; Serrao 2006; Stanganelli 2005;Wollina 2007).We excluded
one additional study from this analysis (Seidenari 1998), due to
suspected population overlap with an included study (Seidenari
1999). These 22 studies provided 23 datasets for meta-analysis
(Mollersen 2015 evaluated two CAD systems, Nevus Doctor and
MoleExpert, in the same lesion population). Eleven studies were
model derivation studies, eight evaluating the resulting classifica-
tion algorithm in an independent population (random division of
one study group into training and test sets: Binder 1994; Binder
1998; Blum 2004a; Burroni 2004; Ferris 2015; Maglogiannis
2015;Menzies 2005; Stanganelli 2005), and three providing insuf-
ficient details to determine the independence of the test population
(Cascinelli 1992; Gilmore 2010; Rubegni 2002a). The remaining
11 studies were external validation studies with prospective (Bauer
2000; Cristofolini 1997;Dreiseitl 2009;Wollina 2007), retrospec-
tive (Piccolo 2002; Piccolo 2014; Seidenari 1999; Serrao 2006), or
unclear (Barzegari 2005; Boldrick 2007; Mollersen 2015) recruit-
ment designs. Only one study did not use excision as an eligibility
criterion (Dreiseitl 2009).
Across the 23 datasets, sensitivity ranged from 17% to 100% and
specificity from 20% to 98%. We pooled a total of 8992 lesions
including 1063 melanomas, giving summary sensitivity of 90.1%
(95% confidence interval (CI) 84.0% to 94.0%) and summary
specificity of 74.3% (95% CI 63.6% to 82.7%) (Table 5; Figure
8; Figure 9).
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Figure 8. Forest plot of different types of digital dermoscopy CAD systems (DermCAD) for the detection of
invasive melanoma or atypical intraepidermal melanocytic variants (invasive melanoma or atypical
intraepidermal melanocytic variants)
30Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 9. Summary plot of digital dermoscopy CAD systems (Derm-CAD) for the detection of invasive
melanoma or atypical intraepidermal melanocytic variants (invasive melanoma or atypical intraepidermal
melanocytic variants)
The prevalence of melanoma ranged from 1% (Dreiseitl 2009)
to 52% (Gilmore 2010; Maglogiannis 2015), and the number
of melanomas missed ranged from 0 (Barzegari 2005; Piccolo
2014; Seidenari 1999) to 16 (Maglogiannis 2015) (not reported
in four studies). Ten of the 22 studies did not provide clear iden-
tification of the target condition (Binder 1994; Blum 2004a;
Cascinelli 1992; Cristofolini 1997; Dreiseitl 2009; Gilmore 2010;
Maglogiannis 2015; Piccolo 2002; Rubegni 2002a; Stanganelli
2005), and the inclusionofmelanoma in situ lesions as disease-pos-
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itive was assumed on the basis that the disease-positive group was
described as ‘melanoma’ and not as ‘invasive melanoma’ or ‘malig-
nant melanoma’. Of the 12 studies that clearly reported including
in situ lesions (Barzegari 2005; Bauer 2000; Binder 1998; Boldrick
2007; Burroni 2004; Ferris 2015;Menzies 2005;Mollersen 2015;
Piccolo 2014; Seidenari 1999; Serrao 2006; Wollina 2007), the
percentage of the disease-positive group (invasive melanoma and
atypical intraepidermal melanocytic variants) described as being
in situ ranged from 12% to 50%. The number of missed in situ
lesions was reported in seven studies, with no missed lesions in
three studies (Barzegari 2005; Piccolo 2014; Seidenari 1999) and
between 7% (1 of 14, Ferris 2015) and 100% (3 of 3, Boldrick
2007) of in situ lesions misdiagnosed by the remaining studies.
Some studies reported difficulties in excluding a malignancy from
clinically benign lesions, particularly non-melanocytic pigmented
lesions such as seborrhoeic keratoses which were reported as an
included lesion by five studies (Barzegari 2005; Cascinelli 1992;
Ferris 2015; Menzies 2005; Mollersen 2015). Four of these pro-
vided lesion diagnoses by CAD result, finding 41 of 61 sebor-
rhoeic keratoses (67%) to have been falsely identified as malig-
nant, while a fifth study highlighted their problematic misclas-
sification of this lesion by both Derm-CAD systems (Mollersen
2015). Other notable false-positive diagnoses include dysplastic
melanocytic naevi (Binder 1994; Binder 1998; Cascinelli 1992;
Ferris 2015; Seidenari 1999), actinic keratosis (Barzegari 2005),
dermatofibroma (Barzegari 2005; Menzies 2005) and haeman-
gioma (Menzies 2005).
One dataset from one study contributed data for the accuracy of
a Derm-CAD system in self-referring patients seeking advice for
pigmented naevi (Wollina 2007) (Table 7). This prospective study
evaluated the DB-MIPS system, a fully-integrated dermoscopy
unit with internal stereomicroscope, storage database and pattern
analysis software, giving it to clinicians to use as a diagnostic aid.
Although 3541 lesions (1308 participants) were examined, only
the excised lesions (n = 466) were analysed by the authors, of
which 357 were recruited in primary-care clinics. These included
19melanomas, and 283 dysplastic melanocytic naevi. The authors
reported a sensitivity of 89.5% (95% CI 68.6% to 97.1%) and
specificity of 84.0% (95% CI 79.7% to 87.5%).
Derm-CAD versus Dermoscopy
Seven studies (32%) reported accuracy data comparing Derm-
CAD with dermoscopy for the detection of invasive melanoma
and atypical intraepidermal melanocytic variants, providing seven
datasets (4104 lesions including 226 melanomas and no other
malignancies). A further four studies reported accuracy data for
dermoscopy in a subsample of the total study population, and
so we excluded them from analysis (Blum 2004a; Ferris 2015;
Menzies 2005; Stanganelli 2005).
Five of the seven studies compared Derm-CAD to diagnosis by
expert dermoscopists using dermoscopic images alone (Binder
1994; Gilmore 2010; Piccolo 2014; Seidenari 1998) or alongside
clinical images (Piccolo 2002) in 765 lesions (153 melanomas).
Two studies compared face-to-face dermoscopic diagnosis by an
expert dermatologist with Derm-CAD systems DB-MIPS (Bauer
2000) and Image J (Dreiseitl 2009).
The accuracy of Derm-CAD was compared with the accuracy of
dermoscopy in:
(a) all 22 Derm-CAD studies (8992 lesions and 1063 melanomas)
and the five image-based dermoscopy studies (765 lesions and 153
melanomas) in an indirect comparison (Figure 10; Figure 11), and
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Figure 10. Forest plot of data for image-based dermoscopy diagnosis and digital dermoscopy CAD systems
(Derm-CAD) for the detection of invasive melanoma or atypical intraepidermal melanocytic variants (invasive
melanoma or atypical intraepidermal melanocytic variants)
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Figure 11. Summary plot of image-based dermoscopy diagnosis versus digital dermoscopy CAD systems
(Derm-CAD) for the detection of invasive melanoma or atypical intraepidermal melanocytic variants (invasive
melanoma or atypical intraepidermal melanocytic variants)
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(b) direct comparisons in the subset of five studies that evaluated
both Derm-CAD and image-based dermoscopy (765 lesions and
153 melanomas; Figure 12; Appendix 7).
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Figure 12. Summary plot of direct comparisons between image-based dermoscopy diagnosis versus digital
dermoscopy CAD systems (Derm-CAD) for the detection of invasive melanoma or atypical intraepidermal
melanocytic variants (invasive melanoma or atypical intraepidermal melanocytic variants)
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In both comparisons similar sensitivities were observed but with
lower specificity for CAD compared to dermoscopy, but none of
the observed differences were statistically significant (Table 6). For
the indirect comparison, the difference (95% CI) in summary
sensitivities (Derm-CAD 90.1% versus dermoscopy 93.3%) was
−3.21% (−11.2% to 4.79%), P = 0.43; the difference (95% CI)
in summary specificities (Derm CAD 74.3% versus dermoscopy
88.5%) was −14.1% (−34.4% to 6.06%), P = 0.17. For the di-
rect comparison the difference (95% CI) in summary sensitivi-
ties (Derm-CAD 94.1% versus dermoscopy 93.9%) was 0.17%
(−6.61% to 6.95%), P = 0.96; the difference (95% CI) in sum-
mary specificities (CAD-Derm 80.8% versus dermoscopy 88.3%)
was −7.44% (−28.4% to 13.6%), P = 0.49.
Contrasting differences in accuracy were produced by the two
studies comparing Derm-CAD with face-to-face dermoscopic di-
agnosis by an expert (Bauer 2000; Dreiseitl 2009; Table 8), but
these differences were imprecise.
Spectro-CAD
We meta-analysed eight datasets to estimate the accuracy of MSI-
CAD systems in referral settings, regardless of the system make,
algorithm used, or whether CAD was used as a stand-alone auto-
mateddiagnosis or as a diagnostic aid (Friedman 2008;Glud2009;
Gutkowicz Krusin 1997; Monheit 2011; Tomatis 2003; Tomatis
2005; Wells 2012; Winkelmann 2016). We excluded one other
dataset (Hauschild 2014) from this analysis as it was a subgroup
of Monheit 2011. Four were model derivation studies (Friedman
2008; Gutkowicz Krusin 1997; Tomatis 2003; Tomatis 2005),
two of which validated the resulting classification algorithm in an
independent population (Friedman 2008; Tomatis 2005), and the
remaining four were prospective (Glud 2009; Monheit 2011) or
retrospective (Wells 2012; Winkelmann 2016) external validation
studies.Melanoma prevalence ranged from7% (Monheit 2011) to
49% (Friedman 2008; Wells 2012). These eight datasets evaluated
2537 excised lesions with 296 melanomas, with sensitivities rang-
ing from 76% (Tomatis 2003) to 100% (Glud 2009; Gutkowicz
Krusin 1997), and specificities ranging from 8% (Wells 2012) to
77% (Tomatis 2005). The pooled sensitivity was 92.9% (95% CI
83.7% to 97.1%) and specificity was 43.6% (95% CI 24.8% to
64.5%) (Table 5; Figure 13; Figure 14). The number ofmelanomas
missed ranged from 0 (Glud 2009; Gutkowicz Krusin 1997) to 9
(Tomatis 2003), although the reporting of false-positive diagnoses
was poor so we could not analyse the data.
Figure 13. Forest plot of different types of multi-spectral imaging CAD (MSI-CAD) for the detection of
invasive melanoma or atypical intraepidermal melanocytic variants (invasive melanoma or atypical
intraepidermal melanocytic variants)
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Figure 14. Summary plot of multi-spectral imaging CAD (MSI-CAD) for the detection of invasive
melanoma or atypical intraepidermal melanocytic variants (invasive melanoma or atypical intraepidermal
melanocytic variants)
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One study evaluated a Spectro-CAD system based on the analysis
of diffuse reflectance spectroscopy data, a non-imaging CAD sys-
tem called OIDRS (Garcia Uribe 2012). This model derivation
study prospectively recruited 136 pigmented skin lesions with a
melanoma prevalence of 7% (final diagnosis determined by his-
tology following biopsy). OIDRS was found to operate with a
sensitivity of 90.0% (95% CI 59.6% to 98.2%) and specificity of
89.7% (95% CI 83.2% to 93.9%) (Table 9).
The two studies evaluating Nevisense, a CAD system using electri-
cal impedance spectroscopy (EIS), included one internal validation
study (Mohr 2013) and one external validation study (Malvehy
2014) (Table 10). Pooling 2389 lesions with 368 melanomas, the
summary sensitivity was 97% (95% CI 94.7% to 98.3%) and
specificity was 33.6% (95% CI 31.6% to 35.7%) (Table 5). Both
studies reported considerable difficulties in the ability ofNevisense
to identify seborrhoeic keratoses, with 69/73 (95%) such lesions
falsely identified as malignant. Other notable false-positive diag-
noses included dysplastic melanocytic naevi, actinic keratoses and
dermatofibroma.
One study evaluated the accuracy of an MSI-CAD system in an
unreferred population (Walter 2012). A series of participants with
pigmented skin lesions who were presenting for a first clinical as-
sessment were prospectively recruited and imaged by GPs, using
a SIAscope™ coupled with MoleMate, a multispectral imaging
device with viewing platform and integrated Primary Care Scor-
ing Algorithm (developed by Emery 2010). This was originally an
RCT comparing patient referrals by GPs using MSI-CAD (exper-
imental arm) with GP clinical assessment only (control arm), and
we extracted the experimental arm data as a prospective case series
evaluating MSI-CAD against histology or clinical follow-up of at
least three months for lesions considered benign, as well as expert
diagnosis without follow-up for some benign lesions. Overall 36
melanomas were identified and an additional 209 false diagnoses
made amongst 766 included lesions; MSI-CAD sensitivity was
100% (95% CI 82.4% to 100%) and specificity was 72.1% (95%
CI 68.7% to 75.2%) (Table 7).
Spectro-CAD versus Dermoscopy
Six MSI-CAD studies (67%) also evaluated the accuracy of der-
moscopy, providing six datasets (684 lesions and 229 malignancies
comprising 220melanomas, 8 BCCs and no cSCCs). One of these
compared Derm-CAD to in-person dermoscopic diagnosis (Bono
2002), and five studies evaluated dermoscopy using expert dermo-
scopists (Friedman 2008; Glud 2009; Hauschild 2014) or derma-
tologists of unreported expertise (Wells 2012; Winkelmann 2016)
to interpret stored dermoscopic images of 371 lesions, including
154 melanomas. Four studies also provided additional diagnostic
information to clinicians in the form of clinical examination notes
(Friedman 2008; Hauschild 2014; Wells 2012) or clinical images
(Winkelmann 2016).
The accuracy of MSI-CAD was compared with the accuracy of
dermoscopy in:
(a) all eight MSI-CAD studies (2401 lesions and 286 melanomas)
and the five image-based dermoscopy studies (371 lesions and 154
melanomas) in an indirect comparison (Figure 15; Figure 16), and
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Figure 15. Forest plot of data for image-based dermoscopy diagnosis and multi-spectral imaging CAD
systems (MSI-CAD) for the detection of invasive melanoma or atypical intraepidermal melanocytic variants
(invasive melanoma or atypical intraepidermal melanocytic variants)
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Figure 16. Summary plot of image-based dermoscopy diagnosis versus multi-spectral imaging CAD systems
(MSI-CAD) for the detection of invasive melanoma or atypical intraepidermal melanocytic variants (invasive
melanoma or atypical intraepidermal melanocytic variants)
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(b) direct comparisons in the subset of five studies that evaluated
both MSI-CAD and image-based dermoscopy (371 lesions and
154 melanomas; Figure 17; Appendix 7).
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Figure 17. Summary plot of direct comparisons between image-based dermoscopy diagnosis versus multi-
spectral imaging CAD systems (MSI-CAD) for the detection of invasive melanoma or atypical intraepidermal
melanocytic variants (invasive melanoma or atypical intraepidermal melanocytic variants)
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In both comparisons MSI-CAD was significantly more sensitive
with lower specificity, although differences in specificity were only
significant for (b), the direct comparison (Table 6). For the indi-
rect comparison (a), the difference (95% CI) in summary sensi-
tivities (MSI-CAD 92.9% versus dermoscopy 74.0%) was 18.9%
(9.58%to28.2%), P =0.003; the difference (95%CI) in summary
specificities (MSI-CAD 43.6% versus dermoscopy 58.7%) was
−15.0% (−40.7% to 10.6%), P = 0.26. For the direct comparison
(b), the difference (95% CI) in summary sensitivities (MSI-CAD
96.8% versus dermoscopy 74.0%) was 22.7% (15.2% to 30.2%),
P < 0.001; the difference (95%CI) in summary specificities (MSI-
CAD 29.8% versus dermoscopy 58.7%) was −28.9% (−56.3%
to −1.48%), P = 0.039.
Four of the five image-based dermoscopy studies used the
MelaFind system (Friedman 2008; Hauschild 2014; Wells
2012; Winkelmann 2016), with the same impact on sensitivity
(MelaFind 96.5% versus dermoscopy 72.5%; difference (95%CI)
of 23.9% (16.0% to 31.9%), P < 0.001) and specificity (MelaFind
22.8% versus dermoscopy 50.7%; difference (95% CI) −27.9%
(−50.1% to −5.66%), P = 0.014) (Table 6).
One study compared the accuracy of MSI-CAD to in-person di-
agnosis by an expert dermatologist (Bono 2002), and we present
the results in Table 8.
Derm-CAD versus Spectro-CAD
None of the studies directly compared the accuracy of Derm-CAD
and MSI-CAD. An indirect comparison of MSI-CAD (8 stud-
ies) and Derm-CAD (22 studies) demonstrated similar sensitivi-
ties (Derm-CAD 90.1% versus MSI-CAD 92.9%) with a differ-
ence (95% CI) of 2.83% (−5.04% to 10.7%), P = 0.48. How-
ever, specificity was lower for MSI-CAD (43.6%) compared to
Derm-CAD (74.3%) with a difference of −30.7% (−53.8% to
−7.64%), P = 0.009 (Table 6).
Secondary analyses for the detection of invasive melanoma
and atypical intraepidermal melanocytic variants
Accuracy of individual Derm-CAD systems
Our ability to compare the accuracy of individual CAD systems
was limited by lack of data. A sufficient number of datasets to
allow separate pooling were available only for the DB-MIPS sys-
tem. Six studies evaluated the DB-MIPS system, using varying
classification algorithms, in a total of 1903 lesions including 502
melanomas (Bauer 2000; Burroni 2004; Rubegni 2002a; Seidenari
1999; Stanganelli 2005;Wollina 2007;we dropped a seventh study
(Seidenari 1998) from this analysis due to population overlap with
Seidenari 1999). Three were external validation studies (Bauer
2000; Seidenari 1999;Wollina 2007), and all six included only ex-
cised lesions. Summary estimates of sensitivity were 95.2% (95%
CI 89.5% to 97.9%) and specificity 89.1% (95% CI 78.7% to
94.8%) (Table 5; Figure 8; Figure 18).
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Figure 18. Summary plot for the multi-spectral imaging CAD system (MSI-CAD) DBMIPS for the detection
of invasive melanoma or atypical intraepidermal melanocytic variants (invasive melanoma or atypical
intraepidermal melanocytic variants)
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Three external validation studies evaluated the MicroDERM sys-
tem in a total of 793 lesions with 54 melanomas. However, due to
the limited number of studies and substantial variability between
studies, we did not perform meta-analysis. Sensitivities ranged
from 17% (95% CI 0% to 64%) to 86% (95% CI 42% to 100%)
and specificities from 50% (95% CI 46% to 54%) to 90% (95%
CI 83% to 95%) (Barzegari 2005; Boldrick 2007; Serrao 2006).
These represent accuracy for thresholds using DANAOS scores of
≥ 6.5 (Serrao 2006), ≥ 7 (Boldrick 2007) and ≥ 7.34 (Barzegari
2005). The outlying sensitivity of 17% observed in Boldrick 2007
is likely due to a skewed sample of lesions, since of the 1000 pig-
mented skin lesions assessed in the study, only 18 received an eli-
gible reference standard (histology, clinical follow-up was not re-
ported) and so could be included. The vast majority of the original
sample (982/1000) were clinically diagnosed as benign lesions not
requiring excision.
Two studies evaluated the Skin View system in 220 excised lesions
with 45 melanomas (Cascinelli 1992; Cristofolini 1997). The ear-
lier publication included a model validation phase using internal
validation (Cascinelli 1992), while Cristofolini 1997 performed
an external validation only. Summary estimates of sensitivity were
80.0% (95% CI 65.8% to 89.3%) and specificity 47.4% (95%
CI 40.1% to 54.8%) (Table 5; Figure 8).
Accuracy of individual Spectro-CAD systems
Five MSI-CAD studies evaluated the MelaFind system in a
total of 1798 lesions including 196 melanomas (Friedman
2008; Gutkowicz Krusin 1997; Monheit 2011; Wells 2012;
Winkelmann 2016). Summary estimates of sensitivity were 97.1%
(95%CI 91.9% to 98.9%) and specificity 29.8% (95%CI 12.3%
to 56.3%) (Table 5; Figure 11; Figure 19).
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Figure 19. Summary plot for the multi-spectral imaging CAD system (MSI-CAD) MelaFind for the
detection of invasive melanoma or atypical intraepidermal melanocytic variants (invasive melanoma or
atypical intraepidermal melanocytic variants)
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Both EIS-CAD studies reported above evaluated the Nevisense
system, in a total of 2389 lesions with 368 melanomas, giving a
summary sensitivity of 97.0% (95% CI 94.7% to 98.3%) and
specificity of 33.6% (95% CI 31.6% to 35.7%).
CAD-only performance versus CAD-aided performance
In sensitivity analyses, we excluded studies that used CAD as a
diagnostic aid. Three of the 22 Derm-CAD studies evaluated the
Derm-CAD system as a diagnostic aid in referral settings (Bauer
2000; Piccolo 2014; Wollina 2007). Two of the six DB-MIPS
studies (both prospective external validation studies) assessed the
system as a diagnostic aid. For MSI-CAD, one of the eight stud-
ies used CAD as a diagnostic aid in a referral setting (MelaFind,
Winkelmann 2016). The results of the sensitivity analyses are
shown in Appendix 8. The results indicate very similar findings to
the main analyses.
Direct evidence was available from one study (Dreiseitl 2009)
which compared Derm-CAD computer diagnoses (CAD only)
with diagnoses produced by clinicians using Derm-CAD as a diag-
nostic aid (CAD-aided). In an external validation study, Dreiseitl
2009 compared CAD-only performance of MoleMax II analysed
with the Image J software programme (using a neural network
classifier), with CAD-aided diagnosis performed by dermatolo-
gists with high experience, low experience, and a third cohort with
mixed experience. In this prospective study, 458 consecutive par-
ticipants were included who were referred to a secondary-care cen-
tre for further investigation of 3021 suspicious pigmented skin
lesions. While lesion-based results were reported for the CAD-
only diagnosis (pooled for the primary objective Derm-CAD ac-
curacy estimates in Figure 10), only participant-based results were
provided for its comparison to CAD-aided diagnoses; it is notable
that the lesion-based sensitivity and specificity for CAD-only di-
agnosis differ substantially from the participant-based estimates
for CAD-only diagnosis (74% versus 89% sensitivity, 84% versus
48% specificity), which is to be expected when many more lesions
were free of disease (true negatives n = 2512) than were partici-
pants (n = 207). The within-study results for the comparison to
CAD-aided diagnosis are reported in Table 8.
A case-control reader study (Hauschild 2014), undertaken in a
referred setting, was the only direct comparison of an MSI CAD-
only diagnosis with MSI CAD-aided diagnosis. The study in-
cluded 65 melanomas and 65 benign pigmented skin lesions that
had been excised to evaluate the ability of MelaFind to accurately
recommend biopsy in pigmented skin lesions. The study sam-
ple was a randomly-selected subset of the consecutively-recruited,
prospective Monheit 2011 population. Differences (95% CI) are
reported in Table 8.
Target Condition: Basal Cell Carcinoma (BCC)
Derm-CAD
Four study populations from referred settings included BCC le-
sions (Cascinelli 1992; Ferris 2015; Menzies 1996; Mollersen
2015); however two did not provide adequate data to derive 2 x
2 data (Menzies 1996; Mollersen 2015) and one included fewer
than the minimum of five lesions to meet our inclusion criteria
for this question (Cascinelli 1992). The remaining study evalu-
ated 11 BCCs amongst 173 dermoscopically atypical lesions using
the output of an unnamed CAD system (CAD-based diagnosis),
in a retrospective case series. Three BCCs were missed, giving a
sensitivity of 73% (95% CI 43.4% to 90.3%) with 108 false pos-
itives, giving a specificity of 33% (95% CI 26.5% to 40.9%) for
the detection of BCC (Ferris 2015). The study used dermoscopic
images of skin lesions excised on the basis of clinical suspicion
of malignancy, and also included melanomas, cSCCs, seborrhoeic
keratosis and benign melanocytic lesions. The very low specificity
was as a result of misclassification of seborrhoeic keratoses (7/11),
low-grade dysplastic naevi (27/47) and lentigo (8/10) asmalignant
lesions.
Spectro-CAD
Two studies evaluated the ability of a Spectro-CAD system to
detect BCC lesions, both using the EIS-CAD Nevisense system
in participants with suspected melanoma referred for excision (
Malvehy 2014; Mohr 2013) (Table 10). Of 2389 analysed lesions,
all 69 BCCs were identified, giving a summary sensitivity of 100%
(95%CI 94.7% to 100%) and very low specificity of 26.3% (95%
CI 24.5% to 28.1%). Since both populations were recruited to
rule out melanoma, few benign keratotic lesions were included
(including lichenoid keratosis (n = 4), seborrhoeic keratosis (n
= 73) and actinic keratosis (n = 8)), a factor which may have
contributed to the very low specificity.
Target condition: cutaneous squamous cell carcinoma
(cSCC)
The only study to evaluate the performance of a CAD system
to detect cSCC used the EIS-based Nevisense system in referred
patients, identifying all seven cSCCs amongst 1943 lesions to give
a sensitivity of 100% (95% CI 64.6% to 100%) and specificity
of 43.4% (95% CI 41.3% to 45.7%) (Malvehy 2014) (Table 10).
The high sensitivity could have been influenced by the study’s
melanoma-focused recruitment selection which resulted in very
few benign different diagnoses being included (lichenoid keratosis
(n = 4), seborrhoeic keratosis (n = 51) and actinic keratosis (n =
8)).
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Secondary target conditions: invasive melanoma
alone
The diagnostic accuracy of CAD assessment for the detection of
invasive cutaneous melanoma alone was reported by seven studies
for a total of 1336 lesions with 236 invasive melanomas.
Of these, two studies evaluated Derm-CAD systems (total 950
lesions with 120 invasive melanomas): SolarScan (Menzies 2005)
and an unnamed system (Menzies 1996), both of which included
model derivation within the same population (Menzies 1996 did
not report the method of dividing lesions into training and test
sets). Both also included pigmented skin lesions referred for exci-
sion (Menzies 1996; Menzies 2005), of which one may have in-
cluded BCCs amongst the target disease-negative group (Menzies
1996 included 18 BCCs in the full study population but did
not report how many were included in the independent test set).
Melanoma prevalence was 10% in Menzies 2005 and 27% in
Menzies 1996. Meta-analysis of these studies provided a summary
sensitivity estimate of 90.8% (95%CI 84.2% to 94.9%) and sum-
mary specificity of 63.5% (95% CI 60.2% to 66.7%) (Table 5).
Menzies 2005 also reported data for the primary target condition,
invasive melanoma and atypical intraepidermal melanocytic vari-
ants, with little difference in sensitivity (92.0% invasive melanoma
only versus 91.0%, 1.0% difference (95%CI−8.7% to 8.2%)) or
specificity (61.5% invasive melanoma only versus 65.1%,−3.6%
difference (95%CI−8.7% to 1.5%)). Despite in situ lesions mak-
ing up 39% (47/122) of disease positives, similar proportions of
in situ (5/47) and invasive lesions (6/75) were missed by the So-
larScan.
OneDerm-CAD study, retrospective and of uncertain design, also
allowed a comparisonwith image-based dermoscopy in 164 lesions
containing 45 invasive melanomas (Menzies 1996). Observer ex-
perience was not reported. Accuracy estimates were similar and
are reported in Table 8.
Five studies evaluated anMSI-CAD system (total 386 lesions with
116 invasive melanomas), regardless of the system make, algo-
rithm used, or whether CAD was used as a stand-alone auto-
mate diagnosis or as a diagnostic aid. All were conducted in le-
sions referred for excision, four solely in pigmented skin lesions
(Ascierto 2010; Bono 1996; Friedman 2008;Hauschild 2014) and
the fifth in any lesion clinically suspected of being a melanoma
(Terstappen 2013). Systems evaluated were MelaFind (Friedman
2008; Hauschild 2014), SpectroShade (Ascierto 2010), Telespec-
trophotometric System (Bono 1996) and SIAscope, version V
(Terstappen 2013).
Sensitivities ranged from 24% (Terstappen 2013) to 100%
(Friedman 2008), and specificities from 29% (Friedman 2008) to
84% (Terstappen 2013). The study producing the highest sensi-
tivity and lowest specificity (Friedman 2008) excluded all high-
grade dysplastic lesions and therefore included only melanomas,
BCCs (n = 2), low-grade dysplastic naevi (n = 32) and other be-
nign melanocytic lesions (n = 14). The lowest sensitivity and high-
est specificity were produced by Terstappen 2013, who further se-
lected their population of clinically suspicious lesions to include
only lesions with a positive CAD result (SIAscope). Both datasets
that evaluated the MelaFind system (Hauschild 2014; Friedman
2008) generated high sensitivities (81% and 100%) and low speci-
ficities (39% and 29%). These five studies (386 lesions including
116 invasive melanomas) gave a summary sensitivity estimate of
76.5% (95% CI 43.0% to 93.3%) and summary specificity of
60.7% (95% CI 38.5% to 79.2%) (Figure 20; Figure 21; Table
5).
Figure 20. Forest plot of different types of multi-spectral imaging CAD system (MSI-CAD) for the detection
of invasive melanoma alone (invasive melanoma)
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Figure 21. Summary plot of different types of multi-spectral imaging CAD (MSI-CAD) for the detection of
invasive melanoma alone (invasive melanoma)
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In sensitivity analyses, we excluded one study that used CAD as a
diagnostic aid, in a referral setting (Hauschild 2014). The results
of the sensitivity analysis are shown in Appendix 8. The results
indicate very similar findings to the main analysis.
One study comparedMSI-CAD (MelaFind) to diagnosis by expert
dermoscopists using dermoscopic images in 99 lesions including
21 invasive melanomas, finding Melafind’s sensitivity to be higher
(100% versus 81%) and specificity lower (29% versus 45%) than
dermoscopy (Friedman 2008) (Table 8).
One other study compared MSI-CAD (SpectroShade) to face-
to-face diagnosis by expert dermatologists in 54 lesions with 12
invasive melanomas, finding SpectroShade’s sensitivity to be lower
(67% versus 100%) and specificity higher (76% versus 45%) than
dermoscopy (Ascierto 2010) (Table 8).
The two studies evaluating the EIS-based Nevisense system
produced accuracy data for 2389 lesions with 226 invasive
melanomas, giving a summary sensitivity of 98.2% (95% CI
95.4% to 99.3%) and specificity of 38.0% (95% CI 36.0% to
40.1%) (Malvehy 2014; Mohr 2013) (Table 5).
A single study contributed data for the accuracy of detecting in-
vasive melanoma in an unreferred setting, reporting the use of
MoleMate with SIAscope by GPs in 766 lesions with 14 invasive
melanomas (Walter 2012). No melanomas were missed: sensitiv-
ity 100% (95% CI 78.5% to 100%); although false-positive find-
ings were high, giving a specificity of 71.7% (95% CI 68.4% to
74.8%) (Table 7).
Secondary target conditions: any lesion requiring
excision
Derm-CAD
Four datasets from three studies (Cascinelli 1992; Ferris 2015;
Mollersen 2015) provided data to evaluate the accuracy of Derm-
CAD to detect any skin cancer or other atypical lesion requir-
ing excision in referred settings. Two were retrospective deriva-
tion studies using stored dermoscopic images to train either the
Skin View system in clinically suspect pigmented skin lesions re-
ferred for excision (Cascinelli 1992), or an unnamed system in
lesions suspected of malignancy also referred for excision (Ferris
2015). The third study conducted a head-to-head external vali-
dation comparison of two systems, in a case series of pigmented
and nonpigmented (if melanoma, BCC, or SCC was a potentially
different diagnosis) skin lesions scheduled for excision (Mollersen
2015). The Nevus Doctor system was the subject of evaluation as
a system still in development, being compared against the com-
mercially availableMole Expert. The three studies provided a total
of 1087 lesions, with the 186 malignancies including 83 BCCs,
9 cSCCs and 1 adnexal carcinoma (Mollersen 2015). Sensitivities
were high, ranging from83% (Cascinelli 1992) to 98% (Mollersen
2015, Nevus Doctor), while specificities were low and more var-
ied ranging from 12% (Mollersen 2015 Nevus Doctor) to 59%
(Cascinelli 1992). The lowest specificities (Nevus Doctor 12%,
Mole Expert 13%) were produced by the study with the lowest
disease prevalence (14%, Mollersen 2015). Mollersen 2015 also
produced the highest sensitivity and was the only study to include
clinically obvious melanomas amongst its lesions.
These accuracy estimates did not differ substantially from those for
the detection of the individual target conditions reported above.
No data were available to compare these results with the use of
standard dermoscopy to detect any skin cancer.
Spectro-CAD
Two datasets evaluated the performance of DRS-CAD systems
in referred settings, both from one study (Garcia Uribe 2012)
evaluating the performance of the Oblique Incidence Diffuse Re-
flectance Spectrometry (OIDRS) system in two cohorts of lesions
(i.e. CAD algorithms trained separately in each cohort). Amongst
136 pigmented skin lesions including 25 lesions to be excised (10
melanoma, 15 severe dysplastic lesions) OIDRS gave a sensitivity
of 92% (95% CI 74.0% to 98.8%) and specificity of 86% (95%
CI 78.9% to 91.6%). Amongst 89 non-pigmented skin lesions
including 64 lesions to be excised (39 BCC, 25 cSCC) OIDRS
gave a sensitivity of 92% (95% CI 83.0% to 96.6%) and speci-
ficity of 92% (95% CI 74.0% to 98.8%). However, caution must
be used to interpret these estimates, as the spread of disease was
different from that intended by our target condition definition
of all malignancies: no malignancies other than melanoma were
included in the pigmented population, and no melanomas were
included in the non-pigmented population.
The twoEIS-CADstudies conducted in referred settings produced
accuracy data for 2389 lesions with 644 malignancies or highly
dysplastic lesions, giving a summary sensitivity of 93.5% (95%
CI 91.3% to 95.1%) and specificity of 32.6% (95% CI 30.4%
to 34.8%) (Malvehy 2014; Mohr 2013) (Table 5). In addition to
the malignancies described above, one Merkel cell carcinoma was
included (Malvehy 2014) and detected by Nevisense.
Two datasets provided data for the use of MSI-CAD in unreferred
settings (Sgouros 2014; Walter 2012) (Table 7). While both used
a SIAscope™ device, Walter 2012 used the MoleMate analysis
system incorporating the Primary Care Scoring Algorithm to anal-
yse lesion images and arrive at a diagnosis (Walter 2012), while
Sgouros 2014 also used the Primary Care Scoring Algorithm but
did not report how imageswere interpreted. Sensitivitywas slightly
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higher inWalter 2012 (92.0% versus 83.9% in Sgouros 2014) and
specificity substantially so (72.5% versus 46.2% Sgouros 2014).
In addition to the probable use of different analysis software, this
difference is likely explained by two factors: firstly CAD test re-
sults were used in different ways, as a diagnostic aid to GPs (af-
ter a period of training) by Walter 2012, and as the diagnostic
output for a CAD-based diagnosis in Sgouros 2014. Second, our
exclusion of 144 benign cases with no reference standard diagnosis
from Sgouros 2014 has created a highly selected (excised only) and
unrepresentative study population in this study (low sample size,
n = 44, and high prevalence of malignancy, 70%). Of the 153 le-
sions considered benign after clinico-dermoscopic assessment (of
which nine were later excised), 122 were diagnosed as naevi, 23 as
seborrhoeic keratoses, seven as dermatofibroma and one as cherry
angioma. SIAscopy gave a negative score (< 6) in 100 of these 153
lesions.
D I S C U S S I O N
Summary of main results
Computer-assisted diagnosis has been evaluated using awide range
of computer systems that analyse lesion images obtained by digital
dermoscopy, lesion images obtained by multispectral imaging, or
that analyse non-visual data from electrical impedance or diffuse
reflectance spectroscopy. These computer systems have used a va-
riety of classification algorithms to scrutinise a diverse selection of
features. CAD sensitivity estimates were generally high, although
with highly variable specificity.
We present six main findings from our review:
1) Included studies inadequately address the review
question due to an abundance of low-quality studies,
poor reporting, and recruitment of highly selected
groups of participants
This review aimed to assess the accuracy of computer-assisted
diagnosis for detecting melanoma, BCC or cSCC in adults.
Most included studies focused on its use for detecting or ruling
out melanoma in lesions scheduled for excision. These studies
therefore do not reveal CAD’s ability to detect clinically missed
melanomas, since most have excluded lesions clinically diagnosed
as benign. Only three studies, all of Derm-CAD systems, exam-
ined lesions not recommended for excision (and thus potentially
missed melanomas) using an adequate reference standard in clin-
ically benign lesions.
Studies were poorly reported and generally at unclear to high risk
of bias across all domains, particularly for the selection of study
participants, the timing of CAD diagnosis in relation to the refer-
ence standard diagnosis, and prespecification of CAD thresholds.
Most studies used restricted groups of participants and failed to
provide details of diagnostic thresholds sufficient for their repro-
ducibility, leading to an almost universally poor clinical applica-
bility of studies.
Poor reporting in the primary studies also hindered attempts to
assess sources of heterogeneity, particularly for the lack of report-
ing CAD results according to the final diagnosis. A substantial
number of included studies (half of Derm-CAD studies and a
third of Spectro-CAD studies) evaluated experimental versions
of CAD systems, in which classification algorithms were trained
alongside preliminary assessments of test performance within the
same source population. The frequency of these internal validation
studies causes high concern for the reliability of accuracy estimates,
chiefly because models are likely to give overly optimistic results
when training and testing datasets are very similar in the spread of
lesion types and severity, as is the case when the same source popu-
lation is used (Altman 2009). In addition, great caution should be
used when considering the applicability of these results to current
clinical practice, since the generalisability of a newmodel can only
be estimated in external validation studies that recruit new groups
of patients from entirely new source populations.
Most study populations were restricted to excised lesions. Since le-
sions which are not excised are more likely to be benign, and with-
out an atypical morphological pattern that could be mistaken for
a malignancy, their absence from datasets may have reduced CAD
specificity estimates from their likely performance in populations
where CAD tests would be used in clinical practice, namely those
being referred for specialist assessment. Including the appropriate
spectrumof benign conditions is key to establishing the accuracy of
any test (Lijmer 1999). Spectrum effects are often observed when
tests that are developed further down the referral pathway have
lower sensitivity and higher specificity when applied in settings
with participants with limited prior testing (Usher-Smith 2016).
However, this direction of effect is not consistent across tests and
diseases, as Leeflang 2013 clearly demonstrates; the mechanisms
in action are often more complex than prevalence alone and can
be difficult to identify. It is therefore crucial that tests are evaluated
in lesions that are representative of those in which the test will be
used in practice. For tests such as CAD that use machine learning,
a representative patient population is vital both for training the
algorithm and for testing its validity. If a narrow range of benign
conditions is used to train a computer algorithm, the resulting
CAD system is likely to struggle in discriminating new, previously
unseen benign lesions at the validation stage. Unfortunately, very
poor reporting of the spectrum of conditions included in studies
prevents any assessment of whether mismatches have occurred be-
tween training and validation populations.
Limited data about the use of CAD as a diagnostic aid further
limits the applicability of study results. Although CAD systems
are designed to be used as diagnostic aids, most studies did not
evaluate how CAD outputs were interpreted and acted upon by
clinicians in their diagnostic decision-making, but instead evalu-
ated the accuracy of the CAD system outputs as stand-alone tests.
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2) CAD systems correctly identify melanoma in highly
selected populations, but their low and very variable
specificity suggest they are unreliable as stand-alone
diagnostic tests, especially in less selected populations
Reflecting the design aims of systemdevelopers, almost all the stud-
ies sought to evaluate the ability of CAD to identify melanomas.
Summary of findings presents key results for the primary target
condition of cutaneous invasive melanoma or atypical intraepider-
mal melanocytic variants. For digital dermoscopy CAD systems,
pooled results from 22 studies (8992 lesions, 1063 melanomas)
provided a sensitivity of 90.1% (95% CI 84.0% to 94.0%) and
specificity of 74.3% (95% CI 63.6% to 82.7%). Summary of
findings illustrates how these estimates would affect diagnoses in
a hypothetical cohort of 1000 lesions clinically suspected of be-
ing melanomas. At the median melanoma prevalence of 20% that
might occur in a highly specialised melanoma referral clinic, dig-
ital dermoscopy CAD systems would on average miss 20 out of
200 melanomas and would result in 206 false-positive diagnoses.
At the lower and upper quartile melanoma prevalence of 7% and
40%, 7 and 40 melanomas would be missed, with 239 and 154
false-positive diagnoses respectively.
For multispectral imaging CAD systems, pooled results from eight
studies (2401 lesions, 286 melanomas) provided a sensitivity of
92.9% (95% CI 83.7% to 97.1%) and specificity of 43.6% (95%
CI 24.8% to 64.5%). In a hypothetical cohort of 1000 lesions
clinically suspected of being melanomas with melanoma preva-
lence of 20%, MSI-CAD systems would on average miss 14 out of
200 melanomas and would result in 451 false-positive diagnoses
(Summary of findings). At the lower and upper quartile melanoma
prevalence of 7% and 40%, 5 and 28melanomas would bemissed,
with 525 and 338 false-positive diagnoses respectively.
These results demonstrate a consistently high sensitivity for
the detection of invasive melanoma and atypical intraepidermal
melanocytic variants by CAD, regardless of type (Derm-CAD
versus Spectro-CAD). However, specificity tends to be low and
varies considerably between studies, particularly for MSI-based
systems. The evidence certainly indicates that some benign le-
sions are more difficult to distinguish frommalignancy using both
Derm-CAD and Spectro-CAD systems, particularly seborrhoeic
keratoses which proved problematic for Derm-CAD and EIS-
CADsystems.However the reporting of benigndiagnoses byCAD
result was very poor, and omitted in 29 of the 42 included stud-
ies. As a result, the performance of MSI-CAD systems for these
lesions remains uncertain. This difficulty in ruling melanoma out
from seborrhoeic keratoses is also encountered when visual exam-
ination and dermoscopy are employed, and for CAD systems is
equally likely to be due to similarities in themorphological appear-
ance of these non-melanocytic pigmented lesions and melanomas
(Menzies 2005; Mollersen 2015).
Poor reporting of other aspects of study conduct also limit our
interpretation of the heterogeneity in specificity, but likely causes
include a wide variation in the spread of disease-negative condi-
tions included in study populations (both for training algorithms
and for validating them), as well as considerable variation in CAD
system characteristics.
3) There is insufficient evidence to assess the
accuracy of CAD systems in primary-care settings
Insufficient data were available from primary-care populations to
draw firm conclusions, particularly for Derm-CAD, with only one
included study which restricted inclusion to excised lesions only.
For MSI-CAD, we found some suggestion of high sensitivity, al-
though the evidence base was limited to two studies evaluating dif-
fering target conditions and with differing approaches to the use of
CAD results (CAD-based versus CAD-aided diagnosis). Limiting
study populations to excised lesions is particularly problematic in
such settings, since the frequency and distribution of disease is far
removed from the range one would expect to see in patients who
have received limited prior testing, such as those self-referring to
specialist pigmented lesion clinics. Only one study examined all
individuals presenting to generalist settings that had lesions which
could not immediately be diagnosed as benign (Walter 2012). A
second study also included all such lesions (Sgouros 2014), but
failed to provide non-excised lesions with any clinical follow-up
and so these lesions had to be excluded from our analysis.
4) Preliminary findings suggest CAD systems are at
least as sensitive as assessment of dermoscopic
images for the diagnosis of invasive melanoma and
atypical intraepidermal melanocytic variants
MSI-CAD was significantly more sensitive than image-based der-
moscopy (92.9% versus 74%, P = 0.003), while direct compar-
isons indicate that it is also significantly less able to rule out truly
benign lesions (29.8% versus 58.7%, P = 0.039). However indi-
rect comparisons did not confirm this difference (43.6% versus
58.7%, P = 0.26) (Table 6). Conversely, our evidence suggests
Derm-CAD may not differ significantly from dermoscopy in its
ability to identify melanomas. However, we caution against draw-
ing firm conclusions from these comparisons in the absence of suf-
ficient data from studies evaluating face-to-face dermoscopy, on
the basis that another review in this series has found such studies
to demonstrate significantly higher accuracy for dermoscopy than
those relying on review of dermoscopic images (Dinnes 2018b).
5) The evidence base for individual systems is too
limited to draw conclusions on which might be
preferred for practice
Despite the large number of included studies, the evidence base
for the accuracy of individual systems to detect the primary target
condition of the detection (invasive melanoma and atypical in-
traepidermal melanocytic variants) remains low, with meta-analy-
sis possible for only two Derm-CAD systems (DB-MIPS and Skin
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View), one MSI-CAD system (MelaFind) and one EIS-CAD sys-
tem (Nevisense). Only one of these, DB-MIPS, demonstrated a
high specificity (89.1%) alongside high sensitivity (95.2%). Even
though they evaluated the same CAD system, the six studies that
we pooled for this estimate of DB-MIPS were very varied in the
classification algorithm used (ANN, SVM, K-NN, discriminant
analysis, Euclidean distances), disease prevalence (5% to 45%), use
of CAD results (two studies evaluated DB-MIPS as a diagnostic
aid and four evaluated the DB-MIPS computer output) and range
of disease-negative conditions included (poorly reported, with a
mixture of common naevus, dysplastic naevus, and only one study
including seborrhoeic keratoses). The clinical settings to which
this estimate applies therefore remain unclear.
We observed considerable variation in test characteristics across all
CAD systems, such as hardware and software technologies used,
the types of classification algorithm employed, methods used to
train the algorithms, andwhich lesionmorphological features were
extracted and analysed. Wide variations in technology specifica-
tions were observed even within the same CAD systems; for ex-
ample, the four studies evaluating the SIAscope (a commercially
available MSI-CAD system) captured between four and eight op-
tical reflectance images at varying wavelengths to inform the fi-
nal image (not reported in two studies), using different SIAscopes
(versions II and V, not reported in two studies) coupled to differ-
ent software programmes (the MoleMate™ in two studies, and
not reported in two studies) using two different thresholds (the
Moncrieff 2002 and Emery 2010 methods). We noted this vari-
ation in CAD method, alongside limited reporting of important
technological variables, in all CAD systems evaluated in this re-
view.
6) Evidence of the ability of CAD to detect
keratinocyte cancers is very limited and studies are
confined to specialist settings
Only three studies included sufficient numbers of BCC cases for
analysis; the one small retrospective study evaluating Derm-CAD
is insufficient to draw any conclusions. For EIS-CAD, the two
large prospective studieswere designed to evaluateNevisense’s abil-
ity to detect melanoma, so that neither recruited populations clin-
ically applicable for keratinocyte cancer detection, casting doubt
on the generalisability of pooled estimates to clinical practice. Sim-
ilarly, evidence for the accuracy of cSCC detection is limited to
one Nevisense study, of unlikely clinical applicability to the target
condition.
Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehen-
sive electronic literature search, systematic reviewmethods includ-
ing double extraction of papers by both clinicians and methodol-
ogists, and contact with authors to allow study inclusion or clarify
data. We adopted a clear analysis structure focusing on estimat-
ing incremental gains in accuracy, and undertook a detailed and
replicable analysis of methodologic quality.
In comparison with the four main existing systematic reviews,
our review extends the time period searched for eligible studies
(from 2002 in Rosado 2003, from 2007 in Rajpara 2009 and
Vestergaard 2008, and from 2011 in Ali 2012), includes all eligible
studies regardless of language (Ali 2012; Rosado 2003), the pres-
ence of melanocytic lesions (Rajpara 2009), or use of a histologi-
cal reference standard (Rajpara 2009). Although Vestergaard 2008
reviewed studies evaluating multispectral imaging CAD, electri-
cal impedance spectroscopy CAD, and digital dermoscopy-based
CAD systems, ours is the first review to meta-analyse data and
provide pooled accuracy estimates for each of these three types of
CAD system. Ours is also the first review to include keratinocyte
cancers as a target condition.
Our stringent application of review inclusion criteria meant that
we excluded some studies included in previous reviews. For exam-
ple, we did not include those developing CAD systems and train-
ing new algorithms (‘derivation studies’) without assessing their
performance in an independent population. Of the 30 studies
included in Rosado 2003, we excluded 23, including 17 deriva-
tion studies without independent test sets (16 Derm-CAD studies
(Andreassi 1999; Binder 2000; Elbaum 2001; Ercal 1994; Ganster
2001; Green 1991; Green 1994; Hintz-Madsen 2001; Horsch
1997; Kahofer 2002; Pompl 2000; Rubegni 2001a; Sboner 2001;
Schindewolf 1994; Schmid-Saugeon 2003; Smith 2000) and one
MSI-CAD study, Farina 2000). We excluded three others for lack
of clarity on the 2 x 2 contingency table (Schindewolf 1993), eval-
uating the diagnostic ability of a single feature (shape, Claridge
1992), and unclear reporting on CAD type and eligibility of the
reference standard (Lefevre 2000). Two others were conference ab-
stracts, and so were not eligible for analysis. Of the 12 Derm-CAD
studies included in Rajpara 2009, we excluded four derivation
studies without independent test sets (Green 1994; Manousaki
2006; Rubegni 2002b; Sboner 2001). Similarly, we excluded four
of the nine Derm-CAD studies in Ali 2012, due to the absence of
independent test sets in derivation studies (Iyatomi 2006; Iyatomi
2008a; Iyatomi 2008b; Iyatomi 2010a), and another that did not
evaluate diagnosis of the presence of skin cancer (Abbas 2011a).
Vestergaard 2008 also required studies to evaluate CAD systems in
an independent test set, and we consequently excluded only one of
the nine studies included in Vestergaard 2008, due to the absence
of a reference standard test in selected participants (Jamora 2003).
Our stringent exclusion of studies without an independent test
population has resulted in the exclusion of all studies evaluating
non-imaging diffuse reflectance spectroscopy (DRS) systems (e.g.
Wallace 2002). This class of technologies used high spectral sam-
pling to achieve a much higher resolution of spectral information
from pigmented skin lesions than is found in the included DRSi
(multispectral imaging) studies, giving an apparently strong per-
formance for the detection of melanoma (Wallace 2000a; Wallace
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2000b). We cannot assess in this review whether these promising
results were overoptimistic due to their study design, or are gen-
uine indicators of diagnostic capability. However, as technology
improves we are likely to see systems with both imaging capabil-
ity and high spectral sampling, making further carefully planned
evaluation worthwhile.
The main concerns for the review are a result of the poor report-
ing of primary studies, limiting our assessment of methodologi-
cal quality, and in particular limiting an understanding of which
malignant and benign conditions were correctly and incorrectly
identified by the CAD systems. The poor reporting is of partic-
ular concern, given the clear heterogeneity in all aspects of study
design, and consequently the clinical applicability of results is dif-
ficult to determine. Poor reporting also precludes identification
of those studies that may have been well designed, but did not
document their design and conduct adequately.
Clear identification of the target condition was not provided in
nine of the 22 Derm-CAD datasets or in four of the eight MSI-
CAD datasets included in our primary analyses for detection of
invasive melanoma or atypical intraepidermal melanocytic vari-
ants. These studies may or may not have included melanoma in
situ lesions. Where studies included other invasive skin cancers
in the study population, we tried to class any that were correctly
identified as true negative results as opposed to false positives, on
the basis that removal of any skin cancer in the attempt to identify
melanomas would not be a negative consequence of the test. This
relied on studies providing a disaggregation of test results accord-
ing to final lesion classification and was not always possible.
Our review is limited to studies published up to August 2016,
and since computer-assisted diagnosis is a rapidly developing field
of technology, the review will have missed some important and
more recent developments in the field of machine learning with
an application to the detection of skin cancer. Deep learning al-
gorithms (Esteva 2017; Han 2018) are one example where recent
advances in computation have been applied to the development
of new CAD systems for the detection of skin cancer. In future,
it is also probable that CAD systems using continuous machine
learning algorithms (where the CAD model continues to refine
itself with exposure to clinical cases) will be developed.
Applicability of findings to the review question
Most of the data included in this review are unlikely to be applica-
ble to the current clinical settings of primary care and dermatology
clinics that exist in many high-income countries. The predomi-
nance of highly selected lesion groups, scarce documentation of
prior testing and frequency of internally validated derivation stud-
ies are likely to restrict the applicability of accuracy estimates to
clinical practice. Poor documentation of the final diagnoses used
to train CAD systems prevents any conclusion about the ideal
target patient group, while very limited reporting of CAD results
by final diagnosis does not allow us to make clear statements re-
garding the expected accuracy of different CAD systems, further
restricting the transferability of results in practice.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The utility of CAD for the primary diagnosis of melanoma in
patients referred to specialist care remains largely unknown, since
most included studies usedCADtodetectmalignancy in lesions al-
ready scheduled for surgical excision, most commonly with a high
clinical suspicion of melanoma. For the detection of melanoma in
people with clinically suspicious lesions, the evidence consistently
shows all CAD types to have high sensitivity. CAD systems could
therefore be useful as a back-up by specialists to assist in minimis-
ing the risk of missing melanomas. However, the evidence base is
currently too poor to understand whether CAD system outputs
translate to different clinical decision-making in practice, and our
sensitivity analysis suggests sensitivity may actually decrease when
CAD is used as a diagnostic aid to triage unreferred patients. In
addition, any projected gains in the early detection of melanomas
must be set against the costs and practicality of implementing new
systems.
Our evidence suggests MSI-CAD may be significantly more sen-
sitive than dermoscopy. Given the paucity of data to allow com-
parison with in-person dermoscopy studies, this finding should be
considered as exploratory.
Insufficient data are available to provide conclusive comments on
the accuracy of CAD in community settings, or its accuracy to
detect BCC and cSCC in any setting.
Implications for research
Further prospective evaluation of the added value of CAD systems
is warranted. Given the technological complexity and variation of
CAD systems, it is certainly challenging to evaluate them in a rig-
orous manner. Nonetheless, studies are needed to evaluate CAD
in its intended position in the patient care pathway in compari-
son to routine clinical examination and dermoscopy. For its use
in specialist referral settings, studies should prospectively recruit
all consecutive participants that have been referred for investiga-
tion of potential malignancy; for melanoma this should include
all pigmented skin lesions, and for keratinocyte cancers any le-
sion suspected of being a BCC or cSCC. These studies should
include lesions that are clinically determined to be benign and not
excised, using specialist follow-up of at least six months as the ac-
curacy reference standard. Comparisons with dermoscopy should
consist of in-person diagnosis by dermatologists with expertise in
dermoscopy. In community-care settings, studies should prospec-
tively recruit all participants presenting to clinic with lesions for
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which the clinician cannot clearly rule out malignancy, with clin-
ical follow-up of all lesions which are not excised. To understand
the clinical validity of CAD systems, studies should further eval-
uate how CAD system outputs are used to alter clinical decision-
making in real-world practice settings.
Future studies must also report CAD test results according to their
final diagnosis, so that its ability to distinguish between morpho-
logically difficult lesions can be established. Crucially, studiesmust
report the full technological specifications of their CAD systems,
including which features were analysed as well as the diagnostic
criteria and thresholds used to determine the presence of malig-
nancy. Information on the distribution of lesions used to train the
CAD system in previous studies would also be a welcome addition
that would enable an interpretation of the system’s accuracy.
In terms of the development of new systems, or refinement of ex-
isting ones, cohorts of lesions should be selected so that training
sets contain the range of benign and malignant lesions that would
be encountered in routine clinical practice. Full descriptions of
included lesions should be reported, together with an indication
of how diagnostic thresholds have been selected. Validation of pre-
liminary results should be assessed in independent populations,
ideally from a different source from that used for model develop-
ment.
Any future research study needs to be clear about the diagnos-
tic pathway followed by study participants, and should conform
to the updated Standards for Reporting of Diagnostic Accuracy
(STARD) guideline (Bossuyt 2015).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ascierto 2010
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective
Period of data collection: Not reported (states in a period of 1 year)
Country: Italy
Test set derived: The training set consisted of 78 PSL images, comprising 19 MMs and 59 naevi of
comparable size. The test set consisted of 383 lesions, including 18 MMs thinner than 0.75 mm (8
in situ). The 59 naevi belonging to the training set were randomly selected from routine material,
whereas the 424 naevi of the test set represented consecutive cases
Patient characteristics and set-
ting
Inclusion criteria: Clinically-relevant cutaneous pigmented lesions, undergoing dermoscopy and
excision; onlymelanocytic lesionsmeeting at least 2 clinical ABCDE criteria underwent dermoscopy
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (participants): N eligible: 54/ N included: 54
Sample size (lesions): 54
Participant characteristics
Age (yrs):
- Median: 41/ Range: 19 - 73 years
Gender: Male: 19 men
Lesion characteristics: NR
Index tests Dermoscopy
Method of diagnosis: In-person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Qualitative - very high risk - lesion with a pigment network and any of the
classical ELM features specific for melanoma (pseudopods, radial streaming, blue-gray veil, atypical
vessel, etc). High risk - lesion with a pigment network and subtle new ELM features that may suggest
melanoma but often are also seen in atypical naevi
Diagnosis based on: Unclear, NR; evaluations made by expert dermatologists
Number of examiners: NR
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users ’expert dermatologists’
Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: SpectroShade (MHT, Verona Italy) (classifier not reported)
System details:
The system provides information including a series of 15 multispectral images into the near-infrared
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Ascierto 2010 (Continued)
bandwidth. 3 spectral areas play a major role in quantification of parameters: 584 nm, 650 - 750
nm, 750 - 950 nm
No derivation aspect (external validation study)
Lesion characteristics assessed: 7 parameters: mean reflectance (MR); variegation (V); area (A);
dark area ratio (DAR); dark island reflectance, DA; dark distribution factor (DDF)
Additional predictors included:
No further information used
Method of diagnosis:
In-person diagnosis
CAD-based diagnosis
Prior/other test data:
Clinical examination or case notes, or both
Dermoscopy
CAD output:
Diagnostic category: 1 no melanoma, 2 doubtful melanoma, 3 suspected melanoma, 4 probable
melanoma
Diagnostic threshold:
Threshold not reported
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Disease-positive: 12 MM; Disease-negative: 42
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 12
’Benign’ diagnoses: 42
Flow and timing No exclusions reported
Time interval to reference test: “Before surgery, all patients were investigated by clinical and
epiluminescence microscopy (ELM) screenings”
Time interval between index test(s): As above
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Ascierto 2010 (Continued)
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Was an adequate spectrum of
cases used to train the algo-
rithm?
No
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 2: Index Test Dermoscopy
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Ascierto 2010 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
78Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ascierto 2010 (Continued)
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Barzegari 2005
Study characteristics
Patient sampling Study design: Case series
Data collection: NR
Period of data collection: NR
Country: Iran
Patient characteristics and set-
ting
Inclusion criteria: Pigmented skin lesions with a clinical diagnosis of melanocytic lesion≤ 15 mm
diameter referred to dermatology clinic for diagnostic evaluation or cosmetic reasons
Setting: Secondary (general dermatology)
Prior testing:
Clinical suspicion of malignancy without dermatoscopic suspicion
Participant request for evaluation/excision
Setting for prior testing: NR
Exclusion criteria: > 15 mm
Sample size (participants): N included: 91
Sample size (lesions): N included: 122
Participant characteristics
Age (yrs):
Mean: 32.3/ Range: 6 - 94
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Barzegari 2005 (Continued)
Gender: Male: 30; 33%
Lesion characteristics: NR
Index tests Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD: microDERM (DANAOS software, ANN classifier)
System details:
“The system consists of a special camera, which had ability to take images at ×15, ×20, ×30, and ×50
magnifications and contains a 752 × 582 pixel charge coupled device. The image analysis software
was Visiomed AG (Ver. 3.50) based on an ANN that was trained using images collected in a Europe-
wide multicentre study (DANAOS)”
No derivation aspect (external validation study)
Lesion characteristics assessed:
Lesion features analysed not described
Additional predictors included:
No further information used
Method of diagnosis:
In-person diagnosis
CAD-based diagnosis
Prior/other test data:
Clinical examination or case notes, or both
CAD Output:
The software produces a score per lesion ranging from 0 to 10
Diagnostic threshold:
2 x 2 data for more than one diagnostic threshold
Threshold determined based on ROC analysis; threshold chosen on basis of similarity to other
microDERM studies: 7.34
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Disease-positive: 6; Disease-negative: 116
Target condition (Final diagnoses)
Melanoma (invasive): 3; Melanoma (in situ): 3
Sebhorrheic keratosis: 2; Benign naevus: 104; Dysplastic naevus 7; DF 1 AK
Flow and timing Excluded participants: None
Time interval between index test(s): Consecutive
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Barzegari 2005 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Was an adequate spectrum of
cases used to train the algo-
rithm?
Low High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
No
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Barzegari 2005 (Continued)
ously published study?
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
82Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bauer 2000
Study characteristics
Patient sampling Study design: Case series
Data collection: NR. Appears retrospective? But refers to a “campaign for the early diagnosis of
cutaneous melanoma (CM) by three dermatologists according to the ABCD system and using ELM
evaluation” (Stanganelli 1995)
Period of data collection: January 1996 to February 1997
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: “Pigmented skin lesions examined during a campaign for the early diagnosis of
cutaneous melanoma (CM)”
Setting: Secondary (general dermatology) from authors’ institution
Prior testing: NR; “campaign for the early diagnosis of cutaneous melanoma (CM)”
Setting for prior testing: NR
Exclusion criteria: None reported
Sample size (participants): N included: 311
Sample size (lesions): N included: 315
Participant characteristics: NR
Lesion characteristics NR
Thickness/depth: 14 < 0.75 mm, 10 0.75 - 1.5 mm, and 6 > 1.5 mm (n = 42 melanoma)
Index tests Dermoscopy
No algorithm, possibly Pattern analysis
Method of diagnosis: In-person diagnosis
Prior test data: Clinical examination or case notes or both
Diagnostic threshold:
Qualitative - Presence of malignancy; threshold not detailed but ELM parameters included irregular
and multicomponent pigmentary network pattern, peripheral dark network patches, sharp network
margin, pseudopods, radial streaming, blue-grey areas, pigment dots (blotches, black dots, brown
globules), black dots at periphery, whitish veil, depigmentation and hypopigmented areas, erythema,
telangiectasia, comedo-like openings, milia-like cysts, red-blue areas. (ABCD appears to related to
naked eye exam)
Diagnosis based on: Consensus (3 observers) “the evaluation was uniform as the diagnosis was
made by consensus amongst the dermatologists (Stanganelli 2005). When they disagreed a fourth
dermatologist, an expert in the diagnosis of PSLs, was consulted.”
Number of examiners: 3
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described
Any other detail: The dermatologists had all been trained in the recognition of PSLs during a training
course on the clinical diagnosis of naevi and melanomas
Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: DB-MIPS (Biomips engineering, Italy) (ANN classifier)
System details: DBDermoMIPS (Dell’Eva-Burroni), “which consists of a stereomicroscope (mag-
nification ranging from 36 to 340), a high-resolution 3CCD RGB video camera and a 486/33 MHz
personal computer equipped with a 300 Mb hard disk and 16 Mb of RAM. The digital images of
the lesions, shown on a second RGB video monitor, are framed at 768 3 576 true colour pixels and
saved onto a 230 Mb magneto-optic removable disk”
Derivation aspect (study type)
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Bauer 2000 (Continued)
Lesion characteristics assessed:
“Once the borders of the lesion have been automatically detected, the system evaluates 38 variables
(grouped into geometries, colours and Burroni’s islands of colours). Suspect areas of the lesion are
highlighted by means of a proper algorithm called ‘Burroni’s islands filter’ based on a local histogram
equalisation to produce a new enhanced image in which the darker areas have been enhanced and
the shades in the green-blue dominant areas (when present) are more evident”
Additional predictors included:
No further information used
Method of diagnosis:
Dermoscopic images
CAD-aided diagnosis (test operator not reported)
Prior/other test data:
No further information used
CAD output:
Diagnosis suggested (e.g. melanoma, benign melanocytic naevus)
Diagnostic threshold:
Threshold not reported
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Disease-positive: 42; Disease-negative: 273
Target condition (Final diagnoses)
Melanoma (invasive): 30; Melanoma (in situ): 12
Severe dysplasia: 25 ’atypical’ dysplastic; 212 benign naevus; 36 nonmelanocytic (SK, thrombosed
angioma)
Flow and timing Excluded participants: None reported
After dermoscopy and CAD, all lesions excised and examined histologically
Time interval between index test(s): Consecutive
Time interval to reference standard: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Bauer 2000 (Continued)
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
Low Unclear
DOMAIN 2: Index Test Dermoscopy
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Bauer 2000 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
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Bauer 2000 (Continued)
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Binder 1994
Study characteristics
Patient sampling Study design: Case-control
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: NR
Country: Austria
Test set derived: From a sample of 200 PSLs, 2 databases were randomly created for learning and
testing purposes. The database was also provided with the histological diagnosis
Patient characteristics and set-
ting
Inclusion criteria: Images of PSLs randomly selected from a PSL image database
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: NR
Exclusion criteria: None reported
Sample size (participants): NR
Sample size (lesions): 200 included (100 test set)
Participant characteristics:
Lesion characteristics: NR
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Binder 1994 (Continued)
Index tests Dermoscopy
(Modified) pattern analysis
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Qualitative -
Diagnosis based on: Consensus (2 observers)
Number of examiners: 3
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users
Any other detail: “The images were obtained by photographing the PSL on 24 x 36 mm colour
slide film, with oil immersion, using a Wild binocular stereomicroscope M 650 (Wild Heerbrugg
AG, Switzerland) at a final magnification of x16 using flashlight illumination.”
Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: name not reported (ANN classifier)
System details:
Computer analysis of stored images captured using digital stereomicroscope
Derivation study (internal validation)
Approach to feature selection: “An input layer of nodes represented external data (ELM charac-
teristics), an output layer represented the class identity (diagnoses). The network processed data by
accepting input patterns (the value 0 for ”ELM criterion not present“) and the value 1 for ”ELM
criterion present“ into the input layer.During the learning process each input pattern (ELMpattern)
had a known output pattern (histological diagnosis as the gold standard of truth) the network was
expected to produce”
Lesion characteristics assessed:
Features analysed as present or absent (pattern analysis): Pigment network, brown globules, radial
streaming, pseudopods, black dots, margin, pigmentation, depigmentation
Additional predictors included:
Unclear
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data:
NR
CAD output:
NR
Diagnostic threshold:
Threshold not reported
Target condition and reference
standard(s)
Reference standard Histological diagnosis alone
Disease-positive: 40; Disease-negative: 60
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 40
Benign naevus: 60 (30 CN, 30 DN)
Flow and timing Excluded participants: None reported
Time interval to reference test: NR
Time interval between index test(s): NR
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Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Yes
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
Unclear High
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
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Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
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Study characteristics
Patient sampling Study design: Case series
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: NR
Country: Austria
Test set derived: Computer-generated random numbers split data into learning and testing sets;
relative proportion of cases in each set was “about 80% and 20%, respectively”
Patient characteristics and set-
ting
Inclusion criteria: PSLs with available oil immersion dermoscopic images
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Unspecified
Exclusion criteria: NR
Sample size (participants): NR
Sample size (lesions): 120 (29 test set); N included: 120
Participant characteristics: NR
Thickness/depth: Other: median 0.72 mm (range 0.3 to 1.4 mm) for 39 melanomas
Index tests Computer-assisted diagnosis - dermoscopy-based
Derm-CAD system: IBAS 2000 workstation (Zeiss, Oberkochen, Germany) (ANN classifier)
System details:
Digital image analysis workstation attached to Wild binocular stereomicroscope M 650 (Wild
Heerbrugg AG, Switzerland). “The images were obtained by photographing the PSLs on 24 x
36 mm colour slide film using a Wild binocular stereomicroscope M 650 (Wild Heerbrugg AG,
Switzerland) at a final magnification of x16 or x25 using flashlight illumination”
Derivation study (internal validation)
Approach to feature selection: “A 3-layer, feed-forward neural-network with 16 input nodes and 3
hidden nodes was trained with a backpropagation algorithm. Each morphological input feature was
assigned a numerical value that was scaled so that each input ranged from 0 to 1. The network was
trained to yield a value from 0 to 1 in the output nodes. The node yielding the greatest numerical
output was then used as the classification result (the winning node).”
Artificial neural networks 2 different ANNs were trained: “the first classified between CN and DN
as benign lesions versus MM as a malignant lesion in a dichotomized model, whereas the second
classified between the 3 entities of PSL examined, i.e. CN versus DN versus MM. We extracted
only data for the first ANN”
Lesion characteristics assessed:
Analysis of 16 morphometric parameters from the lesion and the border image: lesion area and
perimeter: minimum polar distance, maximum polar distance, aspect ratio, circularity shape factor,
variances of grey, number of different colours, range of different colours. Border features and area:
maximum and minimum border width, ratio of border area to lesion area, ratio of border perimeter
to lesion perimeter
Additional predictors included: No further information used
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: No further information used
CAD output: Dichotomous decision: MM vs. benign (CN or DN)
Diagnostic threshold:
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The network was trained to yield a value from 0 to 1 in the output nodes. The node yielding the
greatest numerical output was then used as the classification result
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Histology (not further described):N of participants/lesions: 29/120 lesions included in test set
Disease-positive: 10; Disease-negative: 19
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 39melanomas reported forwhole dataset including
5 in situ melanoma; the test set included 10 melanomas (number in situ not reported).
Other: common naevi and dysplastic naevi: 19
Flow and timing Exclusion of lesions from analysis: 6 lesions excluded due to incorrect segmentation results
Time interval to reference test: NR; “after photography”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Unclear
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Blum 2004a
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective
Period of data collection: 11 November 1998 - 2 March 2000
Country: Germany
Test set derived For validation of a new CAD procedure the complete collection (837 melanocytic
lesions) was divided into 2 equal random subgroups n1 (training set) and n2 (test set)
Patient characteristics and set-
ting
Inclusion criteria: Melanocytic skin lesions imaged prospectively at the Pigmented Lesion Clinic
of the Department of Dermatology, University of Tuebingen, Germany
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: NR
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: images from mucous membrane areas were excluded
Sample size (participants): NR
Sample size (lesions): N eligible: 837/ N included: 837 (test set 418)
Participant characteristics: NR
Lesion characteristics
Thickness/depth:
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≤ 1 mm: Median breslow thickness for all melanomas 0.78 mm (range 0.10 - 3.50)
Index tests Dermoscopy: 7FFM; 7-point checklist; ABCD; Menzies criteria
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: NR
Diagnosis based on: Single observer (n = 1)
Number of examiners: 1
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described
Any other detail: “The colour video camera MediCam 400 with Y/C 1 signal exit had a ¼-inch
charged-couple device shooting element with 470,000 pixels (picture elements). The focal area for
the dermoscopic pictures was defined from 3.5 cm diameter up to infinity. The focal area for the
dermoscopic pictures could be positioned continuously by zoom from 3.2 mm to approx. 1.0 cm,
corresponding to a x20-70 magnification on a 17-inch monitor. Lesions ≤ 12 mm diameter could
be imaged completely. The glass plate contacting the skin was always moistened with disinfectant
spray.”
“According to the established dermoscopic classification rules (ABCD rule, Menzies’ score, 7-point
checklist and7 features formelanoma) the lesionswere prospectively classified as benignormalignant
melanocytic lesions by the principal investigator (AB).” (referenced to Argenziano 1998; Dal Pozzo
1999; Menzies 1996)
Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD: System name NR (Vision algebra classifiers)
System details:
Computer analysis of stored images captured using digital microscope
Derivation study (internal validation)
“The analytical parameters of the digital dermoscopy analysis were reduced by means of a factor
analysis. In a second step, the impact of the different parameters was examined by logistic regression
analysis. The number of parameters included in the multivariate analysis was limited in relation to
the number of malignant melanomas: in the sample of large, partially-imaged lesions it was restricted
to 6 parameters and for small, completely-imaged lesions it was limited to 3 parameters.”
Lesion characteristics assessed:
“Analysis of 64 analytical parameters including: a large number of morphological parameters such
as
margin, geometric parameters (surface area, extent, largest diameter and largest orthogonal diameter)
, invariant moments, symmetry, colours (red, green, blue and grey value), texture (energy, entropy,
correlation, inverse difference moment and inertia), number of regions, focus and difference of the
lesion and its convex cover.”
Additional predictors included: Unclear
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: Unclear
CAD output: NR
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard Histological diagnosis plus follow-up
Histology Disease-positive: 84; Disease-negative: 185
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Clinical follow-up plus histology of suspicious lesions: unexcised lesions were analysed independently
by 2 of the investigators 2 - 3 times in 6 months on the basis of dermoscopic criteria. These lesions
were classified as benign without any suspicion of malignancy by dermoscopic criteria, and follow-
up records for at least 6 months showed no evidence of malignancy. Disease-negative: 568
Target consition (Final diagnoses)
Melanoma (invasive): 71; Melanoma (in situ): 9; Lentigo maligna 4
’Benign’ diagnoses: 766
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Time interval between index test(s): not reported
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear
Low High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Unclear
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
Unclear High
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
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Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
No
High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
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Were all patients included in the
analysis?
Yes
High
Boldrick 2007
Study characteristics
Patient sampling Study design: Case series
Data collection:
Prospective
Retrospective CAD
Period of data collection: January 2002 and August 2005
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: Patients ≥ 18 years of age
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (participants): N eligible: 83; N included: 12
Sample size (lesions): N eligible: 1000; N included: 18
Participant characteristics:
Index tests Computer-assisted diagnosis - Dermoscopy-based
CAD-Derm-Other MicroDerm/DANAOS
Derm-CAD system: MicroDERM (DANAOS software, ANN classifier)
System details:
Dermoscopy unit with internal camera containing DANAOS analysis system. “The hand unit
contained a miniature charged coupled device (3CCD) with a camera with a resolution of 768 3
576 (440,000) pixels. Digital images were stored and compresed using JPEG format.”
No derivation aspect (external validation study)
Lesion characteristics assessed: Dermoscopic features of PSLs based on the ABCD rule
Additional predictors included: None reported
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: No further information used
CAD output: DANAOS score indicating risk of malignancy
Diagnostic threshold:
DANAOS score
2 x 2 data for > 1 diagnostic threshold
Per-patient data reported. Threshold selected on basis of similarity to other microDERM studies:
DANAOS score of ≥ 7
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Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Histology (biopsy): N patients/lesions: 18 PSL
Disease-positive: 6 MM; Disease-negative: 12
Target condition (Final diagnoses)
Melanoma (invasive): 3; Melanoma (in situ): 2; Lentigo maligna 1
Severe dysplasia: 1; Mild/moderate dysplasia: 6; benign naevus: 5
Flow and timing Exclusion of lesions from analysis: Review team - only 18 lesions had an adequate reference
standard; 982 clinically dx benign lesions without a reference standard were not extracted
Interval between index test and reference standard: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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dard?
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Yes
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Bono 1996
Study characteristics
Patient sampling Study design: Unclear
Data collection: NR
Period of data collection: Between March 1993 and Oct 1994
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: Pigmented skin lesions at the Instituto Nazionale Tumori of Milan
Setting: Specialist unit (skin cancer/pigmented lesions clinic) Instituto Nazionale Tumori of Milan
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: None reported
Sample size (participants): N eligible: 45
Sample size (lesions): N eligible: 54/ N included: 43
Participant characteristics: NR
Lesion characteristics: Site - face/ears: 3 (6%); trunk: 39 (72%); limbs: 12 (22%); 10 MM ≤ 1
mm depth; median size: 10 mm (4 to 40 mm)
Index tests Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: Telespectrophotometric System (Linear discriminant classifier)
System details:
Digital camera coupled with an illumination system with interference filters and computer for
storage and analysis of multispectral images
No derivation aspect (external validation study)
Described in prior study Marchesini 1995
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Lesion characteristics assessed:
From each spectral image, 3 parameters (i.e. mean reflectance, variegation index and lesion area)
were derived at the corresponding wavelength
Additional predictors included: None reported
Method of diagnosis:
Spectroscopic images
CAD-based diagnosis
Prior/other test data: Unclear
CAD output: NR
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard
Histological diagnosis - Disease-positive: 18; Disease-negative: 25
Expert opinion - Disease-negative: 11
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 18
Mild/moderate dysplasia: 8 dysplactic naevi
Benign naevus: 17 common melanocytic naevi
Flow and timing Excluded participants: Only 43 lesions had complete clinical and histological information. 11
lesions not surgically removed had only clinical diagnosis (benign) and were not included in the
final accuracy analysis
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
104Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bono 1996 (Continued)
Did the study avoid including
participants with multiple le-
sions?
No
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
No
High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
High
Bono 2002
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective
Period of data collection: June 1998 to March 2000
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: “Cutaneous pigmented lesions with clinical and/or dermatoscopic features that
suggested a more or less important suspicion of CM”
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
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Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria:
Location/site of lesion: Awkwardly situated lesions e.g. interdigital space, ears, nose or eyelids.
Lesions on scalp excluded due to hair interference with reflectance
Lesion size: obvious large, thick melanomas
Sample size (participants): N included: 298
Sample size (lesions): N included: 313
Participant characteristics: Mean age: 40 years (10 - 86); Male: 122 (41%)
Lesion characteristics: Lesion site: head/neck: 3%; trunk: 61%; limbs: 36%; Thickness ≤ 1 mm:
70% (46/66); for 55 invasive MM: median thickness 0.64 mm, range 0.17 - 3.24 mm. Median
diameter: 11 mm (3 - 31 mm)
Index tests Visual inspection (VI) No algorithm (training in the unit is based on ABCD but subjective
experience of the clinician used for diagnosis)
Method of diagnosis: In-person diagnosis
Prior test data: N/A; in-person diagnosis
Diagnostic threshold:
Clinical diagnostic criteria based on subjective experience; emphasise lesion colour over dimensions.
Diagnosis of suspect CM made when the level of suspicion was ’roughly 50% or more’. ABCD
criteria have been the basis of training at the unit, but is not implemented in diagnosis; preferred
emphasis on colour rather than dimensional character
Diagnosis based on: Single observer (n = 1)
Observer qualifications: Surgical oncologists
Experience in practice: High experience or ‘Expert’; over 5 years
Dermoscopy: No algorithm
Method of diagnosis: In-person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold:
Presence of at least 1 of the following criteria: radial streaming, pseudopods, grey-blue veil, regression
and erythema, whitish veil, black dots at the periphery (if network present), thick irregular network
or milky-red background with red dots
Test observers as described for Visual Inspection (above)
Experience with index test: > 5 years
Any other detail:
Dermatoscopy performed by a hand-held monocular microscope equipped with an achromatic lens
permitting a magnification of x10 (Heine Delta 10)
Computer-assisted diagnosis - Spectroscopy-based
CAD-Spect-Other Described as; referenced to
MSI-CAD system: ’telespectrophotometry’ (Linear discriminant classifier)
System details:
The TS consists mainly of a charge-coupled device camera that is provided with a set of 17 inter-
ference filters and a personal computer to allow imaging of cutaneous pigmented lesions at selected
wavelengths from 420 to 1040 nm. The acquired 17 spectral images are stored in the personal com-
puter for offline processing. Intensity levels as well as the dimensions of the image picture elements
(pixels) were calibrated according to a set of 4 reflectance standards and a geometric reference frame,
respectively. Details on the system’s feautres have been reported elsewhere (Marchesini 1995).
No derivation aspect (external validation study): Derivation described in Marchesini 1995
Lesion characteristics assessed:
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For each spectral image, 5 parameters (lesion descriptors) based on ABCD and related to colour and
shape of the imaged lesion were evaluated: mean reflectance, variegation index, roundness, border
irregularity (only four listed in study report)
Additional predictors included: No further information used
Method of diagnosis:
In-person diagnosis
CAD-based diagnosis
Prior/other test data: None
CAD output: NR
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses)
Melanoma (invasive): 55; Melanoma (in situ): 11; BCC: 6
’Benign’ diagnoses: 241; 151 compound naevus, 24 junctional naevus, 12 dermal naevus, 12 lentigo
simplex, 10 dysplastic naevus, 8 spindle-cell naevus, 8 sebhorrheic keratosis, 5 blue naevus, 3 spitz
naevus, 8 other
Flow and timing Excluded lesions from analysis: None reported
Intervals between tests: Appears consecutive but not fully clear
Comparative Time interval between index test(s): Appears consecutive but not fully clear
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
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Was an adequate spectrum of
cases used to train the algo-
rithm?
Yes
Low High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
Low High
DOMAIN 2: Index Test Visual inspection
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear High
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
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Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
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Burroni 2004
Study characteristics
Patient sampling Study design: Case control
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: 1999 - 2003
Country: Italy
Test set derived: For the 3 linear classifiers, “lesions fromeach centre (Rome andSiena)were randomly
allocated to training and test sets. Linear classifier 1 was constructed from the Rome training set
and tested on all lesions from Siena; Linear classifier 2 was constructed on the Siena training set
and tested on all lesions from Rome; Linear classifier 3 was constructed on training sets from both
centres and tested on test sets from both centres. For the K-nearest-neighbour (K-nn) classifiers, a
separate training set of lesions were selected from the image databases of several institutions that
iused the same ELM instrumentation, i.e. IDI-Rome; Siena University Dermatology Clinic; IDI-
Capranica; and the Italian Cancer League Clinics of Grosseto, Livorno, Arezzo, Trento, and Siena.
It was then tested on all lesions from both centres as described above.”
Patient characteristics and set-
ting
Inclusion criteria: All melanomas undergoing ELM and excision at the 2 centres (1999 - 2003)
and random sample of surgically-removed benign melanocytic lesions, inlcuding 85 histologically
atypical naevi
Setting:
Secondary (general dermatology) Dept Dermatology, University of Siena
Specialist unit (skin cancer/pigmented lesions clinic) InstitutoDermatopatico dell’Immacolata (IDI)
, a research hospital for skin diseases in Rome
Prior testing: Selected for excision (no further detail)
Setting for prior testing:
Secondary (general dermatology) Siena
Specialist unit (skin cancer/pigmented lesions clinic) Rome
Exclusion criteria: None reported
Sample size (participants): NR
Sample size (lesions): N included: 821 (475 from Siena; 346 from Rome)
Participant characteristics:
Thickness/depth: Other: 178 (48% of 372 MM) ≤ 0.75 mm
Index tests Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: DB-Mips system (Knn and Linear discrimination classifiers)
Classifier selected at random for analysis in review: Knn
System details:
Dermoscopy unit, internal steromicroscope, internal DB, pattern analysis system
Derivation study (internal validation)
Discriminant analysis used to identify features for which there was a significant (t test) difference
between melanomas and non-melanomas and, within these diagnostic classes, no significant differ-
ence between centres. Details provided. Selected variables were: geometric variables - area, variance
of contour symmetry, fractality of borders. Colour variables - mean skin-lesion gradient, variance of
border gradient, and border interruptions. texture variables - mean contrast and entropy of lesion
islands of colour variables - dark area, blue-grey area*, transition region imbalance
Lesion characteristics assessed:
38 parameters belonged to 4 categories (referenced to Soyer 2000): geometries; colors; textures; and
islands of colour (i.e. colour clusters inside the lesion). These were all described in detail
Additional predictors included: No further information used
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Method of diagnosis:
In-person diagnosis
CAD-based diagnosis
Prior/other test data: None reported
CAD output: Diagnosis suggested (e.g. melanoma, benign melanocytic naevus)
Diagnostic threshold: Threshold not reported
The method of receiver operating characteristic curves was used to identify the threshold value for
a fixed sensitivity of 95%
“The prevalence of melanomas among the first 100 closest neighbours was determined, and the
lesion was assigned to the melanoma group if the prevalence was higher than a threshold value T
100. The method of receiver operating characteristic curves was used to identify the T 100 value
necessary for a sensitivity of 98%”
Target condition and reference
standard(s)
Reference standard
- Histological diagnosis alone
Histology (excision)
N participant/lesions: 821 (475 Siena; 346 Rome)
Disease-positive: 372 (217 Siena; 155 Rome); Disease-negative: 449 (258 Siena; 191 Rome)
Target condition (Final diagnoses)
Melanoma (invasive): 302; Melanoma (in situ): 70 (higher % at Siena than in Rome)
Severe dysplasia: 85 (architectural disorder and melanocytic atypia)
Benign naevus: 364
Flow and timing Participant exclusions: None
Intervals between tests: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
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Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Yes
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Cascinelli 1992
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective
Period of data collection: March - December 1991
Country: Italy
Test set derived:
Derivation of test set not described.Training set: 169 lesions; 124 benign and 45 malignant lesions,
Test series: 44 images, 33 benign lesions and 12 malignant, of which 10 were melanoma
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Patient characteristics and set-
ting
Inclusion criteria: Study inclusion criteria Training set: Pigmented cutaneous lesions were referred
to Institute for a second opinion; Test set: not described
Setting: Secondary (general dermatology) Surgical Oncology
Prior testing: Training set: Referred for second opinion; basis not reported; Test set: not described
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (participants): N included: Training set: 165, Test set: not described
Sample size (lesions): N included: Training set: 169, Test set: 44
Participant characteristics
Age (yrs): Other Training set: 17 aged < 20; 59 aged 21 - 40; 66 aged 41 - 60; 23 aged > 61
Test set: not described
Gender: Male: Training set: 70 (42%); Test set: not described
Lesion site:Head/neck: Training set: 7.7%; trunk: Training set: 45.5%; limbs: Training set: 46.7%
Index tests Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: Skin View (classifier NR)
System details:
Computerised image analysis system, digital television, videocamera. Connectionwith the computer
is through a digitising board able to process colour images
Derivation study (internal validation):
Lesion characteristics assessed:
Features of ABCD system plus clinical data (anatomical site, months of growth, size, shape, colour,
ulceration or regression)
8 binary indicators generated: shape, clinical data, size, colour, darkness, saturation, border, and
texture (all described)
Additional predictors included:
Predictors included clinical data, which takes into account anamnestic data provided by the clinician
(change in size, change in colour) and an objective evaluation made by the clinician (presence of
regression, presence of ulceration)
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: None reported
CAD output: CAD-based diagnosis
Diagnostic threshold: Malignant lesion ≥ 2 positive indicators
Target condition and reference
standard(s)
Reference standard
Histological diagnosis alone
Histology (excision)
N participant/lesions: Test set only: 44
Disease-positive: 12; Disease-negative: 32
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 10; BCC: 2
’Benign’ diagnoses: 32
Flow and timing Excluded participants: NR
Time interval to reference test: NR
Comparative
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Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
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Was the CAD model evaluated
in an independent study popu-
lation?
Unclear
Was
model overfitting accounted for
during model development?
Unclear
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Cristofolini 1997
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective
Period of data collection: November 1992 to September 1993
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: “Patients with small and flat common and atypical pigmented skin lesions
recruited during a health campaign for the early diagnosis of CM underwent clinical diagnosis,
computerised analysis by SVS [Skin View System] and subsequent skin biopsy”
Setting: Secondary (general dermatology)
Prior testing: No prior testing
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: None reported
Sample size (participants): 176 included
Sample size (lesions): 176 included
Participant characteristics: NR
Lesion characteristics: NR
Index tests Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: Skin View (classifier NR)
System details:
Computerised image analysis system, digital television, videocamera. Connectionwith the computer
is through a digitising board able to process colour images
No derivation aspect (external validation)
Lesion characteristics assessed:
Features of ABCD system plus clinical data (anatomical site, months of growth, size, shape, colour,
ulceration or regression)
1. shape (asymmetry); 2. clinical data (changes through time, regression, ulceration); 3. size (mm)
; 4. colour (distribution of hue); 5. darkness (percent of black mixed with the hue); 6. saturation
(percent of white mixed with the hue); 7. border (sharpness of transition between lesion and healthy
skin; 8. texture
Additional predictors included: Clinical data
Method of diagnosis:
Dermoscopy images
CAD-based diagnosis
Prior/other test data: None reported
CAD output: CAD-based diagnosis
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Diagnostic threshold: ≥ 2 of 8 binary (on/off ) indicators indicates malignancy
Target condition and reference
standard(s)
Reference standard Histological diagnosis alone
Disease-positive: 35; Disease-negative: 141
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 35
Other: 141 melanocytic naevi
Flow and timing Excluded participants: Not reported
Time interval to reference test: “subsequent skin biopsy”
Comparative Time interval between index test(s): not reported-appears to be simultaneous
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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dard?
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
Low Unclear
DOMAIN 2: Index Test Visual inspection
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
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Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
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Were all patients included in the
analysis?
Yes
Unclear
Dreiseitl 2009
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective
Period of data collection: Test set: February - November 2004
Country: Austria
Test set derived: Study focuses on test set but gives detail of separate study in which classifier was
trained
Patient characteristics and set-
ting
Inclusion criteria:Patients presenting at PSL clinic atDeptDermatologywhich serves as a secondary
and tertiary referral centre
Setting: Specialist unit (skin cancer/pigmented lesions clinic) “The PSL unit of the Department of
Dermatology at the Medical University of Vienna serves as a secondary and tertiary referral centre”
Prior testing: NR
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (participants): N eligible: 511; N included: 458 with complete information
Sample size (lesions): N eligible: 3827; N included: 3021
Participant characteristics: None reported
Lesion characteristics: None reported
Index tests Dermoscopy: No algorithm
Method of diagnosis: In-person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Not reported
Diagnosis based on: Single observer (n = 1)
Observer qualifications: Expert dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience/‘Expert’ users
Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: Image J (NIH, Bethesda, USA) (ANN classifier)
System details: Image analysis coupled with dermoscope MoleMax II
No derivation aspect (external validation)
Described in prior study Hable 2004 (PhD thesis)
Lesion characteristics assessed:
29 features analysed from 38 extracted features describing shape, form and colour. Approach to
feature selection Prior study: A stepwise feature selectionmethod used to identify 29 features relevant
for the classification process
Additional predictors included: No further information used
Method of diagnosis: In-person diagnosis
CAD-based diagnosis
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CAD-aided diagnosis
Test observers: Single observer (n = 6)
Observer qualifications:
Other: The educational training of the 6 participating physicians ranged from no training in der-
matology to 4 years training in dermatology
Experience in practice:
Mixed experience (low and high experience combined)
Experience with index test:
Mixed experience (low and high experience combined) No physician was specifically trained in
dermatoscopy
Prior/other test data: Clinical examination and/or case notes
CAD output:
2 outputs: 1) Visual rendering of analysis showing coloured areas. 2) Excision vs no-excision decision
(system considers the green zone of the scale as benign (0 to 0.1), the yellow zone suspicious (0.1
to 0.4), and the red zone malignant (0.4 to 1))
Diagnostic threshold: Scale 0 - 1: 0 - 0.1 = benign, 0.1 - 4 = suspicious, > 0.4 = malignant
Target condition and reference
standard(s)
Reference standard Histological diagnosis plus follow-up
Histology (excision); N participant/lesions: NR
Clinical follow-up plus histology of suspicious lesions: Length of follow-up: 6 months; N participants:
NR
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 27 participants; 31 lesions
’Benign’ diagnoses: 431 participants; 2990 lesions
Flow and timing Excluded participants: 806 lesions (53 participants) with inadequate follow-up
Intervals between tests: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
No
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ate?
Did the study avoid including
participants with multiple le-
sions?
No
Was an adequate spectrum of
cases used to train the algo-
rithm?
Yes
Low High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
High High
DOMAIN 2: Index Test Dermoscopy
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
High
Ferris 2015
Study characteristics
Patient sampling Study design: Unclear. Some dermoscopic images were collected prospectively and some were
obtained from a collection of existing images; selection process not described
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: NR
Country: USA
Test set derived:
Some dermoscopic images used to train the classifier were obtained from publicly available or
purchased image libraries,whichwere not included in the reader study or used to test the performance
of the classifier. The image set was randomly divided into 2 by diagnosis, with half used for training
and half used for testing, with the exception that all high-grade dysplastic naevi were exclusively
assigned to the training set to increase the representation of dermoscopic features that could be
present in melanoma. Results are presented only for the test set
Patient characteristics and set-
ting
Inclusion criteria: Dermoscopic images of skin lesions excised on the basis of clinical suspicion of
malignancy, with available histologic diagnoses
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic suspicion; selected for excision (no further detail)
Setting for prior testing: Secondary (general dermatology)
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Exclusion criteria: High-grade dysplastic naevi were not included in the test set
Sample size (participants): N eligible: not reported; N included: not reported
Sample size (lesions):Neligible: 473 (includes 273 randomised to training set and 27 non-biopsied
lesions); N included: CAD-Derm test set 173 lesions; Dermscopy 65 lesions
Participant characteristics: None reported
Lesion characteristics: Test set: mean lesion thickness 0.76 mm, median 0.5 mm, range 0.2 - 2.98
mm); Reader study: mean 0.93 mm, median 0.74 mm, range 0.2 - 2.98 mm
Index tests Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: name NR (Digital forest classifier)
System details: Computer analysis of stored images captured using different dermoscopy/camera
combinations
Derivation study (internal validation)
Lesion characteristics assessed:
54 features analysed, such as border irregularity, eccentricity, length of major and minor axes, and
colour histogram properties. Variations of some features described in Zortea 2014 were included
Additional predictors included: Unclear
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: Unclear
CAD output:
Severity score (the fraction of decision trees (n = 1000) in which the path ends in “malignant”)
Diagnostic threshold: 0.4; a lesion was classified as malignant if its image traced a path to a
malignant node in at least 40% of the decision trees
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
All lesions were biopsied based on clinical suspicion of malignancy. All histologic diagnoses were
rendered by at least 1 board-certified dermatopathologist and were used as the reference standard
for diagnosis
Disease-positive: Derm 25 MM; CAD 39 MM; Disease-negative: Derm 40; CAD 134
Target condition (Final diagnoses)
Melanoma (invasive): Derm 15; CAD 25; Melanoma (in situ): Derm 10; CAD 14; BCC: CAD 11;
cSCC: CAD 3
Mild/moderate dysplasia: CAD 47; Derm 16. Sebhorrheic keratosis: CAD 11; Derm 4. Benign
naevus: CAD 42; Derm 14. Other: CAD 10 lentigines, 5 blue naevi, 2 Spitz naevi, 2 angiomas,
and 1 dermatofibroma; Derm 2 blue naevi, 4 lentigines
Flow and timing Excluded participants: None reported
Time interval to reference test: “Dermoscopic images of skin lesions were collected before biopsy”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
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Was
model overfitting accounted for
during model development?
Unclear
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
Yes
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condition?
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Friedman 2008
Study characteristics
Patient sampling Study design: Case-control
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: NR; lesions selected in July 2005
Country: USA
Test set derived: MelaFind data randomly split into training and test sets, but Melafind has previ-
ously been evaluated, the only difference here being that only small lesions were included. Would
argue that full dataset can reasonably be included here rather than test set only
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Patient characteristics and set-
ting
!nclusion criteria: A database of images of pigmented skin lesions ≤ 6 mm was used to sample
images of melanoma and non-melanoma lesions; high-grade dysplastic naevi were excluded
Setting: A digital dermoscopic database acquired by Electro-Optical Sciences Inc for the develop-
ment and testing of MelaFind; 26 clinical sites have contributed
Prior testing: Selected for excision (no further detail). All lesions excised or underwent shave biopsy
Setting for prior testing: NR
Exclusion criteria:
High-grade dysplastic naevi were excluded. Previously biopsied, ulcerated, or bleeding lesions also
excluded, as were those on mucosal surfaces and lesions that contained foreign matter (e.g. tattoos)
Sample size (participants): N included: 94
Sample size (lesions): N eligible: 1977; N included: 99
Participant characteristics: None reported
Lesion characteristics: 21 invasive MM: median thickness 0.32 mm (0.10 - 1.40 mm). Lesion size:
Range: 2 mm to 22 mm
Index tests Dermoscopy: No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: Clinical examination and/or case notes: sex, age, and lesion location
Diagnostic threshold:
NR. 2 x 2 reported for: diagnostic sensitivity and specificity, i.e melanoma vs not melanoma and
biopsy sensitivity and specificity, i.e excise lesion vs not excise. Each reader had to answer the
question: “Is this lesion a melanoma?” and “Would you biopsy/excise this lesion?” with a reason
for biopsy. If readers indicated that they would biopsy the lesion because they were sure it was
melanoma or to rule out melanoma, then the case was considered true positive (TP)
Diagnosis based on: Average; mean and median reported (n = 10)
Observer qualifications: 9 dermatologists; 1 nurse practitioner specialising in dermatology
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users
Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: MelaFind (EO Sciences, USA) (6 constrained linear classifiers)
System details:
Multispectral imaging system with integrated image analysis software; device takes images in vivo
External validation study
Derivation described in prior study Gutkowicz Krusin 1997; Elbaum 2001; Gutkowicz-Krusin
2000.
Lesion characteristics assessed: NR
Additional predictors included: None reported
Method of diagnosis:
Spectroscopic images
CAD-based diagnosis
Prior/other test data: No further information used
CAD output: Binary output: excise or follow-up
Diagnostic threshold: A lesion is recommended for biopsy to rule out melanoma only if all scores
are above the threshold value
Threshold not reported
Target condition and reference
standard(s)
Reference standard Histological diagnosis alone
Disease-positive: 49; Disease-negative: 50
Target condition (Final diagnoses)
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Melanoma (invasive): 21; Melanoma (in situ): 28; BCC: 2
Mild/moderate dysplasia: 32 low-grade dysplastic; sebhorrheic keratosis: 2; 14 other benign
Flow and timing Excluded participants: None reported
Interval between tests: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Was an adequate spectrum of
cases used to train the algo-
rithm?
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
Low Low
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
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Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
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Garcia Uribe 2012
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective
Period of data collection: NR
Country: USA
Test set derived: “Of the 407 PSLs, 271 were used for the training sets of ANN classi ers (Tables 1
and 2) to separate malignant melanoma from varieties of naevi. The remaining 136 data sets were
used to test the ef cacy of the ANN classi ers.” The non-pigmented lesions consisted of BCCs,
SCCs, benign actinic keratoses, and seborrheic keratoses. Among the 266 non-pigmented lesions,
177 were used to train the ANN classi er and the remaining 89 were used for testing
Patient characteristics and set-
ting
Inclusion criteria: NR
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: NR
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (participants): NR
Sample size (lesions): 136 included
Participant characteristics:
Pigmented (%): 407 pigmented lesions (60%)
Non-pigmented (%): 266 non-pigmented (40%)
Index tests Computer-assisted diagnosis - Spectroscopy-based
DRS-CAD system: OIDRS (ANN classifier)
System details:
Light probe coupled to imaging spectrograph, camera, and computer to store images. “The system
was built onto a portable cart; it was easily moved to the patient examination rooms. To target both
small and large skin lesions, we constructed an optical fiber probe using micromachining technology.
The probe consisted of 3 source fibers and 2 linear arrays of 12 collection fibers within an area of 2.
The collection fibers were coupled to an imaging spectrograph that generated an optical spectrum
from 455 to 765 nm for the collection channel. A charge-coupled device (CCD) camera collected
the spectral images, which were stored on a com- puter for data analysis. The data collection took
less than 5 minutes, and it did not interfere with the standard health care provided to the patients”
Derivation study (internal validation)
“A physician identified the lesion(s) to be measured before the scheduled biopsy. To average out the
effect of structural anisotropy of the skin tissue, themeasurement of each lesion was repeated 4 times
to obtain images fromdifferent orientations. To provide self-references, the samemeasurements were
also repeated on the neighboring healthy skin tissues. The anisotropy is defined as the variation of
themeasurements when conducted in different directions. After the measurements were completed,
a biopsy was carried out for each skin lesion and submitted for histopathologic analysis.”
Lesion characteristics assessed: NR
Additional predictors included: Unclear
Method of diagnosis:
In-person diagnosis
CAD-based diagnosis
Prior/other test data: Unclear
CAD output: Diagnostic category (e.g. CN, MM, DN, BCC, cSCC)
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Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 10
Severe dysplasia: 15; Mild/moderate dysplasia: 83; Benign naevus: common naevi 28
Flow and timing Excluded participants: NR
Time interval to reference test: Biopsy was done after the CAD-OIDRS measurements were taken
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Yes
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Unclear
Was
model overfitting accounted for
during model development?
No
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Gilmore 2010
Study characteristics
Patient sampling Study design: Case series
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: 2003 - 2008
Country: Austria
Test set derived: NR. Training set: 65 melanomas and 65 dysplastic naevi; Test set: 36 melanomas
and 33 dysplastic naevi
Patient characteristics and set-
ting
Inclusion criteria:
Polarised dermoscopic images of atypical melanocytic lesions were obtained from the Department
of Dermatology at the Medical University of Graz in Austria; describes database as a “database may
be considered a random, but representative, cohort” but does not describe method of selection
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic suspicion atypical melanocytic lesions
Setting for prior testing: NR
Exclusion criteria: None reported
Sample size (participants): N included: NR
Sample size (lesions): N included: 199: Derivation set N 130 Test set N 69
Participant characteristics: None reported
Lesion characteristics: None reported
Index tests Dermoscopy: No algorithm; dermoscopic method of diagnosis NR
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
139Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gilmore 2010 (Continued)
Diagnostic threshold: NR; subjective impression to excise or not
Diagnosis based on: Single observer (n = 1)
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience/‘Expert’
Images captured using a DermLite FOTO lens (3Gen LLC; Dana Point, CA, USA) coupled to a
digital camera (Nikon CoolPix4500; Nikon Corporation, Tokyo, Japan) without flash using the
camera’s auto setting
Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: name NR (SVM classifier)
System details: Computer analysis of stored images captured using digital microscope
Derivation study (internal validation)
“Feature data from the training set were first normalised to zeromean and unit variance. We then
reduced the dimensionality of this set by taking the first three principal components, corresponding
to the points to the left and including the infection point of the hyperbolic eigenvalue curve.”
Training set (p832): “At each step, corresponding to a unique parameter regime, we took 60 random
data points (30 of each class) from our 130 training data points to derive a model, and then we tested
that model on 30 randomly chosen data points from the same data set. To assess the effectiveness
of the model in classification, we performed a tenfold cross-validation. Because we are using only a
subset of the total training set to derive each model this is loosely analogous to the subset selection
procedure known as chunking - finding the optimal solution is computationally fast. Each tenfold
cross-validation took approximately 200 s using Mathematica 6.0 on a Macintosh G4 with 4MB
of RAM.”
Lesion characteristics assessed:
14 features investigated: 1. Asymmetry 1 (mean int.) 2. Asymmetry 2 (mean int.) 3. Asymmetry
3 (variance red) 4. Asymmetry 4 (variance red) 5. Variance red 6. Variance green 7. Variance blue
8. Mean red 9. Mean green 10. Mean blue 11. Mean intensity 12. Range red intensit* 13. Range
green intensity 14. Range blue intensity
Additional predictors included: No further information used
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: Unclear
CAD output: NR
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard Histological diagnosis alone
“All lesionswere excised and examinedmicroscopically by expert dermatopathologists using standard
histopathologic diagnostic criteria”
Disease-positive: 36 test set and 65 derivation set; Disease-negative: 33 test set and 65 derivation
set
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 36 test set and 65 derivation set
Dysplastic naevi 33 test set and 65 derivation set
Flow and timing Excluded participants: None reported
Intervals between tests: NR
Comparative
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Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
No
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
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Was the CAD model evaluated
in an independent study popu-
lation?
Unclear
Was
model overfitting accounted for
during model development?
Yes
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear High
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
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Glud 2009
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective
Period of data collection: January to April 2007
Country: Denmark
Patient characteristics and set-
ting
Inclusion criteria: Patients referred for excision biopsy of pigmented lesions where the diagnosis of
melanoma could not be excluded on clinical investigation
Setting: Secondary (other); Dept Plastic Surgery and Burn Unit
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: Secondary (not further specified); Department of Plastic Surgery and
Burn Unit
Exclusion criteria: None reported
Sample size (participants): N included: 65
Sample size (lesions): N included: 83
Participant characteristics: Median age 47 years (18 - 90); Male - 29 (45%)
Lesion characteristics: Melanoma thickness 0.29 mm to 2.18 mm
Index tests Dermoscopy: No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: NR “dermoscopic images were examined by an experienced dermatologist”
Diagnosis based on: Single observer (n = 1)
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience/‘Expert’ users
The dermoscopic and SIAgraphic images were obtained by SIAscope II (Amon Clinica, Cambridge,
UK) and stored using the proprietary Dermetrics software (Astron Clinica)
Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: SIAscope II (Astron Clinica, UK )(classifier NR)
System details:
Skin lesion is interrogated with light of different wavelengths and the reflection spectra are analyzed
by proprietary algorithms showing distribution, position and quantity of melanin, blood, and
collagen within the papillary dermis (the SIAgraphs)
No derivation aspect (external validation)
Derivation described in prior study - See Moncrieff 2002; Govindan 2007
Lesion characteristics assessed:
Analysis of dermal melanin, erythematous blush, lesion asymmetry, collagen ’holes’, blood commas,
or irregularities in the collagen
Additional predictors included: None
Method of diagnosis:
Spectroscopic images, SIAgraphic images
CAD-based diagnosis
Prior/other test data: Unclear
CAD output: Binary (based on Australian Scoring System): ‘strong chance of melanoma’ or ’low
risk of melanoma’
Diagnostic threshold: Australian Scoring System; Threshold not reported
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Target condition and reference
standard(s)
Reference standard Histological diagnosis alone (excision biopsy)
Breslow thickness and Clark level were determined by standard histopathologic examination. Tu-
mour staging was performed as described by Balch 2001 according to the 2001 melanoma staging
system
Disease-positive: 12; Disease-negative: 71
Target condition (Final diagnoses)
Melanoma (invasive): 7; Melanoma (in situ): 5; 1 melanoma metastasis (incl as benign)
Sebhorrheic keratosis: 1; Benign naevus: 57; ’Benign’ diagnoses: Bowens 1; haemangioma 1; lentigo
simplex 2; epidermal naevi 2; DF 6
Flow and timing Participant excluded from analysis: None reported
Interval between tests: NR
Interval to reference standard: Images taken prior to biopsy
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Was an adequate spectrum of
cases used to train the algo-
rithm?
Low High
DOMAIN 2: Index Test Computer-assisted diagnosis
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
Low Low
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
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Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Gutkowicz Krusin 1997
Study characteristics
Patient sampling Study design: Unclear
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: NR
Country: USA (from authors’ institution)
Test set derived NR. The “classifier was then tested blindly on an independentset of 28 images of
melanocytic lesions on slides provided by Dr. A. W. Kopf.”
Patient characteristics and set-
ting
Inclusion criteria: Lesions suspected of early melanoma or atypical melanocytic naevus
Setting: Secondary (general dermatology) From authors’ institution
Prior testing: Selected for excision (no further detail) No details; all lesions excised
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (participants): N included: NR
Sample size (lesions): N included: 104; 76 training; 28 test set
Participant characteristics: NR
Index tests Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: MelaFind precurser (Multiparametric linear classifier)
System details: Digital camera and illumination assembly coupled to a computer, with separate
image analysis
Derivation study (internal validation)
Lesion characteristics assessed: Lesion asymmetry, border, gradient, centroid, texture, colour
Additional predictors included: No further information used
Method of diagnosis: Spectroscopic images
CAD-based diagnosis
Prior/other test data: No further information used
CAD output: NR
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Histology (not further described)
N participants/lesions: 28 in test set
Disease-positive: 5; Disease-negative: 23
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 5
Benign naevus: 23
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Flow and timing Excluded participants: NR
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
No
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Unclear
Was
model overfitting accounted for
during model development?
Unclear
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Hauschild 2014
Study characteristics
Patient sampling Study design: Case-control; all lesions in this study were imaged and analysed by MelaFind in a
previous study (Monheit 2011)
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: NR
Country: USA data from Monheit 2011 study
Patient characteristics and set-
ting
Inclusion criteria:
Subset of PSLs evaluated in the Monheit trial; melanoma and non-melanoma randomly selected;
none were ulcerated, non-pigmented, or located on excluded anatomic sites
Setting: Lesions sampled fromMonheit trial “Seven clinical sites with 23 investigators participated
in this trial. Three sites were academic institutions (University of Pittsburgh, Duke University, and
Northwestern University), and 4 sites were dermatologic practices highly experienced in managing
PLs.”
Prior testing: Selected for excision (no further detail)
Setting for prior testing: NR
Exclusion criteria: Ulcerated, non-pigmented, or located on excluded anatomic sites
Sample size (participants): N included: 130
Sample size (lesions): N eligible: 1632 lesions in Monheit trial; N included: 130
Participant characteristics: None reported
Lesion characteristics: site
Head/neck: 22.3%; trunk: 41.5%; upper limbs/shoulder: 20%; lower limbs/hip: 16.2%. Median
thickness (melanomas) 0.39 mm (range 0.12 - 1.2 mm)
Index tests Dermoscopy: No algorithm
Method of diagnosis: Clinical photographs and dermoscopic images
Prior test data:
Clinical examination and/or case notes. Lesion images consisted of a clinical overview at 53 cm/21
inches, a clinical close-up at 20 cm/8 inches, and a dermatoscopic image. Clinical exam information
consisted of 24 items regarding patient demographics and risk factors for melanoma, such as:
personal or family history of melanoma, number of atypical naevi, Fitzpatrick skin type, number of
severe sunburns before and after age 20, etc
Diagnostic threshold:
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NR. Responses to the questions about whether or not the dermatologist would biopsy the lesion
and reason for biopsy were used to determine dermatologist sensitivity and specificity
Diagnosis based on:
Average (Arm 1: 101 board-certified dermatologists; Arm 2 (MelaFind): further 101 board-certified
dermatologists; Arm 3: 9 PSLs)
Observer qualifications: Dermatologist (Experts (Arm 3) prospectively identified by the Principal
Investigator based on field standing prior to participant recruitment)
Experience in practice: High experience or ‘Expert’; > 90% had more than 10 years experience in
practice
Experiencewith index test:High experience/‘Expert’ users. All except 6were trained in dermoscopy
use; 155/202 always or almost always used dermoscopy for PSLs
Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: MelaFind (classifier NR)
System details:
Multispectral imaging system with integrated image analysis software; device takes images in vivo
No derivation aspect (reader study)
Lesion characteristics assessed: NR
Additional predictors included: None reported
Method of diagnosis:
Spectroscopic images
CAD-based diagnosis
Prior/other test data:
Clinical examination and/or case notes - Study presents system-based diagnosis plus MelaFind
combined with dermatologist decision which was also informed by clinical exam information
CAD output:
Binary output: (1) positive, (lesion should be considered for biopsy to rule out melanoma); and (2)
negative (lesion should be considered for later evaluation)
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard Histological diagnosis alone
Histology (not further described).Disease-positive: 65; Disease-negative: 65
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 65
’Benign’ diagnoses: 65
Flow and timing Participants excluded from analysis: None
Time interval between index tests: Unclear
Time interval to reference standard: Unclear
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
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Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear
Low High
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
Yes
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of the results of the index tests?
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Maglogiannis 2015
Study characteristics
Patient sampling Study design: Case-control
Data collection: Retrospective
Period of data collection: NR
Country: Greece
Random division of 208 lesions into train and test sets (equal numbers)
Patient characteristics and set-
ting
Inclusion criteria: Lesions excised (no further details)
Setting: Specialist: Department of Plastic Surgery and Dermatology (Athens)
Prior testing: Lesions excised (no further details)
Setting for prior testing: Not specified
Exclusion criteria: None reported
Sample size (participants): NR
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Sample size (lesions): 208 lesions,
Participant characteristics:
Index tests Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: name NR (SVM polykernel c = 5 classifier, selected at random for this review)
System details:
Computer analysis of digital dermoscopy images captured using the Molemax II dermatoscope
Derivation study (internal validation)
5 classifiers trained: Multilayer perceptron, kNN, Random forest, SVM polykernel c = 5, SVM
PUK kernel
Lesion characteristics assessed:
Features corresponding to the number, size and asymmetry of dots: (a) number of dots, (b) total
number of pixels in dots, (c) mean number of pixels in dots, (d) variance of num. pixels in dots, (e)
fraction of lesion area occupied by dark dots. Asymmetry: radial, angular, primary axis
Additional predictors included: None reported
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: No further information used
CAD output: NR
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Disease-positive: 50 MM; Disease-negative: 54
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 50
’Benign’ diagnoses (not further specified): 54
Flow and timing No exclusions reported
Time interval to reference test: No details reported
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
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Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Unclear
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Malvehy 2014
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective; dermoscopic images assessed remotely from the participant
Period of data collection: March 2010 and November 2011
Country: Conducted at 5 American and 17 European investigational sites (Sweden, Germany,
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Austria, Hungary, U.K. and Spain)
Patient characteristics and set-
ting
Inclusion criteria:
All patients with skin lesions selected for total excision to rule out melanoma; dermatologists were
encouraged to enrol a mix of lesions with an even distribution of low-, medium- and high-risk
lesions
Setting: Secondary; authors institutions primarily listed as Dept Dermatology with one ”Derma-
tology Clinical Research Center“
Prior testing: Selected for excision
Exclusion criteria: Lesions < 2 mm or > 20 mm and those located: on acral skin, e.g. sole or palm;
areas of scars, crusts, psoriasis, eczema or similar skin conditions; hair-covered areas, e.g. scalp,
beards, moustaches or whiskers; genitalia; in an area that has been previously biopsied or subjected
to any kind of surgical intervention or trauma; mucosal surfaces; with foreign matter, e.g. tattoo or
splinter; acute sunburn; or skin surface not measurable, e.g. lesion on a stalk; surface not accessible,
e.g. inside ears, under nails or not intact (measurement area)
Sample size (participants): N eligible: 1951; N included: 1611
Sample size (lesions): N eligible: 2416; N included: 1943
Participant characteristics: For Nevisense sample: median age: 48 years (range 18 to 91); male 47.
5%; 97.5% of white ethnicity. Fitzpatrick skin types: I (7.3%); II (48.6%); III (37%); IV (9.8%);
V (1.4%); VI (0.1%)
Lesion characteristics: Median Breslow thickness of 0.57 mm (153 invasive melanomas)
Index tests Computer-assisted diagnosis - Spectroscopy-based
EIS-CAD system: Nevisense (SciBase III, Sweden) (SVM classifier)
System details:
Electrical Impedance spectroscopy imaging system with integrated image analysis software. The
system measures the overall electrical resistance and reactance at 35 different frequencies
Derivation aspect (study type)
Lesion characteristics assessed: NR
Additional predictors included: None reported
Method of diagnosis:
Spectroscopic images
CAD-based diagnosis
Prior/other test data: None considered by CAD for diagnosis
CAD output: The system computes both a score (0 - 10) and a dichotomous output (EIS negative/
positive) at a fixed cut-off
Diagnostic threshold:
Score: The fixed threshold is set at 4, i.e. scores < 4 are EIS-negative and scores of ≥ 4 are EIS-
positive
Prior study (Mohr 2013) used dichotomous outcome but recommended score output
Target condition and reference
standard(s)
Type of reference standard: Histological diagnosis alone
Details:
Lesions were excised and underwent usual histopathology at investigational site. ”A further
histopathological evaluation was undertaken for study purposes by a panel of three experienced
histopathologists who evaluatedeach lesion independently and were blinded from the investigational
site’s original histopathology diagnosis“. If they agreed, the diagnosis was considered as the final
diagnosis; if there was significant disagreement two additional experts were consulted to establish
the final lesion diagnosisif agreement was reached. If disgreement as to lesion diagnosis remained,
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the lesion was excluded from the efficacy analysis
Disease-positive: 478; Disease-negative: 1440
Target condition (Final diagnoses)
153 invasive melanomas, 112 melanoma in situ
48 BCC, 1 invasive cSCC; 1 Merkel cell carcinoma
157 severely dysplastic, 988mild tomoderate dysplasia, 352benignnaevi, 5 spitz naevi, 51 seborrheic
keratosis, 6 cSCC in situ; 8 AK; 61 other
Flow and timing Participant exclusions:
473 excluded from Nevisense analysis; all reasons listed; primary reason was investigator oversight
or the inability to render a final histopathological diagnosis; 74 exclusions were device-related (60
with inadequate reference measurement quality and 14 due to device failure)
Index test to reference standard interval:
Appears consecutive; prospective recruitment with imaging and then ”eligible and evaluable lesions
were excised and subjected to the investigational site’s histopathology evaluation and managed
accordingly.“ ”A postprocedure follow-up either by a telephone call or at a participant’s visit to the
investigational site was conducted at 7 +/- 3 days after the Nevisense evaluation, at which time the
patient was evaluated for any adverse events.“
Comparative Interval between index testsConsecutive; ”A photograph and dermoscopic image of each included
lesion was taken before and after Nevisense measurements to document evaluation according to the
protocol.”
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
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Was an adequate spectrum of
cases used to train the algo-
rithm?
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
Low Low
DOMAIN 2: Index Test Visual inspection
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
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Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Study characteristics
Patient sampling Study design: Unclear Describes including melanomas and randomly-selected clinically atypical
non-melanoma lesions
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection NR
Country: Australia
Test set derived: NR; describes ’division’ into a training set and a test set
Patient characteristics and set-
ting
Inclusion criteria:
PSLs from the Sydney Melanoma Unit with dermoscopic images and histological diagnoses;
melanomas and randomly-selected clinically atypical non-melanoma lesions were included
Setting: Specialist unit (skin cancer/pigmented lesions clinic) From authors’ institution
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: Unequivocal non-melanoma excluded
Sample size (participants): N included: NR
Sample size (lesions): N included: 385 (training set 221, test set 164)
Participant characteristics: None reported
Lesion characteristics: None reported
Index tests Dermoscopy:Menzies criteria
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold:
2 negative features of melanoma (i.e. cannot be found). Point and axial symmetry of pigmentation.
Presence of only a single colour. 9 positive features of melanoma were used (at least 1 feature found)
. Multiple (5 - 6) colours Blue-white veil, multiple brown dots, multiple blue/grey, peripheral black
dots or globules. A broadened network, Pseudopods, Radial streaming, Scarlike
Diagnosis based on: NR
Observer qualifications: NR; likely dermatologists
Experience in practice: Not described
Experience with index test: Not described
Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: Name not reported (CART classifier)
System details:
Computer analysis of stored images captured using digital microscope. PSLs were photographed in
vivo by means of immersion oil and a camera (Dermaphot, Heine Ltd). The surface microscopic
images were studied on a viewer (Kodak Ektagraphic Viewer, Model 575AF, Eastman Kodak Co,
Rochester, NY)
Derivation study (Internal validation)
Lesion characteristics assessed:
Approach to feature selection: A classification and regression tree constructed on the training set
produced a 7-node tree
Negative Features: Point and axial symmetry of pigmentation
Presence of only a single colour
Positive features: blue-white, veil, multiple brown dots, pseudopods, radial streaming, scarlike de-
pigmentatlon, peripheral black dots/globules, multiple (5 - 6) colours, multiple blue/grey dots,
broadened network
164Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Menzies 1996 (Continued)
Additional predictors included: Unclear
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: Unclear
CAD output: NR
Diagnostic threshold:
Presence of indicative features (Melanoma = 0/2 morphologically negative features AND at least 1/
9 positive morphological features)
Target condition and reference
standard(s)
Reference standard Histological diagnosis alone
Histology (not further described);Disease-positive: 107; Disease-negative: 278
Target condition (Final diagnoses)
Melanoma (invasive): 107; BCC: 18
?Ephilis lentigo 17; Sebhorrheic keratosis: 23; Benign acquired naevi 58; Dysplastic naevi 105; Blue
naevi 11; Spitz naevi 6; spindle cell naevus 2; dermatofibroma 2; haemangioma 13; solar keratosis
9; other 14
Flow and timing Exclusions from analysis: None reported
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
165Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Menzies 1996 (Continued)
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
Unclear
Was
model overfitting accounted for
during model development?
Unclear
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
Unclear High
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
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Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Menzies 2005
Study characteristics
Patient sampling Study design: Case series
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection June 1998 to September 2003
Country:Multicentre (Australia, USA, Germany)
Test set derived: Study population divided at ratio 2:1 for training: test sets; divison randomised
but stratified by diagnostic category and Breslow
Patient characteristics and set-
ting
Inclusion criteria:
PSLs imaged using SolarScan at 9 different clinical centres including specialist referral centres and
private skin cancer clinics; only the 78 lesions from the Sydney Melanoma Unit included in the
VI/Dermoscopy evaluation. In all but 1 clinic site, the sole indication for imaging was that the
pigmented lesion was to be excised, usually because of a clinical suspicion
Setting: Private skin cancer clinics in Australia, staffed by general practitioners
Prior testing: In 8/9 clinics, included lesions were to be excised, usually because of a clinical
suspicion. “However, clinics were inconsistent in imaging excised lesions from their own practices,
with some clinics obtaining images of lesions with a predominately high probability of melanoma.”
Setting for prior testing: Private care
Exclusion criteria:
Awkwardly situated lesions (eg, eyelids, some parts of the pinna, some genital sites, and perianal
and mucosal surfaces); acral lesions; non-pigmented pure amelanotic lesions (based on dermoscopy
imaging); benign non-melanocytic lesions excluded fromone classifier. Poor-quality index test image
- lesions outside the field of view (24 x 18 mm), contamination of calibration surfaces, or excess
artifacts (hair, air bubbles, or movement artifacts). Ulcerated lesions, or diagnosed as pigmented
basal cell carcinoma, pigmented Bowen’s disease, or squamous cell carcinoma
Sample size (participants): N included: NR
Sample size (lesions): N eligible: 2430; N included: 1644 training; 786 test set
Participant characteristics: None reported
Lesion characteristics: None reported
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Index tests Visual inspection (VI)
Method of diagnosis:
Prior test data:
Diagnostic threshold:
Diagnosis based on:
Number of examiners
Observer qualifications:
Experience in practice:
Experience with index test:
Dermoscopy No algorithm
Method of diagnosis: Dermoscopic images
Prior test data:Clinical examination and/or case notes clinical photographs and participant histories
Diagnostic threshold:Not reported. No details on lesion characteristics used; data can be extracted
at 2 thresholds: correct diagnosis of melanoma (in situ or invasive) - excise decision
Diagnosis based on: Average (n = 13)
Observer qualifications: GP 3; Dermatology registrar 3; Dermatologist 4 (one local practising
dermatologists (Sydney), plus 3 international dermoscopy experts who headed pigmented lesion
clinics)
Experience in practice: Mixed experience (low and high experience combined)
Experience with index test: Mixed experience
Had clinical and dermoscopy photographic images (taken with a Heine Dermaphot camera, Heine
Ltd, Herrsching, Germany)
Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: SolarScan (Polartechnics Lts, Australia) (Linear discriminant analysis classifier)
System details:
Dermoscopy video unit with internal algorithm for image analysis. The algorithm model used by
SolarScan is an optimised set of fixed discriminant variables with associated weighting factors and
relationships features (Australian Patent application No. 20022308395 and Australian Patent No.
2003905998)
Derivation study (internal validation)
Described in prior study Menzies 2001, referenced.
Various properties of colour, pattern, and geometrywere extracted from the segmented lesion images.
The participant history features (see below) and 103 image analysis variables, in combination with
the diagnostic weights (based on a linear representation (range, 0.25 - 20) of correctly classifying
the lesion as benign or melanoma), were used in the training set to model 2 diagnostic algorithms
Lesion characteristics assessed:
103 automated image analysis variables extracted, consisting of various properties of colour, pattern,
and geometry. Number analysed not reported
Additional predictors included:
Predictors includedwhether the lesionhad,within the previous 2 years, bledwithout being scratched,
changed in colour or pattern, or increased in size
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: None reported
CAD output: Probability of melanoma, with cut-off (not provided) for benign vs melanoma
Diagnostic threshold: Threshold not reported
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Target condition and reference
standard(s)
Reference standard Histological diagnosis plus follow-up
Histology (not further described): 71% of total dataset (n = 1725), presumably including all disease-
positive
Clinical follow-up plus histology of suspicious lesions; Length of follow-up: 3 months. 26% of full
dataset (n = 632)
Expert opinion. 3% of image set were diagnosed clinically but not excised
Target condition (Final diagnoses). All numbers are for complete dataset
Melanoma (invasive): 238; Melanoma (in situ): 144
Benign naevus: 1835, benign melanocytic; Other: 213 benign non-melanocytic, incl 140 SK
Flow and timing Exclusions from analysis: None
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Yes
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Unclear
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
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Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
No
High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
High
Mohr 2013
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective; dermoscopic images assessed remotely from the participant
Period of data collection: January 2009 to November 2010
Some overlap in study population with Malvehy 2014 possible (no author reply), as ascertained by
similar recruitment centres and overlapping periods of data collection
Country: Conducted at 19 private and/or academic dermatological centres located in Germany,
Hungary, Sweden, Switzerland, and U.K
Test set derived: Data randomised into training set (approximately 40% of data) and test set
(approximately 60%)
Patient characteristics and set-
ting
Inclusion criteria: Adults of any ethnic group, aged at least 18, with 1 or more primary skin lesion
(s), at least 2 mm in diameter, located on normal uninflamed skin and requiring full excision for
histopathological analysis
Setting: Secondary; authors institutions primarily listed as Dept Dermatology with 1 “Division of
Imaging and Technology”
Prior testing: Selected for excision
Exclusion criteria: > 8 lesions per person; metastatic or recurrent; patients with lesions under finger
and toe nails, in sites where the electrode could not reach, e.g. between toes, those lesions with
abnormal reference areas (usually inflammatory skin disease like eczema and psoriasis), those with
lesion in scars or striae, crusted lesions and those previously subjected to any surgical procedure
Sample size (participants): N eligible: NR; N included: 1134
Sample size (lesions): N eligible: NR; N included: 1300
Participant characteristics: NR
Lesion characteristics: Median Breslow thickness of 0.43 mm (67 invasive melanomas)
Index tests Computer-assisted diagnosis - Spectroscopy-based
EIS-CAD system: Nevisense predecessor (SciBase, Sweden) (SVM classifier)
System details:
Electrical impedance wasmeasured with the SciBase III electrical impedance spectrometer, equipped
with a spring-loaded probe and a disposable 5-bar electrode. The system measures bio-impedance
of the skin at 35 different frequencies, logarithmically distributed from 1.0 kHz to 2.5 MHz, at 4
different depths utilising 10 permutations
Derivation study (internal validation)
Classification algorithm calibration and testing was conducted in 2 stages. In the first stage of
development, the data were randomised into 2 cohorts for calibration and verification, utilising
40% and 60% of the available data respectively. In the second stage approximately 55% of the data
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were used for calibration and the whole data set was used for verification (second algorithm, not
extracted)
Lesion characteristics assessed:
“The electrical impedance data obtained from each measurement represented a very large data set
consisting of the complex ratio of voltage to current, composed of the magnitude and phase shift
at 35 frequencies for 10 permutations yielding a data set of 700 variables for each measurement.
By combining permutations and frequencies, a large EIS feature space could be constructed. The
features’ ability to differentiate between melanoma and benign cutaneous lesions was then ranked
and, by means of cross-validation, the optimum number of features was extracted”
Additional predictors included: None reported
Method of diagnosis:
Stored EIS measurements
CAD-based diagnosis
Prior/other test data: None reported
CAD output: Dichotomous outcome: malignant vs benign
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Type of reference standard: Histological diagnosis alone
Details: Lesions were excised and underwent usual histopathology at investigational site. A fur-
ther histopathological evaluation was undertaken for study purposes by a panel of 3 experienced
histopathologists who evaluated each lesion independently using information from clinical diagno-
sis and histopathology referral reason; blinded from the investigational site’s original histopathology
diagnosis. If they agreed, the diagnosis was considered as the histopathological gold standard (HGS)
Disease-positive: 166; Disease-negative: 280 (Total 446 in test set, after exclusions from analysis)
Target condition (Final diagnoses)
67 invasive melanomas, 30 melanoma in situ, 21 BCC, 4 cSCC
38 severely dysplastic, 185 moderate dysplasia, 64 benign naevi, 22 seborrheic keratosis, 9 other
Flow and timing Participants exclusions from analysis:
549/1300 lesions excluded from analysis, mainly due to poor reference measurement quality (n =
290). Other reasons were: screening failure 2, protocol violations 72, no measurements performed
35, unable to map lesions with measurements 9, lesion not excised 18, poor histopathology 11,
no consensus diagnosis reached by pathologists 20. Expanded exclusions: bleeding, traumatised or
ulcerated lesion 38, lesion located on acral skin 11, surface area not measurable 34, insufficiently
covered with measurements 2, no clinical suspicion of melanoma 5, hair-bearing areas 2
An additional 6 lesions excluded by review team: 6 undefined thickness melanomas excluded from
MM1 to give total sample of 446 − 6 = 440
Time interval to reference test:
Consecutive, excision within 2 weeks of EIS measurements; prospective recruitment: “After obtain-
ing informed consent from each patient, eligible lesions destined for excision weremeasured with the
SciBase III electrical impedance spectrometer (SciBase AB, Stockholm, Sweden). After a maximum
of 14 days the lesions were surgically excised and subjected to histopathological evaluation.”
Comparative
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Yes
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
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Was
model overfitting accounted for
during model development?
Yes
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
Unclear High
DOMAIN 2: Index Test Visual inspection
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
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the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
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Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Mollersen 2015
Study characteristics
Patient sampling Study design: Case series
Data collection: Unclear
Period of data collection: March to December 2013
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria:
Adult patients scheduled for excision of a PSL and those with nonpigmented skin lesions if
melanoma, BCC, or SCC was a potential differential diagnosis. The presence of hairs and bubbles,
lesion size, inadequate segmentation, etc. were not used as exclusion criteria
Setting: Private dermatology practice
Prior testing: Scheduled for excision on basis of clinical diagnosis, because of concern about ma-
lignancy or when requested by the patient for other reasons (no further details)
Setting for prior testing: Unspecified
Exclusion criteria: NR
Sample size (participants): Eligible NR, Included 516
Sample size (lesions): Eligible NR, Included 877
Participant characteristics: Median age: 53 yrs (range 18 to 93); male 53%
Lesion characteristics:Median Breslow thickness of 0.50 mm (23 invasive melanomas); maximum
Breslow thickness 2.25 mm
Index tests Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: Naevus Doctor (ND) (classifier NR)
System details:
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Computerised image analysis system coupled to digital dermoscope. ND takes a dermoscopic image
from the Canon/DermLite device as input and classifies the lesion. ND is still in an experimental
phase
“All skin lesions were photographed prior to excision with a digital camera (Canon G10, Canon
Inc., Tokyo, Japan) with an attached dermoscope (DermLite FOTO, 3Gen LLC, California, USA)
and with a videodermoscope (DermoGenius ultra, DermoScan GmbH, Regensburg,Germany)”
No derivation aspect (external validation study)
Described in previous study Mollersen 2015 in press, reference #37
Lesion characteristics assessed: NR
Additional predictors included: None reported
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: Clinical diagnosis
CAD output: Probability of malignancy
Diagnostic threshold: CAD system tuned to 95% melanoma sensitivity
Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: MoleExpert (ME) (classifier NR)
System details:
ME (MoleExpert micro Version 3.3.30.156) takes a dermoscopic image from the DermoGenius
device as input. ME is intended for use on melanocytic lesions only
“All skin lesions were photographed prior to excision with a digital camera (Canon G10, Canon
Inc., Tokyo, Japan) with an attached dermoscope (DermLite FOTO, 3Gen LLC, California, USA)
and with a videodermoscope (DermoGenius ultra, DermoScan GmbH, Regensburg,Germany)”
No derivation aspect (external validation study)
No information provided (ME is a commercial system developed by others and used as a comparator
in this study)
Lesion characteristics assessed:
Features of ABCD system plus other features (not listed), e.g. colour variation and grey veil
Additional predictors included: None reported
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: Clinical diagnosis
CADoutput:Number between−5.00 and 5.00, where high values indicate suspicion of melanoma
Diagnostic threshold: CAD system tuned to 95% melanoma sensitivity
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Details: All excised lesions were examined by a dermatopathologist. In the case of a malignant
diagnosis, a second dermatopathologist examined the excised lesion and a consensus diagnosis was
set
Disease-positive: 107; Disease-negative: 278
Target condition (Final diagnoses)
Melanoma: invasive 25, in situ 19; BCC: 70, cSCC 6, adnexal carcinoma 1
Benign diagnoses: 38 benign non-melanocytic; 13 collision tumours; 13 AK; 11 Bowen’s disease;
79 Sebhorrheic keratosis; 595 benign naevus
Flow and timing Exclusions from analysis:
1 lesion lacking clinical diagnosis; of 875 lesions with histopathological diagnosis, 4 were excluded
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because ME did not give an output (1 naevus, 1 seborrheic keratosis, 1 BCC, and 1 SCC) and 1
was excluded because the Canon/DermLite image was lost (melanoma in situ)
Time interval to reference test: NR
Time interval between index test(s): Appears consecutive
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
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Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Monheit 2011
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective
Period of data collection: January 2007 to July 2008
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: PSLs scheduled for biopsy in toto, with diameter ≥ 2 mm
Setting: Specialist unit (skin cancer/pigmented lesions clinic). 3 sites were academic institutions
and 4 sites were dermatologic practices highly experienced in managing PLs
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Unspecified
Exclusion criteria:
Difficult-to-diagnose lesions; Location/site of lesion anatomic site of pigmented lesion not accessible
to the device; within 1 cm of the eye; or on palmar, plantar, or mucosal (eg, lips, genitals) surface
or under nails; lesion size diameter < 2 mm or > 22 mm excluded
Previous history of skin cancer/prior treatment at site lesion previously biopsied, excised, or trau-
matised
Other characteristics: known allergy to isopropyl alcohol; skin not intact (e.g. open sores, ulcers,
bleeding); in an area of visible scarring; or containing foreignmatter (eg, tattoo ink, splinter, marker)
Sample size (participants): Eligible: 1383; Included 1257
Sample size (lesions): Eligible: 1831; Included 1632
Participant characteristics:Median age 46 yrs (Range 7 - 97); Male 575 (45.7%); Ethnicity:White
1232 (98%), Black or African-American 2 (0.2%), Asian 17 (1.4%), Other 6 (0.5%). Thickness/
depth: ≤1 mm: 69/70 invasive MM (99%), 1.01 - 2.00 mm: 1/70 (1%)
Median Breslow 0.36 mm (70 invasive MM)
Index tests MSI-CAD system: MelaFind (EO Sciences, USA) (classifier NR)
System details:
Multispectral imaging system with integrated image analysis software; device takes images in vivo.
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MelaFind takes images at 10 spectral bands, between 430 - 950 nm
No derivation aspect (external validation study)
The properties of these images as well as image analysis methods have been previously described
(Gutkowicz Krusin 1997, Gutkowicz-Krusin 2000, Gutkowicz-Krusin 2007 and Elbaum 2001)
Lesion characteristics assessed: NR
Additional predictors included: None
Method of diagnosis:
In-person diagnosis
CAD-based diagnosis
Prior/other test data: No further information used
CAD output:
Binary output: (1) positive, (lesion should be considered for biopsy to rule out melanoma); and
(2) negative (lesion should be considered for later evaluation)
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Histology (not further described)
N participants/lesions: 1632
Disease-positive: 175, Disease-negative: 1457
Target condition (Final diagnoses)
Melanoma: invasive 70, in situ 57; BCC: 23; cSCC: 10, Severe dysplasia: 43
Benign diagnoses: Mild/moderate dysplasia 998; Sebhorrheic keratosis 93; Benign naevus 217,
atypical melanocytic hyperplasia (AMH) or atypical melanocytic proliferation (AMP) 5, actinic
keratosis 16, other keratosis 10, lentigo 16, other 14
Flow and timing Exclusions from analysis:
20 lesions with the pre-biopsy dermatologic diagnosis of melanoma were excluded from the primary
MelaFind analysis; 1 withdrew, 3 clinician deemed ineligible, 14 dermatopath deemed ineligible, 19
missing/inadequate histology slides, 162 imaging failed (operator errors, too many bubbles, lesion
not centred), 36 MelaFind or camera malfunction, 61 operator or MelaFind error (lesion too small
to visualise, automatic segmentation falied)
Time interval to reference test: Unclear
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
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Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Was an adequate spectrum of
cases used to train the algo-
rithm?
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
Low High
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DOMAIN 2: Index Test Visual inspection
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Piccolo 2002
Study characteristics
Patient sampling Study design: Case series
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: NR; 6-month period
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: Pigmented lesions excised because of equivocal dermoscopic findings or at the
patient’s request
Setting: Secondary (general dermatology); from authors’ institution
Prior testing: Dermatoscopic suspicion; Patient request for evaluation/excision
Setting for prior testing: NR
Exclusion criteria: None reported
Sample size (participants): N included: 289
Sample size (lesions): N included: 341
Participant characteristics: Mean age 33.6 yrs (range 3 - 83); Male: 127 (43.9%); Fitzpatrick
phototype I to II (31.4%); Type III (42.2%); Type IV - V (26.4%)
Lesion characteristics: None reported
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Index tests Dermoscopy No algorithm
Method of diagnosis: Clinical photographs and dermoscopic images Cases were clinically and
dermoscopically evaluated on a high-resolution colour monitor, in a random sequence
Prior test data: Unclear. Not specifically described but appears to be images only
Diagnostic threshold: NR
Diagnosis based on: Single observer (n = 2)
Observer qualifications: Dermatologist; Resident clinician with minimal training in PSLs
Experience in practice:
High experience or ‘Expert’ 5 years of experience; Low experience or recently qualified minimal
training in PSLs (6months of experience, comprising 8 hours of specialised training on 3 consecutive
days and 2 hours a week in the routine of dermoscopy)
Experience with index test: Mixed
Any other detail: Stereomicroscope with magnifications varying from x6 to x40
Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: DEM-MIPS (Digital Epi Microscopy Melanoma Image Processing Software;
Biomips SRL, Siena, Italy) (ANN classifier)
System details:
“DEM-MIPS is designed to evaluate different colorimetric and geometric parameters of a lesion
automatically in real time. All digital images of PSLs were collected in a Truevision Advanced
Graphic Array format file with a size of 887 kB for each image.” Digital dermoscopic images were
framed at x16 magnification before analysis with DEM-MIPS
No derivation aspect (External validation study)
Described in prior study “DEM-MIPS is based on an ANN trained with 100 PSLs (50non-
melanomas and 50 melanomas) and is designed toevaluate different colorimetric and geometric
parametersof a lesion automatically in real time.” No citation given
Lesion characteristics assessed: Evaluates colorimetric and geometric features (NR)
Additional predictors included: None reported
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: No further information used
CAD output: NR
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Histology (not further described);Disease-positive: 13; Disease-negative: 328
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or NR): 13
Sebhorrheic keratosis: 3; Benign naevus: 316; Other: 7 dermatofibromas, 2 angiomas
Flow and timing Time interval to reference test: NR
Comparative
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
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Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear
Low High
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
Yes
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condition?
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Piccolo 2014
Study characteristics
Patient sampling Study design: Case series
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: September 2010 and October 2013
Country: Italy
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Patient characteristics and set-
ting
Inclusion criteria: Dermoscopically atypical PSLs selected from the archives of the Dermatology
Department at the University of L’Aquila, Italy
Setting: Secondary (general dermatology)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: Location/site of lesion - acral sites and the face
Sample size (participants): N included: 165
Sample size (lesions): N included: 165
Participant characteristics: Mean age 43.5 yrs (range 12 - 84); Male: 59.4%
Lesion characteristics: Lesion site: upper extremities 18 (11%); lower extremities 53 (32.1%); 62
(37.5%) on the back; 32 (19.4%) on the chest. Melanoma thickness 87.9% (29/33) < 0.75 mm;
12.1% (4/33) >1 .5 mm
Index tests Visual inspection (VI)
Method of diagnosis:
Prior test data:
Diagnostic threshold:
Diagnosis based on:
Number of examiners
Observer qualifications:
Experience in practice:
Experience with index test:
Dermoscopy ABCD
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Semi-quantitative. Total dermoscopic score is calculated (TDS) - a PSL with
a TDS < 4.75 benign, TDS 4.75 to 5.45 suspicious of malignancy, TDS > 5.45 highly suggestive
of melanoma
Diagnosis based on: Single observer (n = 4)
Observer qualifications: 3 dermatologists and 1 GP with different degrees of dermoscopic experi-
ence
Experience in practice: Mixed
Experience with index test:
Experience scored using following criteria: number of years specialising in dermoscopy (score: 1. 0
- 1 year; 2. 2 - 5 years; 3. > 5 years); number of PSLs assessed by dermoscopy on a daily basis (1. <
10 lesions/day; 2. 11 - 20 lesions; 3. 21 - 30 lesions; 4. > 30 lesions); number of relevant workshops/
seminars attended (1. 0 - 1 workshops/seminars; 2. 2 - 5 workshops/seminars; 3. > 5 workshops/
seminars); and the number of authored publications on dermoscopy (1. 0 - 1 publications; 2. 2 - 5
publications; 3. 6 - 10 publications; 4. > 10 publications)
Observer 4 considered low experience (underwent dermoscopic training by studying an interactive
atlas of dermoscopy between T0 and T1); Observer 1 High experience /‘Expert’; Observers 2 and
3 ); moderately experienced
Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: Nevuscreen ® (Arkè s.a.s., Avezzano, Italy) (classifier NR)
System details:
Digital database containing image analysis software, coupled to digital dermoscope. Nevuscreen
software automatically analyses ABCD features
No derivation aspect (external validation study)
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Lesion characteristics assessed:
ABCD features. “After image scanning, each pixel is classified in accordance with the main der-
moscopic colour to which it is closest. Once the different colour regions are identified, DDA can
also calculate asymmetry by considering the overall asymmetry parameter.”**Differential dermo-
scopic structures Pigment network, Globules, Streaks, Black dots and Structureless areas represent
notable criteria in dermoscopic evaluation. “Various digital filters (median filters, essentially) are
used to obtain a morphological analysis for recognising particles of various dimensions, which are
subsequently evaluated for size and shape and compared to numerous sample images. Once the
different structures have been recognised, their asymmetry is calculated as a contribution to the
overall asymmetry parameter”
Additional predictors included: Clinicians use CAD output to assist their diagnosis
Method of diagnosis:
In-person diagnosis
CAD-aided diagnosis
Prior/other test data: 4 test operators 4
Operator qualifications:
GP
Dermatologist
Experience in practice: Mixed experience (low and high experience combined)
Experience with index test: Mixed experience (low and high experience combined)
CAD output: TDS
Diagnostic threshold:
TDS: < 4.75 benign, 4.75 - 5.45 suspicious, > 5.45 highly suggestive of melanoma
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Target condition (Final diagnoses)
Melanoma (invasive): 23; Melanoma (in situ): 10
Benign naevus: 105 Clark naevi; 19 Spitz/Reed naevi; 5 blue naevi; 3 dermal naevi
Flow and timing Excluded participants: NR
Time interval to reference test: Reference test conducted first not clear what the time interval is
between this and the current index test(s)
Time interval between index test(s): Not clear - looks like it was simultaneous
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
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Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Was an adequate spectrum of
cases used to train the algo-
rithm?
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear
Low High
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DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Rubegni 2002a
Study characteristics
Patient sampling Study design: Case series
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: 1996 to 2001
Country: Italy
Test set derived:NR. “To train the SLP-ANN, 550 of the 588 available cases were used (30 nevi and
200 melanomas in 550 sessions, each with 2 subsets); 549 cases were used for training, and 1 case
at a time was used to check overfitting and stepwise feature selection. A third small, independent
subset consisting of the other 17 melanomas and 21 nevi was used to test SLP-ANN diagnostic
performance on data not used in the training process.”
Patient characteristics and set-
ting
Inclusion criteria: Excised PSL, clinically atypical (asymmetrical with variegated colour), flat and
impalpable. “All were difficult to diagnose and therefore suitable for morphologic and parametric
evaluation of early melanoma”
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion; selected for exci-
sion (no further detail). Described as clinically atypical and difficult to diagnose
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria:
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Difficult-to-diagnose lesions: Location/site of lesion acral, lesion size only 0.4 - 1 cm in diameter
were included; non-melanocytic appearance pink skin lesions (amelanotic melanoma and classical
Spitz naevi); blue naevi were excluded, as were lentigo maligna, lentigo maligna melanoma
Sample size (participants): N included: 588 included (1 per participant)
Sample size (lesions): N eligible: 4200 PSLs excised; N. included: 588 included (38 in test set)
Participant characteristics: Mean age 49 yrs (± 15); Male: 40% (of full sample; n = 588); 100%
pigmented
Median Breslow 0.4 mm (157 invasive melanomas)
Index tests Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: DB-Mips (Biomips Engineering, Italy) (ANN classifier)
System details:
Dermoscopy unit, internal stereomicroscope, internal DB, pattern analysis system. Lesions were
imaged by ELM at a magnification of x16 with the DBDermo-Mips apparatus
Derivation study (internal validation)
Described in prior study Andreassi 1999
Lesion characteristics assessed:
Approach to feature selection: Computer-aided stepwise technique to choose the number of dis-
criminant features for optimum generalization
“The parameters, as previously described, belonged to 4 categories: geometries, colors, textures
and islands of color. Geometric: area, maximum and minimum* diameters, radius, variance of
contour symmetry, circularity*, fractality of borders and ellipsoidality. Color: mean values of red*,
green and blue inside the lesion; mean values of red, green* and blue of healthy skin around the
lesion; deciles of red*, green and blue inside the lesion; quartiles of red, green and blue* inside
the lesion, mean skin-lesion gradient*, variance of the border gradient, border homogeneity and
interruptions of the border. Texture: mean contrast* and entropy of lesion as well as contrast and
entropy fractality. Islands of color: peripheral dark regions*; dark area; imbalance of dark region;
green area; red area; dominant green region imbalance; blue-gray area; blue-gray regions; transition
area*; transition region imbalance*; background area*; background region imbalance*; red, green and
blue multicomponent; and number of red, green and blue percentiles inside the lesion.” (referenced
to Andreassi 1999); the asterisks were added by the review team and correspond to the features
selected by the model
Additional predictors included: No further information used
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: None reported
CAD output: Diagnosis suggested (e.g. melanoma, benign melanocytic naevus)
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Histology (not further described)
Histopathologic diagnosis of melanoma and naevi was made according to the criteria of the NIH
Consensus Conference (1992). Histopathologic diagnosis discordance was c9%. These were classi-
fied as melanoma or naevi when at least 2 of 3 dermopathologists agreed on the diagnosis
N participants/lesions: 588, 38 in test set
Disease-positive: 17; Disease-negative: 21
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 17
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Benign diagnoses: 21 (not further specified)
Flow and timing Exclusions from analysis: None reported
Time interval to reference test: NR, but appears consecutive
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Was an adequate spectrum of
cases used to train the algo-
rithm?
Yes
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Unclear
Was
model overfitting accounted for
during model development?
Yes
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
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Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Seidenari 1998
Study characteristics
Patient sampling Study design: Case-control
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection NR; 4-year period
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria:
Melanomas and benign PSLs from a larger series of PSLs used to develop a new automated classifier;
all melanomas with x20 magnification images were included plus a random sample of benign lesions
with the same magnification. For the larger series, lesions were referred by dermatologists or general
physicians because of 1 or more PSLs that were difficult to interpret on clinical grounds alone,
numerous PSLs, or because the patients were at increased risk for melanoma or had had a malignant
PSL in the past
Setting: Secondary
Prior testing: Clinical suspicion of malignancy
Setting for prior testing: Primary; secondary (general dermatology)
Exclusion criteria: None reported
Sample size (participants): NR
Sample size (lesions): N eligible: 917; N included: 100
Participant characteristics: None reported
Lesion characteristics: Melanoma thickness: ≤ 1 mm : 70.8% (n = 46), < 1 mm 58.5% (n = 38).
mean thickness 0.73 ± 0.69 mm
Index tests Dermoscopy No algorithm
Method of diagnosis: Dermoscopic images; (obtained via videomicroscopy)
Prior test data: No further information used; “Images appeared in a random sequence on the
computer screen, and no information about the patient (such as history, skin site, age of the patient,
evolution of the lesion) was given to the evaluators”
Diagnostic threshold: Clinical diagnosis
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Diagnosis based on: Single observer (n = 2)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Low - 1 “untrained” dermatologist; High - 1 routinely used videomi-
croscopy
Any other detail
For instrumental examination a 10- (39 cases), 20- (501 cases), or 50-fold-magnification (377 cases)
was chosen according to the size of the lesion, enabling the whole lesion to be seen on the monitor.
For the study, the 31MMs with x20 magnification were selected plus a random sample of 59 benign
Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: DB-MIPS (Biomips Engineering, Italy) (Multivariate discriminant analysis
classifier)
System details:
Digital videomicroscope equipped with a dedicated programme for the diagnosis of melanocytic
PSL by evaluating digital features referring to benign and malignant PSL images. For this study an
NTSC VMS-110A videomicroscope (Scalar, Mitsubishi, Tama-shi, Tokyo, Japan) was used
No derivation aspect (external validation study)
Lesion characteristics assessed:
Radius, area and perimeter of the lesion, symmetry and circularity, fractality (shape), texture analysis,
colour expressed as red, green and blue components, skin lesion gradient, ’dark areas’ inside the
lesion. All described in detail
Additional predictors included:
Unclear: for each participant personal data and information such as the site of the lesion, the
magnification, the clinical and the histological diagnosis were recorded. Unclear how these were
used
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: Unclear, NR
CAD output:
Graphical output and numerical output of features provided. Diagnosis suggested (e.g. melanoma,
benign melanocytic naevus)
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Details: describes using “conventional histopathologic criteria”
Disease-positive: 31; Disease-negative: 59
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 31
’Benign’ diagnoses: 59 “nonmelanoma cases consisted of nevi including dysplastic nevi”
Flow and timing Participant exclusions: None reported
Index test to reference standard interval: Not described
Comparative
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
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Was
model overfitting accounted for
during model development?
Yes
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
Unclear High
DOMAIN 2: Index Test Visual inspection
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
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the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Seidenari 1999
Study characteristics
Patient sampling Study design: Case-control
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: NR
Country: Italy
Test set derived: Not clearly reported, but appears that the training set was randomly sampled, but
the melanomas in the training set were supplemented with images of lesions of comparable size but
thicker than 0.75 mm, randomly selected from other melanoma images
Patient characteristics and set-
ting
Inclusion criteria: PSLs with x20 magnification images
Setting: Secondary (general dermatology) From authors’ institution
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (participants): NR
Sample size (lesions): N eligible: 461; N included: 383 in test set, 78 in training set
Participant characteristics: Thickness ≤ 1 mm: 18 (100%) < 0.75 mm (8 in situ)
Index tests Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: DB-MIPS (Biomips Engineering, Italy) (Multivariate discriminant analysis
classifier)
System details:
Dermoscopy unit, internal stereomicroscope, internal DB, DB-MIPS pattern analysis system -
integrated database stores the patient’s data and the description of the lesion along with the image
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icons. 38 features analysed (grouped into geometries, colours and Burroni’s islands of colours)
Derivation study (internal validation)
Lesion characteristics assessed:
The borders of the lesion were automatically identified, plus estimation of radius, area and perimeter
of the lesion, symmetry and circularity, fractality (shape), texture analysis, colour expressed as red,
green and blue components, skin lesion gradient, ’dark areas’ inside the lesion. All described in detail
Approach to feature selection DBDermo-MIPS software. “Discriminant analysis enables the iden-
tification of variables that are important for distinguishing between the groups in the training set
in order to develop a procedure for predicting group membership for new cases in which group
membership is undetermined (test set). Using the training set data, a threshold score was established
that enabled the attribution of each malignant lesion to the right group (100% sensitivity). The
same value was employed for discriminating benign and malignant lesions belonging to the test set”
Additional predictors included:
Unclear; for each participant personal data and information such as the site of the lesion, the
magnification, the clinical and the histological diagnosis were recorded. Unclear how these were
used
Method of diagnosis:
In-person diagnosis
CAD-based diagnosis
Prior/other test data: Unclear
CAD output: NR
Diagnostic threshold:
Threshold not reported. Using the training set data, a threshold score was established that enabled
the attribution of each malignant lesion to the right group (100% sensitivity). The same value was
used for discriminating benign and malignant lesions belonging to the test set
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Histology (not further described)
N participants/lesions: 461 (383 in training set)
Disease-positive: 18; Disease-negative: 365
Target condition (Final diagnoses):
Melanoma: invasive 10, in situ 8
’Benign’ diagnoses: 365 non-melanoma cases consisted of benign naevi including commonnaevi and
clinically dysplastic naevi (> 5mm indiameter, irregular or ill-definedborder, irregular pigmentation)
Flow and timing Exclusions from analysis: None
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
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Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
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Serrao 2006
Study characteristics
Patient sampling Study design: Case series
Data collection: Retrospective
Period of data collection: September 2002 to September 2005
Country: Portugal
Patient characteristics and set-
ting
Inclusion criteria:
Melanocytic lesions from patients with multiple atypical naevi, personal/familiar melanoma history
or doubtful cases on clinical inspection who were referred to a Dermoscopy Unit
Setting: Specialist dermatoscopy unit (skin cancer/pigmented lesions clinic)
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion. Mixed popula-
tion; high risk or clinically suspicious, or both
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: Unequivocal appearance/diagnosis. Clearly benign lesions by clinical examina-
tion were not referred
Sample size (participants): N eligible: 1186; N included: 344
Sample size (lesions): N included: 652
Participant characteristics: Mean age 40 years (SD ± 14), age range: 11 to 84 years; 49% in the
35 - 64 age group, 33% aged 25 to 34 years old, 3% aged under 18; Male: 33% (114)
High-risk characteristics: history of melanoma/skin cancer (%) 19%, family history of melanoma
(%) 3%, 24% history of dysplastic naevi
Lesion site: Trunk: back 56% chest 20%, Lower limbs/hip: 13%
Thickness/depth: ≤ 1 mm: 29/41 plus 8 in situ; > 1 mm: 3
Index tests Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: microDERM (Visiomed AG, Germany) (ANN classifier)
System details:
Dermoscopy unit with internal camera containing analysis system. DANAOS software combines
analytical system based on ABCD with database of 21,000 PSLs. The system has an integrated filter
that reduces influence of hairs in the analysis of lesions
No derivation aspect (external validation study): Described in prior study Fidalgo 2003
Lesion characteristics assessed: Lesions assessed for about 50 parameters (geometrical, colour and
internal pattern)
Additional predictors included: None reported
Method of diagnosis:
Dermoscopic images
CAD-based diagnosis
Prior/other test data: Unclear
CAD output: DANAOS score indicating risk of malignancy
Diagnostic threshold: High-risk DANAOS score (> 6.5); data also presented for score of > 7.5
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Criteria used for excision were:
Dermoscopic suspicious lesions, irrespective of the DANAOS score
All lesions with high-risk DANAOS score (> 6.5)
Significant dermoscopic or clinical architectural change, irrespective of the DANAOS score
Disease-positive 41; Disease-negative 611
Target condition (Final diagnoses)
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Melanoma: invasive 32; in situ 9
Benign diagnoses: 472 Benign naevus, 139 dysplastic naevus
Flow and timing Exclusions from analysis: None
Time interval to reference test: Unclear; CAD performed in advance of histology
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Was an adequate spectrum of
cases used to train the algo-
rithm?
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
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Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Sgouros 2014
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective
Period of data collection: 3-month period; dates not specified
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria:
Pigmented skin tumours, clinically suspicious for the diagnosis of melanoma, BCC or SCC and the
inability to establish a definite diagnosis on clinical grounds only
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (participants): N eligible: 180
Sample size (lesions): N eligible: 188; N included: 44 excised (authors included remaining 144
non-excised lesions but these only received expert diagnosis with no follow-up so not eligible for
our review)
Participant characteristics: Mean age 43 yrs (range: 2 - 95) (n = 188); Male: 97 (51.6%)
Index tests Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: SIAscope (MedX Health Corp, Canada) (classifier NR)
System details:
Spectrophotometric imaging system with hand-held skin probe (SIAscope, version NR) and inte-
grated software
No derivation aspect (external validation study)
Derivation described in prior study Moncrieff 2002
Lesion characteristics assessed:
Analysis of dermal melanin, erythematous blush, lesion asymmetry, collagen ’holes’, blood commas,
or irregularities in the collagen
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Additional predictors included: None
Method of diagnosis:
In-person diagnosis
CAD-based diagnosis
Prior/other test data:
Clinical examination and/or case notes
Dermoscopy
CAD output: SIAgraph and PCSA (see below)
Diagnostic threshold: Primary care scoring algorithm (PCSA) (Emery 2010); score ≥ 6 regarded
as suspicious
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Histology (excision)
N participant/lesions: 44
Disease-positive: 31; Disease-negative: 13
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 18
BCC: 10, cSCC: 3
’Benign’ diagnoses: 14
Flow and timing Excluded participants: 144 with only expert final diagnosis (excluded by review team)
Time interval between index test(s): Appears consecutive
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Yes
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Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear Low
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Stanganelli 2005
Study characteristics
Patient sampling Study design: Case series
Data collection:Retrospective image selection/Prospective interpretation **Dataset previously used
in Stanganelli 2000.
Period of data collection: NR
Country: Italy
Test set derived A training set of 22 melanomas and 218 melanocytic nevi was randomised from the
dataset. The test set was formed by the complement (the remaining 20 melanomas and 217 naevi)
. A further subset of images from the original dataset, consisting of 31 melanomas and 103 naevi,
was used for the comparison between observers and CAD; derivation of the subset not reported
Patient characteristics and set-
ting
Inclusion criteria: Melanocytic lesions from patients referred to the Skin Cancer Unit and under-
going clinical and dermoscopic evaluation
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
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Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (participants): N eligible: 1556 referred; N included: NR
Sample size (lesions): N eligible: 3274; N included: 477 melanocytic lesions; 237 in test set and
134 in comparison between CAD and human operators
Participant characteristics: None reported
Lesion characteristics: Melanoma thickness 61.2% < 0.75 mm
Index tests Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: DB-MIPS (Biomips Engineering, Italy) (SVM classifier)
System details:
Dermoscopy unit, internal steromicroscope, internal DB, pattern analysis system. Automatic Data
Analysis for Melanoma early detection (ADAM) software which analyses boundary shape, texture
and colour distribution
Derivation study (internal validation)
see also Stanganelli 1995 and Stanganelli 2000
Lesion characteristics assessed:
ADAM software is based on a quite recent mathematical technique of shape representation: the Size
Functions. “These are very general invariants designed to capture, in a formal and quantitative way,
the essential behaviour of some specified aspects (the so called measuring functions) of a signal (27,
28). In the present case, the examined signal is the image of a melanocytic lesion, and the aspects
concerned are: boundary shape, texture and color distribution. Size Functions are standardized
objects, easy to compute, to store and to compare. So the study is performed on the Size Function
instead of the original image. This yields a great simplification and, above all, a greatly focussed
analysis. The Size Function obtained from a curve with the distance from point C as measuring
function is shown in Figure 1”
Additional predictors included: No further information used
Method of diagnosis:
Dermoscopy images
CAD-based diagnosis
Prior/other test data: None reported
CAD output: Low risk, intermediate risk or high risk of melanoma
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard: Histological diagnosis plus cancer registry
All included lesions underwent histology but some were identified using a cancer-registry-based
follow-up of benign diagnoses
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 42 in full sample; 31 in CAD vs human observer
interpretation and 20 in test set
’Benign’ diagnoses: 435 melanocytic naevi; 103 in CAD-observer comparison and 217 in test set
Flow and timing Exclusions from analysis: None
Time interval to reference test: NR
Comparative
Notes -
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
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Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Yes
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
Low High
DOMAIN 2: Index Test Visual inspection
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear High
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DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Unclear
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
High
Terstappen 2013
Study characteristics
Patient sampling Study design: Case series
Data collection: NR
Period of data collection: NR
Country: Sweden
Patient characteristics and set-
ting
Inclusion criteria: Lesions clinically suspicious for melanoma and showing positive SIAscopic
findings
Setting: Secondary (general dermatology) (details from authors’ institution)
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion, showing positive
SIAscopic findings
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: Poor-quality index test image: 9 lesions excluded due to technical problems
Sample size (participants): N eligible: 69; N included: 60
Sample size (lesions): N eligible: 69; N included: 60
Participant characteristics:≤ 1 mm thickness: 17/29 melanomas; 8/29 melanomas Breslow thick-
ness < 0.76 mm (Clark II - III) and 9/29 Breslow thickness 0.76 − ≤ 1.0 mm (Clark II - III) and
12 lesions Breslow thickness ≥ 1.1 (Clark III - V)
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Index tests Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: SIAscope (Astron Clinica, UK) (classifier NR)
System details:
Spectrophotometric imaging systemwith hand-held skin probe (SIAscopeV) and integrated software
(Dermetrics Version 2.0, Astron Clinica Ltd., Great Britain)
No derivation aspect (external validation study)
Lesion characteristics assessed:Dermalmelanin, blooddisplacement, collagenholes, erythematous
blush
Additional predictors included: No further information used
Method of diagnosis:
In-person spectroscopic images (SIAgraphs)
CAD-based diagnosis
Prior/other test data: None reported
CAD output:
The instrument generates 4 images depicting the concentration of haemoglobin, melanin, collagen
and dermal melanin
Diagnostic threshold:
“SIAscopic findings indicating melanoma were applied using the method described by Moncrieff
(2002)” Results described for: “the combined features (presence of blood displacement with erythe-
matous blush, collagen holes and presence of dermal melanin)”. NBMoncrieff 2002 is a derivation
study for SIAscope and suggests a number of combinations of features indicative of melanoma, the
same features investigated here
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
The excised specimens were routinely processed and the histological sections, 4 µm thick, were
stained with haematoxylin and eosin. Before cutting the specimen in slices, the lesion was oriented
and the positions of the SIAscopic areas of interest were outlined by comparisons with the overview
clinical photo of the lesion
N participants/lesions: 60
Disease-positive: 29; Disease-negative: 31
Target condition (Final diagnoses)
Melanoma: invasive 29, in situ 13 (included as D-)
BCC: 2
Benign diagnoses: 2 sebhorrheic keratosis; 4 melanocytic lesions; 10 dysplastic naevi
Flow and timing Exclusions from analysis: 9/69 lesions (2 invasive melanoma, 2 melanoma in situ, and 5 benign
lesions) had to be excluded due to technical problems
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
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Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Study characteristics
Patient sampling Study design: Case series
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: January 1995 to March 2000 (test set April 1999 to March 2000)
Country: Italy
Test set derived: Chronological; acquired in last year of recruitment. Study population not ran-
domised (training set enriched with melanomas)
Patient characteristics and set-
ting
Inclusion criteria: Cutaneous pigmented lesions that required a surgical biopsy for diagnosis
Setting: Specialist unit (skin cancer/pigmented lesions clinic) Tumour Institute of Milan
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Unspecified
Exclusion criteria:
“Difficult to diagnose” lesions, thick and/or large melanomas and awkwardly situated lesions. like
those placed at the interdigital spaces, on ears, nose, eyelids, etc.; lesions on the scalp due to hair
interference
Sample size (participants): N eligible NR; N included: 534
Sample size (lesions): N eligible NR; N included: 573
Participant characteristics: Median age 36 yrs (range 10 - 95); 59.7% Male; thickness ≤ 1 mm:
91/132 MM (68.9%); thickness 0.16 to 3.24 mm. Median Breslow 0.68 mm; Mean diameter: 10
mm (range 3 to 39 mm)
Index tests Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: Telespectrophotometric system (ANN classifier; Linear discriminant classifier
also trained and reported, ANN selected at random for review)
System details:
Digital camera coupled with an illumination system with interference filters and computer for
storage and analysis of multispectral images. The Telespectrophotometric System consists of a CCD
camera, a set of 17 interference filters. a PC. and an illumination system composed by 2 halogen (
2 x 100 W) and 2 lamps (2 x 150 W) with emission in the infrared region
Derivation study (internal validation)
The training set is required for the instruction of the classifiers whose diagnostic performances
are evaluated against an independent verify set. The considerable fraction of cases devoted to the
classifier training was selected to include an adequate number of positives
Derivation described in prior studies Marchesini 1995, Tomatis 1998, Furina 2000
Lesion characteristics assessed:
For each spectral image, 5 parameters (lesion descriptors) were evaluated, based on ABCD and
related to colour and shape of the imaged lesion: mean reflectance, variegation index, compactness,
roughness, and area
Additional predictors included: No further information used
Method of diagnosis:
Spectroscopic images
CAD-based diagnosis
Prior/other test data: None reported
CAD output: NR
Diagnostic threshold: Threshold selected by authors using ROC analysis. No further information
provided
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Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Histology (not further described)
N participants/lesions: 573 (210 in test set)
Disease-positive: 132 (37 in test set); Disease-negative: 441 (136 in test set)
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 37 (test set)
’Benign’ diagnoses: 136 (test set)
Flow and timing Exclusions from analysis: None
Time interval to reference test: Appears consecutive: “images acquired in vivo before surgery”.
Interval not reported
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Was an adequate spectrum of
cases used to train the algo-
rithm?
Yes
Low High
DOMAIN 2: Index Test Computer-assisted diagnosis
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Was the CAD model evaluated
in an independent study popu-
lation?
No
Was
model overfitting accounted for
during model development?
Yes
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Tomatis 2005
Study characteristics
Patient sampling Study design: Case series
Data collection: Prospective
Period of data collection: September 2002 to April 2004
Country: Italy
Test set derived: The study population was split into 3 sets: train, verify and test. The cases were
randomly assigned to the above sets among all the 1391 lesions with histology
Patient characteristics and set-
ting
Inclusion criteria:
Cutaneous pigmented lesions with clinical and/or dermoscopic features that supported a suspicion
for cutaneous melanoma and therefore eligible for excision. A further set of lesions all diagnosed as
clearly benign common naevi at both clinical and dermoscopic evaluations that did not undergo
excision; data for these have not been included as > 50% of benign group must undergo histology
or active follow-up
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria:Difficult-to-diagnose lesions, Poor-quality index test image incorrectly acquired
or not correctly segmented by the system
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Sample size (participants): N eligible: 1359
Sample size (lesions): N eligible: 1485; N included: 1391 excised (94 excluded: lesions out of
focus, 46 cases, 3%, or system failure to correctly segment the lesion border (48 cases, 3%))
Participant characteristics: Median age 36 yrs (range 5 to 88); Male: 597 (43.9% of 1359);
Pigmented (%): 100%; Located on: head/neck: 2.9%, trunk: 66.2%, upper limbs/shoulder: 9.1%,
lower limbs/hip: 17%, limbs: 4.8%
Thickness/depth: ≤ 1 mm: 140/164 (85%) invasive MM; median thickness 0.58 mm, (0.1 mm to
2.7 mm), for 164 invasive MM. median size: 9 mm in maximum diameter; ≤ 6 mm in 44 cases
(24%)
Index tests Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: SpectroShade (MHT, Verona, Italy) (ANN classifier)
System details:
Illumination assembly located inside a PC and an external detection device placed in a hand-held
probe, with integrated image analysis software
Derivation study (internal validation)
“The training group (696 cases, including 90 melanomas) was used to optimise the inner fitting
weights of the neural network by means of a training algorithm. The verify set (348 cases, including
53melanomas) was used to properly stop the training process, preventing the so-called overlearning,
i.e. a drop in the generalisation capabilities of the classifier which would otherwise fit the noise
pattern of the data instead of defining a proper boundary between malignant and benign moles.
The test set (347 cases, including 41 melanomas) was used to confirm, by independent data, the
discrimination performances of the system as obtained from the previous data sets.”
Also described in prior studies Marchesini 1995, Tomatis 1998, Tomatis 2003
Lesion characteristics assessed:
Features analysed: (i) reflectance (R); (ii) variegation (V); (iii) area (A); (iv) dark area ratio (DAR)
; (v) dark island reflectance (DIR); (vi) dark distribution factor (DDF); (vii) dark permanence (D
PER)
Additional predictors included: No further information used
Method of diagnosis:
Spectroscopic images
CAD-based diagnosis
Prior/other test data: No further information used
CAD output: NR
Diagnostic threshold: Threshold set to produce sensitivity of 80%
Target condition and reference
standard(s)
Reference standard: - Histological diagnosis alone. Data provided for subgroup (test set) that all
underwent excision
Histology (not further described)
N participants/lesions: 1391 (347 in test set)
Disease-positive: 184 (41 in test set); Disease-negative: 1207 (306 in test set)
Target Condition (Final diagnoses)
Melanoma (invasive): 164 (full sample, number in test set NR);Melanoma (in situ): 20 (full sample,
number in test set NR); - Melanoma (in situ and invasive, or not reported): 41 (test set only)
BCC: 7 (full sample, number in test set NR)
Sebhorrheic keratosis: 27 (full sample, number in test set NR); ’Benign’ diagnoses: 280 dysplastic
naevus, rest various benign (893)
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Tomatis 2005 (Continued)
Flow and timing Time interval to reference test: NR “Before surgery, images of the 1485 pigmented lesions were
acquired in vivo.”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Was an adequate spectrum of
cases used to train the algo-
rithm?
Yes
Low High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Tomatis 2005 (Continued)
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Yes
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
No
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
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Tomatis 2005 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Walter 2012
Study characteristics
Patient sampling Study design: Randomised controlled trial, only experimental group included
Data collection: Prospective
Period of data collection: March 2008 to May 2010
Country: UK
Patient characteristics and set-
ting
Inclusion criteria:
Adults with any suspicious PSL, i.e. any lesion presented by a patient, or opportunistically seen by
a family doctor or practice nurse, that could not immediately be diagnosed as benign and about
which the patient could not be reassured
Setting: Primary 15 general practices in eastern England
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: Primary
Exclusion criteria: Those unable to give informed consent or considered inappropriate to include
by their family doctor
Sample size (patrticipants): N eligible: 1297; N included: 1293 in RCT, 643 in experimental
group
Sample size (lesions): N eligible: 1580; N included: 1583 in RCT, 788 in experimental group
Participant characteristics (whole population):Mean age: 44.6 yrs (SD 16.8). Male: 465 (36%)
. Ethnicity: white 1214 (93.9%); mixed 45 (3.5%); missing: 34 (2.6%)
Lesion characteristics. Lesion thickness ≤ 1 mm: in ’more than half ’ of MM
Index tests Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: SIAscope + MoleMate (classifier NR)
System details:
SIAscopy with MoleMate (software image management system) viewing platform and integrated
primary care scoring algorithm
No derivation aspect (external validation study)
Lesion characteristics assessed: Not described
Additional predictors included: None reported
Method of diagnosis:
In-person diagnosis, spectroscopic images (SIAgraphs)
CAD-aided diagnosis
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Walter 2012 (Continued)
Prior/other test data: Clinical history and naked-eye examination
Operators: 28 clinicians
Operator qualifications:
GP
2 nurse practitioners
Experience in practice: Mixed experience (low and high experience combined) as previously
recorded
Experience with index test: Low experience/novice users
CAD output: SIAgraphs and lesion score using Primary Care Scoring Algorithm
Diagnostic threshold: Primary Care Scoring Algorithm (6 or more points regarded as suspicious)
Target condition and reference
standard(s)
Reference standard: Histological diagnosis plus follow-up and expert opinion
Histology (not further described) 215 (histology result missing in further 4)
Disease-positive: 35; Disease-negative: 180
Clinical follow-up plus histology of suspicious lesions:22of the 411 referred participantsweremonitored
(not further described); 566 of the 1162 not referred underwent expert review and were then re-
assessed at 3 - 6 months
Disease-positive: 1; Disease-negative: 588
Expert opinion. Reviewed by 2 dermatology experts using the recorded clinical history and exami-
nation, a digital photograph, and MoleMate image where available
Disease-positive: 0; Disease-negative: 725
Target condition (Final diagnoses)
Melanoma (invasive): 30; Melanoma (in situ): 6; BCC: 10
’Benign’ diagnoses: 1306
Flow and timing Excluded participants: 417 withdrew from control group after randomisation - 10 did not attend
for dermatology assessment; 19 excluded; 1 died; 4 missing histology (in referred group; included
as benign?); plus 12 with unknown outcome (in non-referred group, assumed benign and included)
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
231Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Walter 2012 (Continued)
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
No
Was an adequate spectrum of
cases used to train the algo-
rithm?
Low High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
Low High
DOMAIN 2: Index Test Visual inspection
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Walter 2012 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
No
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Walter 2012 (Continued)
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
No
High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
High
Wells 2012
Study characteristics
Patient sampling Study design: Case-control
Data collection: Retrospective - MelaFind diagnoses from acquisition study were used
Retrospective image selection/Prospective interpretation - Clinical and dermoscopic images
Period of data collection NR
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: Pigmented lesions cases selected from a repository of lesions amassed during an
acquisition study conducted by MELA Sciences Inc for the US Food and Drug Administration
Setting: Company database (MELA Sciences Inc) of lesion images amassed during an acquisition
study for the FDA
Prior testing: Selected for excision (no further detail)
Setting for prior testing: NR
Exclusion criteria: None reported
Sample size (participants): NR
Sample size (lesions): N eligible NR; N included: 47
Participant characteristics: None reported
Lesion characteristics: None reported
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Wells 2012 (Continued)
Index tests Dermoscopy No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: Clinical images and detailed clinical history
Diagnostic threshold: NR; Decision to biopsy the lesion/Melanoma or not
Diagnosis based on: Average (n = 39)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described
Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: MelaFind (EO Sciences, USA) (classifier NR)
System details:
Multispectral imaging system with integrated image analysis software; device takes images in vivo
No derivation aspect (external validation study)
Described in prior study Monheit 2011
Lesion characteristics assessed: NR
Additional predictors included: None reported
Method of diagnosis:
In-person diagnosis
CAD-based diagnosis
Prior/other test data: Unclear
CAD output:
Binary output: (1) positive, (lesion should be considered for biopsy to rule out melanoma); and
(2) negative (lesion should be considered for later evaluation)
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard: Histological diagnosis alone
Disease-positive: 23; Disease-negative: 24
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 23
’Benign’ diagnoses: 24
Flow and timing Exclusions from analysis: None
Time interval to reference test: NR; Images taken prior to biopsy
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Wells 2012 (Continued)
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
Unclear
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Wells 2012 (Continued)
ously published study?
Unclear High
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Winkelmann 2016
Study characteristics
Patient sampling Study design: Case-control
Data collection: Retrospective image selection/Prospective interpretation
Period of data collection: NR
Country: NR
Patient characteristics and set-
ting
Inclusion criteria: Images of PSLs previously analysed by a digital classifier MSDSLA; method of
selection of the 12 not reported
Setting: Dermoscopy conference
Prior testing: NR
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (participants): NR
Sample size (lesions): N eligible; N included: 12
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Winkelmann 2016 (Continued)
Participant characteristics: None reported
Lesion characteristics: None reported
Index tests Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: Unclear
Diagnostic threshold: NR - biopsy decision
Diagnosis based on: Average (n = 70)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described
Other detail:
Practitioners with a particular interest in skin cancer or technology may have chosen to attend this
conference and/or self-selected to take part in the study
Dermoscopy No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: Clinical images
Diagnostic threshold: NR - biopsy decision
Test observers: As described for Visual Inspection (above)
Computer-assisted diagnosis - Spectroscopy-based
MSI-CAD system: MelaFind (EO Sciences, USA) (Logistic regression classifier)
System details:Multispectral imaging system with integrated image analysis software; device takes
images in vivo
No derivation aspect (reader study)
Lesion characteristics assessed: NR
Additional predictors included: None
Method of diagnosis:
Spectroscopic images
CAD-aided diagnosis
Prior/other test data: Clinical and dermoscopic images
CAD output:
Binary output: (1) positive, (lesion should be considered for biopsy to rule out melanoma); and
(2) negative (lesion should be considered for later evaluation)
Diagnostic threshold: Threshold not reported
Target condition and reference
standard(s)
Reference standard Histological diagnosis alone
Disease-positive: 5; Disease-negative: 7
Target condition (Final diagnoses)
Melanoma (invasive): 3; Melanoma (in situ): 2
Mild/moderate dysplasia: 7 low-grade dysplastic naevi
Flow and timing Exclusions from analysis: None
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Was an adequate spectrum of
cases used to train the algo-
rithm?
High High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
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Winkelmann 2016 (Continued)
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Yes
Low Unclear
DOMAIN 2: Index Test Visual inspection
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear High
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
Yes
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Winkelmann 2016 (Continued)
the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Was the CAD model evaluated
in an independent study popu-
lation?
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
ously published study?
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Unclear
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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Winkelmann 2016 (Continued)
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
Yes
Unclear
Wollina 2007
Study characteristics
Patient sampling Study design: Case series
Data collection: NR
Period of data collection: January 2003 to October 2004
Country: Germany (Dresden); Switzerland (Locarno and Lugarno)
Patient characteristics and set-
ting
Inclusion criteria: PSLs
Setting: Secondary (general dermatology) Dept Dermatology, Dresden; Primary (private clinic),
Locarno and Lugano
Prior testing:
No prior testing Lugano and Locarno (described as representing “a sort of first-screening check”)
Clinical and/or dermatoscopic suspicion Dresden (described as having many patients referred for a
second-level control)
Setting for prior testing: Unspecified
Exclusion criteria: NR
Sample size (patients): N eligible: 1308; N included: NR
Sample size (lesions): N eligible: 3541; N included: 466
Participant characteristics: Male: 566; 43.2% (full sample)
Thickness/depth: ≤ 1 mm: 38 (incl 8 in situ) Dresden: 22 (incl 4 in situ) Locarno: 7 (incl 2 in
situ) Lugano 9 (incl 2 in situ)
Index tests Computer-assisted diagnosis - Dermoscopy-based
Derm-CAD system: DB-MIPs (Biomips Engineering, Italy) (Euclidian distances classifier)
System details:
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Wollina 2007 (Continued)
Dermoscopy unit, internal steromicroscope, internal DB, pattern analysis system. DDA software
analysis - analyses 50 parameters subdivided into 3 categories, i.e. geometries, colours, and textures
and islands of colours (Burroni islands)
No derivation aspect (external validation study)
Lesion characteristics assessed:
35 variables including: variance of symmetry,maximumdiameter, border’s gradient, skin red average,
red average, red tenth, unbalance, dark areas towards periphery, dishomogeneity, blue dominant,
transition, unbalance of transition
Additional predictors included: No further information used
Method of diagnosis:
In-person diagnosis
CAD-aided diagnosis
Operator qualifications: Not reported
Experience in practice: Not described
Experience with index test: Not described. States that test operators do not need special training
Prior/other test data: CAD used as part of clinical analysis
CAD output: Not specified
Diagnostic threshold:
The automated diagnosis was run at similprob = 45 and similprob = 75 thresholds, the latter being
more sensitive but less specific. Similprob = 75 threshold selected at random for review
Target condition and reference
standard(s)
Reference standard:
Histological diagnosis alone. Unclear whether data relate to compariaon with histology alone or to
whole set of lesions, in which case the reference standard is not reported for most benign lesions,
although the ’decision to follow-up’ is mentioned
Histology (not further described)
N participants/lesions: 466
Disease-positive: 52 (incl 8 in situ); Disease-negative: Either 414 or 3489
Target condition (Final diagnoses)
Melanoma (invasive): 44; Melanoma (in situ): 8
’Benign’ diagnoses: 414
Flow and timing Exclusions from analysis: None
Time interval to reference test: CAD performed during clinical diagnosis, before histopathology.
Interval to surgery not reported
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Wollina 2007 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Was an adequate spectrum of
cases used to train the algo-
rithm?
Unclear High
DOMAIN 2: Index Test Computer-assisted diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Was the CAD model evaluated
in an independent study popu-
lation?
Yes
Was
model overfitting accounted for
during model development?
Was the diagnostic threshold to
determine presence or absence
of disease established in a previ-
Yes
245Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wollina 2007 (Continued)
ously published study?
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Was the use of expert opinion
(with no histological confirma-
tion) avoided as the reference
standard?
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults likely to correctly clas-
sify the target condition (disease
negative)?
Yes
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Included studies: Two quality assessment items could not be evaluated for all studies, and so were left blank:
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Patient Selection: Concerns regarding applicability: “Was an adequate spectrum of cases used to train the algorithm? (training set)”
(Could only be answered if the study included a derivation aspect). CAD Risk of Bias: “Was model overfitting accounted for during
model development?” (Could only be answered if the study included a derivation aspect)
Index test - CAD: Concerns regarding applicability: “Was the test interpretation carried out by an experienced examiner? (Could
only be answered if the study gave computer generated CAD results to clinicians to make a diagnosis [CAD-aided diagnosis])”
7FFM: 7 features for melanoma; ABCD: asymmetry, border, colour, dimension; AK: actinic keratosis; BCC: basal cell carcinoma; CM:
cutaneous melanoma; CN: common naevus; cSSC: cutaneous squamous cell carcinoma; DF: dermatofibroma; DN: dysplastic naevus;
ELM: epiluminescence microscopy; Knn: K nearest neighbour; MM: malignant(invasive) melanoma; NR: not reported; OIDRS: non-
imaging diffuse reflectance spectroscopy; PSL: pigmented skin lesion; SK: seborrheic keratosis; SVS: Skin View System; TDS: total
dermoscopic score.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbas 2010 Target condition: border detection not diagnosis
Abbas 2011a Index test: test used to determine border
Abbas 2011b Target condition: border detection not diagnosis
Abbas 2012 No independent test set: Reports training on 20% and testing on 80% of images but results presented
only for whole dataset
Author contacted, responded but cannot help
Abbas 2013a Target condition: border detection not diagnosis
Abbas 2013b Individual lesion characteristics: focus on border detection
Derivation study
Abuzaghleh 2015 Derivation study
Authors contacted.
In the experiments, 75% of the database images are used for training and 25% are used for testing.
No breakdown of D+/D- in the test set, cannot back-calculate from the sensitivity and specificity
values given
Afonso 2012 Index test: Not used to differentiate malignant from benign lesions
Alfed 2015 Derivation study: no independent test set used
Ali 2012 Not a primary study
Altamura 2008 Index test: study of optimal surveillance/appropriate follow-up times not initial diagnosis
Andreassi 1999 Derivation study:
Uses jack knife validation
Armengol 2011 Index test; derivation study
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(Continued)
Arroyo 2011 Individual lesion characteristics; derivation study
Ballerini 2012 Target condition: D+ includes AK
Barata 2012a Derivation study
Barata 2012b Derivation study
Barata 2013 Derivation study
Barata 2015a Derivation study; uses LOO procedure
Barata 2015b Derivation study: uses 10-fold classification
Barata 2015c Derivation study; uses 10-fold classification
Binder 2000 Derivation study; no independent test set
Bjerring 2001 Not a primary study: leaflet
Blum 2004b Overlapping study population (Blum 2004a)
Boden 2013 Derivation study: uses LOO method; no independent test set
Bono 1999 Derivation study; exclude on 2 x 2 data: LFR: not a test accuracy study
Borlu 2008 Not a primary study - not test accuracy; no patient data in this study
Brown 2000 Not a primary study; systematic review
Carrara 2007 Reference standard: < 50% benign lesions had histology or clinical follow-up
Celebi 2008 Derivation study: no independent test set
Chen 2003 Individual lesion characteristics: investigates colour only; Derivation study; Inadequate 2 x 2 data
Cheng 2012 Individual lesion characteristics: only telengiectasia used to evaluate whether a BCC or not. No other
characteristics are evaluated;
Derivation study
Cheng 2013 Derivation study; 2 x 2 data
Christensen 2010 Derivation study
Claridge 1992 Individual lesion characteristics; shape of lesion
Cukras 2013 Not a primary study
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Day 2001 Reference standard: 16/73 excised; 9 were melanoma
Debeir 1999 Derivation study
Di 2010 Derivation study: primarily derivations study with small paragraph on a validation study with limited
details - se/sp given for validation study for individual characteristics but not for overall se/sp of the
system; 2 x 2 data
Ding 2015 Derivation study; uses LOO technique
Dreiseitl 2005 Index test: not test accuracy and the CDSS recommendations were simulated
Durg 1993 Target condition:
detection of variegated colouring
Elbaum 2001 Derivation study:
uses LOO procedure
Emery 2010 Reference standard: 111/1211 lesions excised, remaining lesions did not have any reported follow-up
Engin 2016 Sample size
Reference standard
Ercal 1994 Derivation study
Faal 2013 Derivation study:
The 436 images were split into 60% training and 40% test sets. They combined the results of the
training and tests sets as an average of the performace of the test, no breakdown of the classifer rate
according to the test and training images
Farina 2000 Derivation study - no test set
Ferris 2016 Not a primary study
Fidalgo 2003 2 x 2 data; Duplicate or related publication: Appears to be superseded by Serrao 2006
Fikrle 2007 Reference standard: Follow-up study with < 50% of participants receiving lesion excision
Fikrle 2013 Reference standard: Follow up study <50% of study participants have their final diagnosis reached by
histopathology
Fruhauf 2012 Reference standard: 35/219 underwent histology; 13 followed up; 171 expert clinical diagnosis
Fueyo-Casado 2009 Reference standard:
< 50% of the study population recieved histology as a test. No information given on those who were
followed up
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Ganster 2001 Derivation study:
Uses leave-one-out methods for cross-validation, “test set” for the automated diagnosis but data given
in Table 1 incorporates data from the training set
Garcia-Uribe 2004 Index test:
reflectance spectrometry/spectroscopy;
Derivation study: results use training and test sets
Garcia-Uribe 2010 2 x 2 data:
only give the values for sensitivity and specificity but do not give a breakdown of disease positive or
negative totals in the test set
Contact authors
García 2014 Target condition:
test aims to detect presence of pigment network, is not an evaluation of detection of MM
Garnavi 2012 Reference standard:
not properly defined, it could be the images were sampled from a database of histopathologically
diagnosed lesions but reporting is unclear
Gerger 2003 Reference standard:
no reference standard in 133 naevi, unclear whether these were in the test set; Derivation study:
Training sets (n = 2) and test set must overlap as total number of lesions (n = 423) add up to more
than total included lesions (n = 136)
Glotsos 2015 Derivation study:
uses LOO procedure
Gniadecka 2004 Index test:
Raman spectroscopy;
Derivation study:
methods report use of a ’test set’, but this is not further described
2 x 2 data.
Govindan 2007 Reference standard:
“Six hundred and twenty seven (71%) lesions were diagnosed as benign and were discharged from
the PLC” “As the patients who were clinically diagnosed as having benign lesions did not undergo
biopsy of their lesions, the false negative rate for the consultant could not be determined. None of the
patients with benign lesions from this study have reported back to the PLC with any concern about
their lesions and none have had excision biopsy of their lesions.”
Green 1991 Derivation study - no independent test set
Green 1994 Derivation study:
no independent test set
Guerra-Rosas 2015 Derivation study: no test set; 2 x 2 data: no se/sp presented
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Guillod 1996 Derivation study
Gutkowicz-Krusin 2000 Sample size: 2 melanoma; Derivation study.
Hacioglu 2013 Target condition: Does not provide 2 x 2 data for separate keratinocyte cancers
Haenssle 2004 Target condition
Haenssle 2010 2 x 2 data: Does not report specificity
Duplicate or related publication: Same patients as Haenssle 2004
Haniffa 2007 Reference standard:
approximately 20% of patients received a final diagnosis by histology. 179 biopsies were performed.
Total sample was 881 lesions
Hintz-Madsen 2001 Derivation study: uses LOO technique
Hoffmann 2003 Derivation study:
Uses LOO procedure
2 x 2 data:
Only reports ROC values, so not able to extract a 2 x 2 table
Horsch 1997 Derivation study
Huang 1996 Individual lesion characteristics:
Border irregularity not overall diagnosis
2 x 2 data
Ikuma 2013 Derivation study:
uses LOO procedure
Isasi 2011 Derivation study
Iyatomi 2006 Derivation study:
uses LOO procedure;
2 x 2 data.
Iyatomi 2008a Derivation study
Iyatomi 2008b Derivation study
Iyatomi 2008c Derivation study:
performance evaluated by averaging both combinations (training and test sets). Data not presented
separately; uses LOO procedure
2 x 2 data:
Not test accuracy; compares automated with manual extraction of tumour area
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Iyatomi 2010a Individual lesion characteristics
2 x 2 data:
not a test accuracy study
Iyatomi 2010b Target condition:
differentiates melanocytic from non-melanocyitc lesinos and not malignant from benign
Iyatomi 2011 Index test:
colour calibration rather than MM detection
Individual lesion characteristics
2 x 2 data:
not a test accuracy study.
Jain 2015 Not a primary study
Jakovels 2013 Reference standard
test not reported
Jamora 2003 Ineligibile reference standard
no referene standard for index test negatives
Jaworek-Korjakowska 2016a Derivation study
no separate test set
Jaworek-Korjakowska 2016b Derivation study: uses cross-validation with no separate test set;
2 x 2 data:
only gives accuracy, not se/sp
Jeddi 2016 Study population:
unclear whether data for BCC includes only those with lesions actually suspicious for BCC
Ineligible index test:
limited details
Ineligibile reference standard:
appears to be expert Dx
Kahofer 2002 Derivation study.
Lesions not split into training/test
Kaur 2015 Ineligibile reference standard:
% of benign with histology versus expert dx not reported
2 x 2 data:
Only gives AUC and not se/sp
Contact authors:
1. reference standard in benign group 2. se/sp for model using all four features neededDrWV Stoeker
e-mail: wvs@mst.edu
Korotkov 2012 Not a primary study:
narrative review
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Kuzmina 2011 Derivation study.
Ineligibile reference standard:
reference standard test not reported
Landau 1999 Derivation study.
No indication that system has previously been evaluated
LeAnder 2010 Derivation study.
no separate 2 x 2 data for training set and test set
Lefevre 2000 Ineligible index test
Limited test detail; cannot tell whether clinical or dermoscopic images used
Ineligibile reference standard
No details of reference standard
Lihacova 2013 Derivation study.
No test set
Liu 2012 Derivation study:
asymmetry detection; 10-fold cross-validation
2 x 2 data
Machado 2015 Ineligible target condition
detection of reticular pattern not MM
Maglogiannis 2004 Derivation study.
2 x 2 data
Maglogiannis 2006 Derivation study.
They incorporated the training set population together with the test set as shown below “A training set
of 500 cases was randomly selected from the dataset of the total cases. The accuracy of the classification
algorithm was examined using a test set consisted of the full set of 1041 cases.”
Manousaki 2006 Derivation study. - Training set only
Marchesini 1992 Derivation study. - no independent data set
Masood 2013 Derivation study.
Menzies 1999 Not a primary study
Mete 2011 Derivation study.
2 x 2 data
Not test accuracy
Mhaske 2013 Derivation study.
2 x 2 data
Not test accuracy
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Moncrieff 2002 Derivation study. - no independent test set
Morrow 2010 Not a primary study
narrative review
Nagaoka 2012 2 x 2 data:
they did not give the number of lesions in test set, they state “The sensitivity of 90% and specificity of
84% were obtained by applying this threshold value to the validation set.” Cannot see how to work
out the 2 x 2 data from this information
Contact authors:
Can you provide us with the number of lesions in the test set, with a breakdown of number of
melanoma vs other lesions? We can then use the sensitivity of 90% and specificity of 84% provided
to work out the 2 x 2
Nagaoka 2013 Derivation study.
index was developed on nonglabrous skin and is being applied to acral skin for first time, which makes
it a derviation study?
Ineligibile reference standard
No reference standard reported for D-
Nagaoka 2015 Ineligibile reference standard
Contact authors:
reference standard not clearly reported - “Lesions that were clinically judged benign were not biopsied
because of ethical reasons.” T. Nagaoka e-mail: nagaoka@aoni.waseda.jp
Previous contact for prior studies was unsuccessful
Noroozi 2016 Ineligible index test
Oka 2004a Not a primary study
letter
Oka 2004b Derivation study.
uses LOO procedure
Oka 2006 Not a primary study
letter
Pellacani 2004a Individual lesion characteristics
Pellacani 2004b Assessesindividual lesion characteristics only; looks at
colours in melanocytic lesion (ML) images.
Pellacani 2006 Derivation study.
looks at detection of asymmetry between clinicians and computer
2 x 2 data:
2 x 2 could be derived for overall asymmetry or border cut-off but not overall diagnosis
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Perrinaud 2007 Inadequate sample size
CAD - fewer than 5 melanomas (not including ’typical’ melanomas)
Ineligible index test
Does not provide data for visual inspection alone
Pompl 2000 Derivation study.
Training set (60 mel and 60 benign) reincluded for model evaluation
Rajpara 2009 Not a primary study
Systematic review
Rastgoo 2015 Derivation study.
Describes splitting each set of 180 lesions into 70% for training, 15% for validation and 15% for
testing (n=27?). But it’s difficult to follow what the results relate to, especially as the classifier is
repeated 10 times with different sets of dysplastic lesions but the same melanoma cases
Rigel 2012 Duplicate or related publication
CAD - all lesions included in Monheit 2011
Rosado 2003 Not a primary study
Systematic Review
Rubegni 2001a Not a primary study
letter
Rubegni 2001b Derivation study.
paper states that the accuracy estimates (sensitivity, specificty) are given using the LOO method but
they have not given a breakdown of the actually number. It is not possible to tell if they used the
whole study sample
Rubegni 2002b Derivation study.
the training and test data not given separately
Rubegni 2005 Not a primary study
Editorial
Rubegni 2010 Derivation study:
uses LOO procedure
2 x 2 data
Rubegni 2013 Derivation study.
Sadeghi 2013 Individual lesion characteristics:
irregular streaks
2 x 2 data:
Only given the AUC values not possible to work out 2 x 2 from this
Safi 2011 Derivation study.
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Salerni 2012 Ineligible index test
test used for surveillance
Sboner 2001 Duplicate or related publication
same data as Sboner 2004
Sboner 2003 Derivation study.
describes 10-fold cross-validation pocess for training/testing classifier
Sboner 2004 Derivation study.
Uses LOO method with no independent test set for validation
The whole set of cases is divided in 10 disjoint sets, which are used as test cases. For each test set, the
remaining 9 sets are used to train the classifiers (training set). The final results are the average values
computed on the 10 test sets
Schindewolf 1993 2 x 2 data
not given enough information to populate 2 x 2 table
Schindewolf 1994 Ineligible index test
evaluates CAD not VI
Derivation study.
uses cross-validation
Schmid-Saugeon 2003 Derivation study.
no separate test set for validation
Schumacher 2016 Not a primary study
comment paper
Seidenari 1995 Ineligible index test
comparing 2 ways of attaining videomicroscope images no accuracy data provided
2 x 2 data
Seidenari 2005 Ineligibile reference standard
All D+ were excised (n = 95) but only 45% of benign group were excised (76 AN plus 30% of BN
(86/288)) and methods of estabishing final diagnosis were not reported for the remainder
EXCLUDE but contact authors
We would like to include test accuracy results from this study, however in order to do so we would
need some further information on how the final diagnosis was reached for thos lesions that were
not excised. We have noted that all D+ lesions were excised (n = 95) and 45% of benign lesions
were excised (76 atypical naevi plus 30% of benign (86/288)). Can you advise us as to how the final
diagnosis was reached for the remaining 126 benign lesions?
Seidenari 2007 Individual lesion characteristics
CAD only - CAD system based on single characteristic
Seidenari 2012 Ineligible index test:
CAD ONLY - does not evaluate a CAD system
Individual lesion characteristics
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2 x 2 data
Contact authors:
Table 3 provides mean ABCD and 7-point checklist scores; are you able to provide us with a cross-
tabulation of results with each checklist at ’standard’ thresholds against final diagnosis? e.g. ABCD >
4.75 and > 5.45 for MIS and benign groups 7-point checklist: presence ≥ 2 chars and ≥ 3 chars?
Shakya 2012 Ineligible target condition
SCC in situ is not included in target condition
She 2007 Derivation study.
She 2013 Derivation study.
no separate data for training and test set. used LOO technique
Shimizu 2012 Derivation study.
The performance was evaluated under the LOO cross-validation test
Skrovseth 2010 Not a primary study
Statistical paper for developing a new algorithm
Smith 2000 Derivation study.
Sober 1994 Individual lesion characteristics
Reports separately for shape, radii and border but not overall classification; note these are results for
1 centre taking part in a larger multicentre study
Stanganelli 1995 Ineligible index test
aim of study is to assess the intraobserver agreement
Stanley 2007 Individual lesion characteristics
Derivation study.
Stanley 2008 Derivation study.
cross-validation study (check eligibility)
Stoecker 2005 Individual lesion characteristics
Derivation study.
Swanson 2010 Ineligible index test
reflectance spectroscopy
Derivation study.
This looks like an include as they mention a pilot study of 47 initial patients. There is an additional
47 patients included, but it seems that they have combined the data so for this reason it would be an
excluded if derivation study, as the training data and test data are combined
Tehrani 2006 Derivation study.
Borderline exclude - 4 features of NMSC identifed in pilot study and re-examined in larger sample
here; diagnostic model then created based on significaince of characteristics and se/sp data give. No
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test set presented
Terstappen 2007 Ineligible study population:
Includes only BCC - looking for BCC characteristics on Siascope
Derivation study.
Derivation study; first application of Siascope to pigmented BCC; 21/25 lesions were BCCs
Varol 2006 Not a primary study
Link to study with correction “Error in Byline. In the the Study by Menzies et al titled “The Per-
formance of SolarScan: An Automated Dermoscopy Image Analysis Instrument for the Diagnosis of
Primary Melanoma,” published in the November 2005 issue of the ARCHIVES (2005;141:1388-
1396), the name of the one of the authors was misspelled. The author’s name is Alexandra Varol, B
Med.”
Vestergaard 2008 Not a primary study
systematic review
Wallace 2000a Derivation study.
uses LOO technique
Wallace 2000b 2 x 2 data
Wallace 2002 Derivation study. - Uses LOO cross-validation
Walter 2010 Not a primary study
clinical trial protocol
Watson 2009 2 x 2 data
Not test accuracy; training in MoleMate
Wazaefi 2012 Derivation study.
no separate independent test set they used a 20-fold cross-validation
Wells 2011 Duplicate or related publication
see Wells 2012
Wilson 2013 2 x 2 data
this study is an economic evaluation of a SIAscopy, which itself was trialled in another paper - not
enough data to populate 2 x 2 table
Winkelmann 2015a Duplicate or related publication
Winkelmann 2015b Ineligible target condition
D+ includes 15 lesions with moderate dysplasia
Inadequate sample size
only 1 MM
Winkelmann 2015c Inadequate sample size
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Winkelmann 2015d Duplicate or related publication
Winkelmann 2016a Ineligible index test
aim of the test to to investigate correlation with clinical histology features (development of new CAD
system?)
Wood 2008 2 x 2 data
Not test accuracy - acceptability etc
Yoo 2015 Conference abstract only
Zagrouba 2004 Ineligibile reference standard
No reference standard details provided
Contacted re reference standard. Author responded - cannot help
Zhou 2010a Derivation study
Zhou 2010b Individual lesion characteristics
Zortea 2014 Derivation study.
Although data are divided into training and test sets, the test set data is used more than once over
20 realisations of each model, especially the melanomas, for which the same 10 are used in each
realisation
Zouridakis 2004 Ineligible study population
Inadequate sample size
Derivation study.
AK: actinic keratosis; AN: atypical naevus; LOO: leave-one-out; se: sensitivity; sp: specificity
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Derm-CAD Microderm
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
3 793
2 Derm-CAD DBMIPS (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
6 1903
3 Derm-CAD DBMIPS vs
Dermoscopy (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
2 405
4 Derm-CAD DEMMIPS
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
1 341
6 Derm-CAD SkinView (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
2 220
7 Derm-CAD SkinView (Any
lesion requiring excision)
1 44
8 Derm-CAD NevusDr (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
1 870
9 Derm-CAD NevusDr (Any
lesion requiring excision)
1 870
10 Derm-CAD ImageJ (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
1 3021
11 Derm-CAD IBAS2000
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
1 29
12 Derm-CAD Nevuscreen
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
1 165
260Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
13 Derm-CAD SolarScan (invasive
melanoma)
1 786
14 Derm-CAD SolarScan
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
1 786
15 Derm-CAD No name (invasive
melanoma)
1 164
16 Derm-CAD No name
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
5 864
17 Derm-CAD No name (Any
lesion requiring excision)
1 173
18 Derm-CAD No name (BCC) 1 173
19Derm-CADDBMIPS˙UNREF
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
1 357
20 MSI-CAD SIAscope˙UNREF
(invasive melanoma)
1 766
21 MSI-CAD SIAscope˙UNREF
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
1 766
22 MSI-CAD SIAscope˙UNREF
(Any lesion requiring excision)
1 766
23 MSI-CAD SpectroShade
(invasive melanoma)
1 54
24 MSI-CAD SpectroShade
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
1 347
25 EIS-CAD-Nevisense (invasive
melanoma)
2 2389
26 EIS-CAD-Nevisense (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
2 2389
27 EIS-CAD-Nevisense (Any
lesion requiring excision)
2 2389
28 EIS-CAD-Nevisense (BCC) 2 2389
29 EIS-CAD-Nevisense (cSCC) 1 1943
30 MSI-CAD Melafind (invasive
melanoma)
2 229
31 MSI-CAD Melafind (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
5 1798
261Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
32 MSI-CAD Melafind˙vs
Dermoscopy (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
4 288
34 MSI-CAD SIAscopy (invasive
melanoma)
1 60
35 MSI-CAD SIAscopy (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
1 83
36 MSI-CAD SIAscope
Only˙UNREF (Any lesion
requiring excision)
1 44
37 DRS-CAD OIDRS (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
1 136
38 DRS-CAD OIDRS (Any +
dysplastic)
1 136
39 DRS-CADOIDRS (Any lesion
requiring excision)
1 89
40 MSI-CAD TS (invasive
melanoma)
1 43
41 MSI-CAD TS (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
1 173
42 CAD-DRS-TS vs Dermoscopy
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
1 313
46 PersonDERM-
DigidermDBMIPS (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
1 315
47 ImageDERM-
DigidermDBMIPS (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
1 90
48 ImageDERM-
DigidermDEMMIPS (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
1 341
49 PersonDerm-DigidermImageJ
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
1 458
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50 ImageDerm-
DigidermNevuscreen (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
1 165
51 ImageDerm-DigidermNR
(invasive melanoma)
1 164
52 ImageDerm-DigidermNR
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
2 169
53 PersonDERM-DRS-
SpectroShade (invasive
melanoma)
1 54
54 ImageDERM-DRSMelafind
(invasive melanoma)
1 99
55 ImageDERM-DRSMelafind
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
4 288
56 ImageDERM-DRSSIA
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
1 83
57 PersonDERM-DRSTS
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
1 313
58 Derm-CAD (direct comparison
only) (invasive melanoma
or atypical intraepidermal
melanocytic variants)
10 2233
59 Image-based Dermoscopy
(for Derm-CAD comparison)
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
5 765
60 In-person based Dermoscopy -
Derm-CAD studies (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
2 773
61 MSI-CAD (direct comparison
only) (invasive melanoma
or atypical intraepidermal
melanocytic variants)
8 1059
62 Image-based Dermoscopy
(for MSI-CAD comparison)
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
5 371
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63 MSI-CAD All systems
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
8 2401
64 Derm-CAD All systems
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
22 8992
65 Derm-CAD MoleExpert (Any
lesion requiring excision)
1 870
66 Derm-CAD All systems
(invasive melanoma)
2 950
67 Image-based Dermoscopy -
Derm-CAD studies (invasive
melanoma)
1 164
68 MSI-CAD All (Melafind)
(invasive melanoma or atypical
intraepidermal melanocytic
variants), CAD + Clinician
(diagnostic aid) only
2 142
69 MSI-CAD All (invasive
melanoma or atypical
intraepidermal melanocytic
variants), CAD only
6 777
70 MSI-CAD Melafind (invasive
melanoma or atypical
intraepidermal melanocytic
variants), CAD only
3 174
71 Derm-CAD All (invasive
melanoma or atypical
intraepidermal melanocytic
variants), CAD + Clinician
(diagnostic aid) only
3 589
72 Derm-CAD All (invasive
melanoma or atypical
intraepidermal melanocytic
variants), CAD only
19 8403
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Test 1. Derm-CAD Microderm (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 1 Derm-CAD Microderm (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barzegari 2005 6 12 1 104 0.86 [ 0.42, 1.00 ] 0.90 [ 0.83, 0.95 ]
Boldrick 2007 1 2 5 10 0.17 [ 0.00, 0.64 ] 0.83 [ 0.52, 0.98 ]
Serrao 2006 29 305 12 306 0.71 [ 0.54, 0.84 ] 0.50 [ 0.46, 0.54 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. Derm-CAD DBMIPS (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 2 Derm-CAD DBMIPS (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bauer 2000 39 6 3 267 0.93 [ 0.81, 0.99 ] 0.98 [ 0.95, 0.99 ]
Burroni 2004 365 108 7 341 0.98 [ 0.96, 0.99 ] 0.76 [ 0.72, 0.80 ]
Rubegni 2002a 16 1 1 20 0.94 [ 0.71, 1.00 ] 0.95 [ 0.76, 1.00 ]
Seidenari 1999 18 30 0 335 1.00 [ 0.81, 1.00 ] 0.92 [ 0.88, 0.94 ]
Stanganelli 2005 16 44 4 173 0.80 [ 0.56, 0.94 ] 0.80 [ 0.74, 0.85 ]
Wollina 2007 31 16 2 60 0.94 [ 0.80, 0.99 ] 0.79 [ 0.68, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. Derm-CAD DBMIPS vs Dermoscopy (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 3 Derm-CAD DBMIPS vs Dermoscopy (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bauer 2000 39 6 3 267 0.93 [ 0.81, 0.99 ] 0.98 [ 0.95, 0.99 ]
Seidenari 1998 29 3 2 56 0.94 [ 0.79, 0.99 ] 0.95 [ 0.86, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Derm-CAD DEMMIPS (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 4 Derm-CAD DEMMIPS (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Piccolo 2002 12 85 1 243 0.92 [ 0.64, 1.00 ] 0.74 [ 0.69, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 6. Derm-CAD SkinView (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 6 Derm-CAD SkinView (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cascinelli 1992 8 15 2 19 0.80 [ 0.44, 0.97 ] 0.56 [ 0.38, 0.73 ]
Cristofolini 1997 28 77 7 64 0.80 [ 0.63, 0.92 ] 0.45 [ 0.37, 0.54 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 7. Derm-CAD SkinView (Any lesion requiring excision).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 7 Derm-CAD SkinView (Any lesion requiring excision)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cascinelli 1992 10 13 2 19 0.83 [ 0.52, 0.98 ] 0.59 [ 0.41, 0.76 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. Derm-CAD NevusDr (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 8 Derm-CAD NevusDr (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mollersen 2015 42 662 2 164 0.95 [ 0.85, 0.99 ] 0.20 [ 0.17, 0.23 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 9. Derm-CAD NevusDr (Any lesion requiring excision).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 9 Derm-CAD NevusDr (Any lesion requiring excision)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mollersen 2015 119 662 2 87 0.98 [ 0.94, 1.00 ] 0.12 [ 0.09, 0.14 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 10. Derm-CAD ImageJ (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 10 Derm-CAD ImageJ (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dreiseitl 2009 23 478 8 2512 0.74 [ 0.55, 0.88 ] 0.84 [ 0.83, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 11. Derm-CAD IBAS2000 (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 11 Derm-CAD IBAS2000 (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Binder 1998 9 14 1 5 0.90 [ 0.55, 1.00 ] 0.26 [ 0.09, 0.51 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 12. Derm-CAD Nevuscreen (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 12 Derm-CAD Nevuscreen (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Piccolo 2014 33 36 0 96 1.00 [ 0.89, 1.00 ] 0.73 [ 0.64, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 13. Derm-CAD SolarScan (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 13 Derm-CAD SolarScan (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Menzies 2005 69 274 6 437 0.92 [ 0.83, 0.97 ] 0.61 [ 0.58, 0.65 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
269Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 14. Derm-CAD SolarScan (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 14 Derm-CAD SolarScan (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Menzies 2005 111 232 11 432 0.91 [ 0.84, 0.95 ] 0.65 [ 0.61, 0.69 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 15. Derm-CAD No name (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 15 Derm-CAD No name (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Menzies 1996 40 29 5 90 0.89 [ 0.76, 0.96 ] 0.76 [ 0.67, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 16. Derm-CAD No name (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 16 Derm-CAD No name (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Binder 1994 38 7 2 53 0.95 [ 0.83, 0.99 ] 0.88 [ 0.77, 0.95 ]
Blum 2004a 32 59 8 319 0.80 [ 0.64, 0.91 ] 0.84 [ 0.80, 0.88 ]
Ferris 2015 38 78 1 56 0.97 [ 0.87, 1.00 ] 0.42 [ 0.33, 0.51 ]
Gilmore 2010 32 12 4 21 0.89 [ 0.74, 0.97 ] 0.64 [ 0.45, 0.80 ]
Maglogiannis 2015 38 12 16 38 0.70 [ 0.56, 0.82 ] 0.76 [ 0.62, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 17. Derm-CAD No name (Any lesion requiring excision).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 17 Derm-CAD No name (Any lesion requiring excision)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ferris 2015 49 67 4 53 0.92 [ 0.82, 0.98 ] 0.44 [ 0.35, 0.54 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 18. Derm-CAD No name (BCC).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 18 Derm-CAD No name (BCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ferris 2015 8 108 3 54 0.73 [ 0.39, 0.94 ] 0.33 [ 0.26, 0.41 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 19. Derm-CAD DBMIPS˙UNREF (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 19 Derm-CAD DBMIPS˙UNREF (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wollina 2007 17 54 2 284 0.89 [ 0.67, 0.99 ] 0.84 [ 0.80, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 20. MSI-CAD SIAscope˙UNREF (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 20 MSI-CAD SIAscope˙UNREF (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Walter 2012 14 213 0 539 1.00 [ 0.77, 1.00 ] 0.72 [ 0.68, 0.75 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
272Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 21. MSI-CAD SIAscope˙UNREF (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 21 MSI-CAD SIAscope˙UNREF (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Walter 2012 18 209 0 539 1.00 [ 0.81, 1.00 ] 0.72 [ 0.69, 0.75 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 22. MSI-CAD SIAscope˙UNREF (Any lesion requiring excision).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 22 MSI-CAD SIAscope˙UNREF (Any lesion requiring excision)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Walter 2012 23 204 2 537 0.92 [ 0.74, 0.99 ] 0.72 [ 0.69, 0.76 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 23. MSI-CAD SpectroShade (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 23 MSI-CAD SpectroShade (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ascierto 2010 8 10 4 32 0.67 [ 0.35, 0.90 ] 0.76 [ 0.61, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 24. MSI-CAD SpectroShade (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 24 MSI-CAD SpectroShade (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tomatis 2005 33 70 8 236 0.80 [ 0.65, 0.91 ] 0.77 [ 0.72, 0.82 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 25. EIS-CAD-Nevisense (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 25 EIS-CAD-Nevisense (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Malvehy 2014 151 1095 2 695 0.99 [ 0.95, 1.00 ] 0.39 [ 0.37, 0.41 ]
Mohr 2013 71 246 2 127 0.97 [ 0.90, 1.00 ] 0.34 [ 0.29, 0.39 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 26. EIS-CAD-Nevisense (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 26 EIS-CAD-Nevisense (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Malvehy 2014 256 1095 9 583 0.97 [ 0.94, 0.98 ] 0.35 [ 0.32, 0.37 ]
Mohr 2013 101 246 2 97 0.98 [ 0.93, 1.00 ] 0.28 [ 0.24, 0.33 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 27. EIS-CAD-Nevisense (Any lesion requiring excision).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 27 EIS-CAD-Nevisense (Any lesion requiring excision)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Malvehy 2014 444 963 34 502 0.93 [ 0.90, 0.95 ] 0.34 [ 0.32, 0.37 ]
Mohr 2013 158 214 8 66 0.95 [ 0.91, 0.98 ] 0.24 [ 0.19, 0.29 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 28. EIS-CAD-Nevisense (BCC).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 28 EIS-CAD-Nevisense (BCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Malvehy 2014 48 1359 0 536 1.00 [ 0.93, 1.00 ] 0.28 [ 0.26, 0.30 ]
Mohr 2013 21 351 0 74 1.00 [ 0.84, 1.00 ] 0.17 [ 0.14, 0.21 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 29. EIS-CAD-Nevisense (cSCC).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 29 EIS-CAD-Nevisense (cSCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Malvehy 2014 7 1095 0 841 1.00 [ 0.59, 1.00 ] 0.43 [ 0.41, 0.46 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 30. MSI-CAD Melafind (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 30 MSI-CAD Melafind (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Friedman 2008 21 55 0 23 1.00 [ 0.84, 1.00 ] 0.29 [ 0.20, 0.41 ]
Hauschild 2014 29 57 7 37 0.81 [ 0.64, 0.92 ] 0.39 [ 0.29, 0.50 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 31. MSI-CAD Melafind (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 31 MSI-CAD Melafind (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Friedman 2008 48 28 1 22 0.98 [ 0.89, 1.00 ] 0.44 [ 0.30, 0.59 ]
Gutkowicz Krusin 1997 5 9 0 14 1.00 [ 0.48, 1.00 ] 0.61 [ 0.39, 0.80 ]
Monheit 2011 112 1356 2 142 0.98 [ 0.94, 1.00 ] 0.09 [ 0.08, 0.11 ]
Wells 2012 22 22 1 2 0.96 [ 0.78, 1.00 ] 0.08 [ 0.01, 0.27 ]
Winkelmann 2016 4 3 1 4 0.80 [ 0.28, 0.99 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 32. MSI-CAD Melafind˙vs Dermoscopy (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 32 MSI-CAD Melafind˙vs Dermoscopy (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Friedman 2008 48 28 1 22 0.98 [ 0.89, 1.00 ] 0.44 [ 0.30, 0.59 ]
Hauschild 2014 63 59 2 6 0.97 [ 0.89, 1.00 ] 0.09 [ 0.03, 0.19 ]
Wells 2012 22 22 1 2 0.96 [ 0.78, 1.00 ] 0.08 [ 0.01, 0.27 ]
Winkelmann 2016 4 3 1 4 0.80 [ 0.28, 0.99 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 34. MSI-CAD SIAscopy (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 34 MSI-CAD SIAscopy (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Terstappen 2013 7 5 22 26 0.24 [ 0.10, 0.44 ] 0.84 [ 0.66, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 35. MSI-CAD SIAscopy (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 35 MSI-CAD SIAscopy (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Glud 2009 12 29 0 42 1.00 [ 0.74, 1.00 ] 0.59 [ 0.47, 0.71 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 36. MSI-CAD SIAscope Only˙UNREF (Any lesion requiring excision).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 36 MSI-CAD SIAscope Only˙UNREF (Any lesion requiring excision)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Sgouros 2014 26 7 5 6 0.84 [ 0.66, 0.95 ] 0.46 [ 0.19, 0.75 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 37. DRS-CAD OIDRS (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 37 DRS-CAD OIDRS (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Garcia Uribe 2012 9 13 1 113 0.90 [ 0.55, 1.00 ] 0.90 [ 0.83, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 38. DRS-CAD OIDRS (Any + dysplastic).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 38 DRS-CAD OIDRS (Any + dysplastic)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Garcia Uribe 2012 23 15 2 96 0.92 [ 0.74, 0.99 ] 0.86 [ 0.79, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 39. DRS-CAD OIDRS (Any lesion requiring excision).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 39 DRS-CAD OIDRS (Any lesion requiring excision)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Garcia Uribe 2012 59 2 5 23 0.92 [ 0.83, 0.97 ] 0.92 [ 0.74, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 40. MSI-CAD TS (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 40 MSI-CAD TS (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bono 1996 15 7 3 18 0.83 [ 0.59, 0.96 ] 0.72 [ 0.51, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 41. MSI-CAD TS (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 41 MSI-CAD TS (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tomatis 2003 28 58 9 78 0.76 [ 0.59, 0.88 ] 0.57 [ 0.49, 0.66 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 42. CAD-DRS-TS vs Dermoscopy (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 42 CAD DRS TS vs Dermoscopy (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bono 2002 53 126 13 121 0.80 [ 0.69, 0.89 ] 0.49 [ 0.43, 0.55 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 46. PersonDERM-DigidermDBMIPS (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 46 PersonDERM-DigidermDBMIPS (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bauer 2000 33 10 9 263 0.79 [ 0.63, 0.90 ] 0.96 [ 0.93, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 47. ImageDERM-DigidermDBMIPS (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 47 ImageDERM-DigidermDBMIPS (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Seidenari 1998 25 3 6 56 0.81 [ 0.63, 0.93 ] 0.95 [ 0.86, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 48. ImageDERM-DigidermDEMMIPS (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 48 ImageDERM-DigidermDEMMIPS (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Piccolo 2002 12 2 1 326 0.92 [ 0.64, 1.00 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 49. PersonDerm-DigidermImageJ (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 49 PersonDerm-DigidermImageJ (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dreiseitl 2009 26 121 1 310 0.96 [ 0.81, 1.00 ] 0.72 [ 0.67, 0.76 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 50. ImageDerm-DigidermNevuscreen (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 50 ImageDerm-DigidermNevuscreen (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Piccolo 2014 33 69 0 63 1.00 [ 0.89, 1.00 ] 0.48 [ 0.39, 0.57 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 51. ImageDerm-DigidermNR (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 51 ImageDerm-DigidermNR (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Menzies 1996 41 35 4 84 0.91 [ 0.79, 0.98 ] 0.71 [ 0.62, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 52. ImageDerm-DigidermNR (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 52 ImageDerm-DigidermNR (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Binder 1994 38 6 2 54 0.95 [ 0.83, 0.99 ] 0.90 [ 0.79, 0.96 ]
Gilmore 2010 34 17 2 16 0.94 [ 0.81, 0.99 ] 0.48 [ 0.31, 0.66 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 53. PersonDERM-DRS-SpectroShade (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 53 PersonDERM-DRS-SpectroShade (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ascierto 2010 12 23 0 19 1.00 [ 0.74, 1.00 ] 0.45 [ 0.30, 0.61 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 54. ImageDERM-DRSMelafind (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 54 ImageDERM-DRSMelafind (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Friedman 2008 17 43 4 35 0.81 [ 0.58, 0.95 ] 0.45 [ 0.34, 0.57 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 55. ImageDERM-DRSMelafind (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 55 ImageDERM-DRSMelafind (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Friedman 2008 35 25 14 25 0.71 [ 0.57, 0.83 ] 0.50 [ 0.36, 0.64 ]
Hauschild 2014 47 30 18 35 0.72 [ 0.60, 0.83 ] 0.54 [ 0.41, 0.66 ]
Wells 2012 18 14 5 10 0.78 [ 0.56, 0.93 ] 0.42 [ 0.22, 0.63 ]
Winkelmann 2016 3 3 2 4 0.60 [ 0.15, 0.95 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 56. ImageDERM-DRSSIA (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 56 ImageDERM-DRSSIA (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Glud 2009 11 13 1 58 0.92 [ 0.62, 1.00 ] 0.82 [ 0.71, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 57. PersonDERM-DRSTS (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 57 PersonDERM-DRSTS (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bono 2002 60 63 6 184 0.91 [ 0.81, 0.97 ] 0.74 [ 0.69, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 58. Derm-CAD (direct comparison only) (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 58 Derm-CAD (direct comparison only) (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bauer 2000 39 6 3 267 0.93 [ 0.81, 0.99 ] 0.98 [ 0.95, 0.99 ]
Binder 1994 38 7 2 53 0.95 [ 0.83, 0.99 ] 0.88 [ 0.77, 0.95 ]
Blum 2004a 32 59 8 319 0.80 [ 0.64, 0.91 ] 0.84 [ 0.80, 0.88 ]
Dreiseitl 2009 24 224 3 207 0.89 [ 0.71, 0.98 ] 0.48 [ 0.43, 0.53 ]
Ferris 2015 38 78 1 56 0.97 [ 0.87, 1.00 ] 0.42 [ 0.33, 0.51 ]
Gilmore 2010 32 12 4 21 0.89 [ 0.74, 0.97 ] 0.64 [ 0.45, 0.80 ]
Maglogiannis 2015 38 12 16 38 0.70 [ 0.56, 0.82 ] 0.76 [ 0.62, 0.87 ]
Piccolo 2002 12 85 1 243 0.92 [ 0.64, 1.00 ] 0.74 [ 0.69, 0.79 ]
Piccolo 2014 33 36 0 96 1.00 [ 0.89, 1.00 ] 0.73 [ 0.64, 0.80 ]
Seidenari 1998 29 3 2 56 0.94 [ 0.79, 0.99 ] 0.95 [ 0.86, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 59. Image-based Dermoscopy (for Derm-CAD comparison) (invasive melanoma or atypical
intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 59 Image-based Dermoscopy (for Derm-CAD comparison) (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Binder 1994 38 6 2 54 0.95 [ 0.83, 0.99 ] 0.90 [ 0.79, 0.96 ]
Gilmore 2010 34 17 2 16 0.94 [ 0.81, 0.99 ] 0.48 [ 0.31, 0.66 ]
Piccolo 2002 12 2 1 326 0.92 [ 0.64, 1.00 ] 0.99 [ 0.98, 1.00 ]
Piccolo 2014 33 69 0 63 1.00 [ 0.89, 1.00 ] 0.48 [ 0.39, 0.57 ]
Seidenari 1998 25 3 6 56 0.81 [ 0.63, 0.93 ] 0.95 [ 0.86, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 60. In-person based Dermoscopy - Derm-CAD studies (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 60 In-person based Dermoscopy - Derm-CAD studies (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bauer 2000 33 10 9 263 0.79 [ 0.63, 0.90 ] 0.96 [ 0.93, 0.98 ]
Dreiseitl 2009 26 121 1 310 0.96 [ 0.81, 1.00 ] 0.72 [ 0.67, 0.76 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 61. MSI-CAD (direct comparison only) (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 61 MSI-CAD (direct comparison only) (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bono 2002 53 126 13 121 0.80 [ 0.69, 0.89 ] 0.49 [ 0.43, 0.55 ]
Friedman 2008 48 28 1 22 0.98 [ 0.89, 1.00 ] 0.44 [ 0.30, 0.59 ]
Glud 2009 12 29 0 42 1.00 [ 0.74, 1.00 ] 0.59 [ 0.47, 0.71 ]
Gutkowicz Krusin 1997 5 9 0 14 1.00 [ 0.48, 1.00 ] 0.61 [ 0.39, 0.80 ]
Hauschild 2014 63 59 2 6 0.97 [ 0.89, 1.00 ] 0.09 [ 0.03, 0.19 ]
Tomatis 2005 33 70 8 236 0.80 [ 0.65, 0.91 ] 0.77 [ 0.72, 0.82 ]
Wells 2012 22 22 1 2 0.96 [ 0.78, 1.00 ] 0.08 [ 0.01, 0.27 ]
Winkelmann 2016 4 3 1 4 0.80 [ 0.28, 0.99 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 62. Image-based Dermoscopy (for MSI-CAD comparison) (invasive melanoma or atypical
intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 62 Image-based Dermoscopy (for MSI-CAD comparison) (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Friedman 2008 35 25 14 25 0.71 [ 0.57, 0.83 ] 0.50 [ 0.36, 0.64 ]
Glud 2009 11 13 1 58 0.92 [ 0.62, 1.00 ] 0.82 [ 0.71, 0.90 ]
Hauschild 2014 47 30 18 35 0.72 [ 0.60, 0.83 ] 0.54 [ 0.41, 0.66 ]
Wells 2012 18 14 5 10 0.78 [ 0.56, 0.93 ] 0.42 [ 0.22, 0.63 ]
Winkelmann 2016 3 3 2 4 0.60 [ 0.15, 0.95 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 63. MSI-CAD All systems (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 63 MSI-CAD All systems (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Friedman 2008 48 28 1 22 0.98 [ 0.89, 1.00 ] 0.44 [ 0.30, 0.59 ]
Glud 2009 12 29 0 42 1.00 [ 0.74, 1.00 ] 0.59 [ 0.47, 0.71 ]
Gutkowicz Krusin 1997 5 9 0 14 1.00 [ 0.48, 1.00 ] 0.61 [ 0.39, 0.80 ]
Monheit 2011 112 1356 2 142 0.98 [ 0.94, 1.00 ] 0.09 [ 0.08, 0.11 ]
Tomatis 2003 28 58 9 78 0.76 [ 0.59, 0.88 ] 0.57 [ 0.49, 0.66 ]
Tomatis 2005 33 70 8 236 0.80 [ 0.65, 0.91 ] 0.77 [ 0.72, 0.82 ]
Wells 2012 22 22 1 2 0.96 [ 0.78, 1.00 ] 0.08 [ 0.01, 0.27 ]
Winkelmann 2016 4 3 1 4 0.80 [ 0.28, 0.99 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 64. Derm-CAD All systems (invasive melanoma or atypical intraepidermal melanocytic variants).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 64 Derm-CAD All systems (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barzegari 2005 6 12 1 104 0.86 [ 0.42, 1.00 ] 0.90 [ 0.83, 0.95 ]
Bauer 2000 39 6 3 267 0.93 [ 0.81, 0.99 ] 0.98 [ 0.95, 0.99 ]
Binder 1994 38 7 2 53 0.95 [ 0.83, 0.99 ] 0.88 [ 0.77, 0.95 ]
Binder 1998 9 14 1 5 0.90 [ 0.55, 1.00 ] 0.26 [ 0.09, 0.51 ]
Blum 2004a 32 59 8 319 0.80 [ 0.64, 0.91 ] 0.84 [ 0.80, 0.88 ]
Boldrick 2007 1 2 5 10 0.17 [ 0.00, 0.64 ] 0.83 [ 0.52, 0.98 ]
Burroni 2004 365 108 7 341 0.98 [ 0.96, 0.99 ] 0.76 [ 0.72, 0.80 ]
Cascinelli 1992 8 15 2 19 0.80 [ 0.44, 0.97 ] 0.56 [ 0.38, 0.73 ]
Cristofolini 1997 28 77 7 64 0.80 [ 0.63, 0.92 ] 0.45 [ 0.37, 0.54 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dreiseitl 2009 23 478 8 2512 0.74 [ 0.55, 0.88 ] 0.84 [ 0.83, 0.85 ]
Ferris 2015 38 78 1 56 0.97 [ 0.87, 1.00 ] 0.42 [ 0.33, 0.51 ]
Gilmore 2010 32 12 4 21 0.89 [ 0.74, 0.97 ] 0.64 [ 0.45, 0.80 ]
Maglogiannis 2015 38 12 16 38 0.70 [ 0.56, 0.82 ] 0.76 [ 0.62, 0.87 ]
Menzies 2005 111 232 11 432 0.91 [ 0.84, 0.95 ] 0.65 [ 0.61, 0.69 ]
Mollersen 2015 42 662 2 164 0.95 [ 0.85, 0.99 ] 0.20 [ 0.17, 0.23 ]
Piccolo 2002 12 85 1 243 0.92 [ 0.64, 1.00 ] 0.74 [ 0.69, 0.79 ]
Piccolo 2014 33 36 0 96 1.00 [ 0.89, 1.00 ] 0.73 [ 0.64, 0.80 ]
Rubegni 2002a 16 1 1 20 0.94 [ 0.71, 1.00 ] 0.95 [ 0.76, 1.00 ]
Seidenari 1999 18 30 0 335 1.00 [ 0.81, 1.00 ] 0.92 [ 0.88, 0.94 ]
Serrao 2006 29 305 12 306 0.71 [ 0.54, 0.84 ] 0.50 [ 0.46, 0.54 ]
Stanganelli 2005 16 44 4 173 0.80 [ 0.56, 0.94 ] 0.80 [ 0.74, 0.85 ]
Wollina 2007 31 16 2 60 0.94 [ 0.80, 0.99 ] 0.79 [ 0.68, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 65. Derm-CAD MoleExpert (Any lesion requiring excision).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 65 Derm-CAD MoleExpert (Any lesion requiring excision)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mollersen 2015 117 652 4 97 0.97 [ 0.92, 0.99 ] 0.13 [ 0.11, 0.16 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 66. Derm-CAD All systems (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 66 Derm-CAD All systems (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Menzies 1996 40 29 5 90 0.89 [ 0.76, 0.96 ] 0.76 [ 0.67, 0.83 ]
Menzies 2005 69 274 6 437 0.92 [ 0.83, 0.97 ] 0.61 [ 0.58, 0.65 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 67. Image-based Dermoscopy - Derm-CAD studies (invasive melanoma).
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 67 Image-based Dermoscopy - Derm-CAD studies (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Menzies 1996 41 35 4 84 0.91 [ 0.79, 0.98 ] 0.71 [ 0.62, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 68. MSI-CAD All (Melafind) (invasive melanoma or atypical intraepidermal melanocytic variants),
CAD + Clinician (diagnostic aid) only.
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 68 MSI-CAD All (Melafind) (invasive melanoma or atypical intraepidermal melanocytic variants), CAD + Clinician (diagnostic aid) only
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hauschild 2014 51 35 14 30 0.78 [ 0.67, 0.88 ] 0.46 [ 0.34, 0.59 ]
Winkelmann 2016 4 3 1 4 0.80 [ 0.28, 0.99 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 69. MSI-CAD All (invasive melanoma or atypical intraepidermal melanocytic variants), CAD only.
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 69 MSI-CAD All (invasive melanoma or atypical intraepidermal melanocytic variants), CAD only
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Friedman 2008 48 28 1 22 0.98 [ 0.89, 1.00 ] 0.44 [ 0.30, 0.59 ]
Glud 2009 12 29 0 42 1.00 [ 0.74, 1.00 ] 0.59 [ 0.47, 0.71 ]
Gutkowicz Krusin 1997 5 9 0 14 1.00 [ 0.48, 1.00 ] 0.61 [ 0.39, 0.80 ]
Tomatis 2003 28 58 9 78 0.76 [ 0.59, 0.88 ] 0.57 [ 0.49, 0.66 ]
Tomatis 2005 33 70 8 236 0.80 [ 0.65, 0.91 ] 0.77 [ 0.72, 0.82 ]
Wells 2012 22 22 1 2 0.96 [ 0.78, 1.00 ] 0.08 [ 0.01, 0.27 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 70. MSI-CADMelafind (invasive melanoma or atypical intraepidermal melanocytic variants), CAD only.
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 70 MSI-CAD Melafind (invasive melanoma or atypical intraepidermal melanocytic variants), CAD only
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Friedman 2008 48 28 1 22 0.98 [ 0.89, 1.00 ] 0.44 [ 0.30, 0.59 ]
Gutkowicz Krusin 1997 5 9 0 14 1.00 [ 0.48, 1.00 ] 0.61 [ 0.39, 0.80 ]
Wells 2012 22 22 1 2 0.96 [ 0.78, 1.00 ] 0.08 [ 0.01, 0.27 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 71. Derm-CAD All (invasive melanoma or atypical intraepidermal melanocytic variants), CAD +
Clinician (diagnostic aid) only.
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 71 Derm-CAD All (invasive melanoma or atypical intraepidermal melanocytic variants), CAD + Clinician (diagnostic aid) only
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bauer 2000 39 6 3 267 0.93 [ 0.81, 0.99 ] 0.98 [ 0.95, 0.99 ]
Piccolo 2014 33 36 0 96 1.00 [ 0.89, 1.00 ] 0.73 [ 0.64, 0.80 ]
Wollina 2007 31 16 2 60 0.94 [ 0.80, 0.99 ] 0.79 [ 0.68, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 72. Derm-CAD All (invasive melanoma or atypical intraepidermal melanocytic variants), CAD only.
Review: Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults
Test: 72 Derm-CAD All (invasive melanoma or atypical intraepidermal melanocytic variants), CAD only
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barzegari 2005 6 12 1 104 0.86 [ 0.42, 1.00 ] 0.90 [ 0.83, 0.95 ]
Binder 1994 38 7 2 53 0.95 [ 0.83, 0.99 ] 0.88 [ 0.77, 0.95 ]
Binder 1998 9 14 1 5 0.90 [ 0.55, 1.00 ] 0.26 [ 0.09, 0.51 ]
Blum 2004a 32 59 8 319 0.80 [ 0.64, 0.91 ] 0.84 [ 0.80, 0.88 ]
Boldrick 2007 1 2 5 10 0.17 [ 0.00, 0.64 ] 0.83 [ 0.52, 0.98 ]
Burroni 2004 365 108 7 341 0.98 [ 0.96, 0.99 ] 0.76 [ 0.72, 0.80 ]
Cascinelli 1992 8 15 2 19 0.80 [ 0.44, 0.97 ] 0.56 [ 0.38, 0.73 ]
Cristofolini 1997 28 77 7 64 0.80 [ 0.63, 0.92 ] 0.45 [ 0.37, 0.54 ]
Dreiseitl 2009 23 478 8 2512 0.74 [ 0.55, 0.88 ] 0.84 [ 0.83, 0.85 ]
Ferris 2015 38 78 1 56 0.97 [ 0.87, 1.00 ] 0.42 [ 0.33, 0.51 ]
Gilmore 2010 32 12 4 21 0.89 [ 0.74, 0.97 ] 0.64 [ 0.45, 0.80 ]
Maglogiannis 2015 38 12 16 38 0.70 [ 0.56, 0.82 ] 0.76 [ 0.62, 0.87 ]
Menzies 2005 111 232 11 432 0.91 [ 0.84, 0.95 ] 0.65 [ 0.61, 0.69 ]
Mollersen 2015 42 662 2 164 0.95 [ 0.85, 0.99 ] 0.20 [ 0.17, 0.23 ]
Piccolo 2002 12 85 1 243 0.92 [ 0.64, 1.00 ] 0.74 [ 0.69, 0.79 ]
Rubegni 2002a 16 1 1 20 0.94 [ 0.71, 1.00 ] 0.95 [ 0.76, 1.00 ]
Seidenari 1999 18 30 0 335 1.00 [ 0.81, 1.00 ] 0.92 [ 0.88, 0.94 ]
Serrao 2006 29 305 12 306 0.71 [ 0.54, 0.84 ] 0.50 [ 0.46, 0.54 ]
Stanganelli 2005 16 44 4 173 0.80 [ 0.56, 0.94 ] 0.80 [ 0.74, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Glossary of terms
Term Definition
Artificial intelligence Computer systemsundertaking tasks that normally require human intelligence,
such as decision-making or visual perception
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Table 1. Glossary of terms (Continued)
Atypical intraepidermal melanocytic variant Unusual area of darker pigmentation contained within the epidermis that may
progress to an invasive melanoma; includes melanoma in situ and lentigo ma-
ligna
Atypical naevi Unusual looking but noncancerous mole or area of darker pigmentation of the
skin
Basaloid cells Cells in the skin that look like those in epidermal basal layer
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in
the control of cell growth. BRAF mutations (damaged DNA) occur in around
40% of melanomas, which can then be treated with particular drugs
BRAF inhibitors Therapeutic agents which inhibit the serine-threonine protein kinase BRAF
mutated metastatic melanoma
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a
microscope, measured in mm from the top layer of skin to the bottom of the
tumour
Congenital naevi A type of mole found on infants at birth
Dermoscopy Whereby a handheld microscope is used to allow more detailed, magnified,
examination of the skin compared to examination by the naked eye alone
Dermo-epidermal junction The area where the lower part of the epidermis and top layer of the dermis
meet
Dermis Layer of skin below the epidermis, composed of living tissue and containing
blood capillaries, nerve endings, sweat glands, hair follicles and other structures
Desmoplastic subtypes of SCC An aggressive squamous cell carcinoma variant characterised by a proliferation
of fibroblasts and formation of fibrous connective tissue
Electrodesiccation The use of high-frequency electric currents to cut, destroy or cauterise tissue.
It is performed with the use of a fine needle-shaped instrument
Electrical impedance spectroscopy The measurement of electrical current properties as they pass through skin
tissues, to retrieve information on cellular structures
Epidermis Outer layer of the skin
False negative An individual who is truly positive for a disease, but whom a diagnostic test
classifies them as disease-free
False positive An individual who is truly disease-free, but whom a diagnostic test classifies
them as having the disease
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Table 1. Glossary of terms (Continued)
Histopathology/Histology The study of tissue, usually obtained by biopsy or excision, for example under
a microscope
Incidence The number of new cases of a disease in a given time period.
Index test A diagnostic test under evaluation in a primary study
Interferometry The measurement of waves of light or sound after interference in order to
extract information
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which
includes malignant cells but with no invasive growth. May progress to an
invasive melanoma
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containingwhite blood cells)
that travels around the body to help fight disease; they are located throughout
the body often in clusters (nodal basins)
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as
‘moles’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of
individual studies
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the
bloodstream or the lymphatic system
Morbidity Detrimental effects on health.
Mortality Either (1) the condition of being subject to death; or (2) the death rate, which
reflects the number of deaths per unit of population in relation to any specific
region, age group, disease, treatment or other classification, usually expressed
as deaths per 100, 1000, 10,000 or 100,000 people
Multidisciplinary team A team with members from different healthcare professions and specialties (e.
g. urology, oncology, pathology, radiology, and nursing). Cancer care in the
National Health Service (NHS) uses this system to ensure that all relevant
health professionals are engaged to discuss the best possible care for that patient
Naevus A mole or collection of pigment cells (plural: naevi or nevi)
Optical coherence tomography (OCT) Based on the same principle as ultrasound, OCT uses a handheld probe to
measure the optical scattering of near-infrared (1310 nm) light waves (rather
than sound waves) from under the surface of the skin
Prevalence The proportion of a population found to have a condition.
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Table 1. Glossary of terms (Continued)
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect
the patient’s prognosis
Receiver operating characteristic (ROC) plot A plot of the sensitivity and 1 minus the specificity of a test at the different
possible thresholds for test positivity; represents the diagnostic capability of a
test with a range of binary test results
Receiver operating characteristic (ROC) analysis The analysis of a ROC plot of a test to select an optimal threshold for test
positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This
can occur either at the site of the original tumour or at other sites in the body
Reference Standard A test or combination of tests used to establish the final or ‘true’ diagnosis of
a patient in an evaluation of a diagnostic test
Reflectance confocal microscopy (RCM) A microscopic technique using infrared light (either in a handheld device or a
static unit) that can create images of the deeper layers of the skin
Resolution Resolution in an imaging system refers to its ability to distinguish two points
in space as being separate points; resolution is measured in two directions: axial
and lateral
Sensitivity In this context the term is used to mean the proportion of individuals with a
disease who have that disease correctly identified by the study test
Specificity The proportion of individuals without the disease of interest (in this case with
benign skin lesions) who have that absence of disease correctly identified by
the study test
Spectroscopy Study of the interaction between matter and electromagnetic radiation
Spindle subtypes of SCC A squamous cell carcinoma variant characterised by poorly differentiated spin-
dle cells surrounded by collagenous stroma
Staging Clinical description of the size and spread of a patient’s tumour, fitting into
internationally agreed categories
Stratum corneum The outermost layer of the epidermis. This layer is the most superficial layer
of skin, which is composed of flattened skin cells organised like a brick wall.
In normal conditions cells are not nucleated at this layer
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical
or physical examination
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Table 2. A cross-tabulation of studies by CAD type, reported comparisons and target conditions
Study CAD type CAD system CAD diagnosis Comparison with
dermoscopy
Target conditionsa
Bauer 2000 Derm-CAD DB-MIPs CAD diagnostic aid in-person dermoscopy 1
Wollina 2007 Derm-CAD DB-MIPs CAD diagnostic aid No 1
Burroni 2004 Derm-CAD DB-MIPs CAD only No 1
Rubegni 2002a Derm-CAD DB-MIPs CAD only No 1
Seidenari 1998 Derm-CAD DB-MIPs CAD only image-based
assessment
1
Seidenari 1999 Derm-CAD DB-MIPs CAD only No 1
Stanganelli 2005 Derm-CAD DB-MIPs CAD only No 1
Piccolo 2002 Derm-CAD DEM-MIPS CAD only image-based
assessment
1
Binder 1998 Derm-CAD IBAS 2000 CAD only No 1
Barzegari 2005 Derm-CAD MicroDERM CAD only No 1
Boldrick 2007 Derm-CAD MicroDERM CAD only No 1
Serrao 2006 Derm-CAD MicroDERM CAD only No 1
Dreiseitl 2009 Derm-CAD Image J (MoleMax II) CAD only in-person dermoscopy 1
Maglogiannis
2015
Derm-CAD System name NR
(MoleMax II)
CAD only No 1
Mollersen 2015 Derm-CAD Nevus Doctor
Mole Expert
CAD only No 1,5
Piccolo 2014 Derm-CAD Nevuscreen CAD diagnostic aid image-based
assessment
1
Cascinelli 1992 Derm-CAD Skin View CAD only No 1,5
Cristofolini 1997 Derm-CAD Skin View CAD only No 1
Menzies 2005 Derm-CAD SolarScan CAD only Excluded (different
sample sizes)
1,4
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Table 2. A cross-tabulation of studies by CAD type, reported comparisons and target conditions (Continued)
Binder 1994 Derm-CAD System name NR CAD only image-based
assessment
1
Blum 2004a Derm-CAD System name NR CAD only Excluded (different
sample sizes)
1
Ferris 2015 Derm-CAD System name NR CAD only Excluded (different
sample sizes)
1,2,5
Gilmore 2010 Derm-CAD System name NR CAD only image-based
assessment
1
Menzies 1996 Derm-CAD System name NR CAD only image-based
assessment
4
Hauschild 2014 MSI-CAD MelaFind CAD diagnostic aid image-based
assessment
1,4
Winkelmann 2016 MSI-CAD MelaFind CAD diagnostic aid image-based
assessment
1
Friedman 2008 MSI-CAD MelaFind CAD only image-based
assessment
1,4
Monheit 2011 MSI-CAD MelaFind CAD only No 1
Wells 2012 MSI-CAD MelaFind CAD only image-based
assessment
1
Sgouros 2014 MSI-CAD Siascope (versionNR) CAD only No 5
Glud 2009 MSI-CAD Siascope II CAD only image-based
assessment
1
Terstappen 2013 MSI-CAD Siascope V CAD only No 4
Walter 2012 MSI-CAD Siascope V (Mole-
Mate)
CAD diagnostic aid No 1,4,5
Tomatis 2005 MSI-CAD Spectroshade CAD only No 1
Ascierto 2010 MSI-CAD Spectroshade CAD only in-person dermoscopy 4
Gutkowicz Krusin
1997
MSI-CAD System name NR CAD only No 1
Tomatis 2003 MSI-CAD Telespectrophoto-
metric system
CAD only No 1
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Table 2. A cross-tabulation of studies by CAD type, reported comparisons and target conditions (Continued)
Bono 1996 MSI-CAD Telespectrophoto-
metric System
CAD only No 4
Bono 2002 MSI-CAD Telespectrophoto-
metric System
CAD only in-person dermoscopy 1
Garcia Uribe 2012 DRS-CAD OIDRS CAD only No 1,5
Malvehy 2014 EIS-CAD Nevisense CAD only Excluded (different
sample sizes)
1,2,3,4,5
Mohr 2013 EIS-CAD Nevisense CAD only No 1,2,4,5
Key: Derm-CAD - Dermoscopy-based computer-assisted diagnosis; DRS-CAD - diffuse reflectance spectroscopy computer-assisted
diagnosis; EIS-CAD - Electrical impedance-based computer-assisted diagnosis; MSI-CAD - Multispectral imaging-based computer-
assisted diagnosis; NR - Not reported; OIDRS - oblique incidence reflectance spectroscopy
a1 - Invasive melanoma and atypical intraepidermal melanocytic variants; 2 - Basal cell carcinoma; 3 - cutaneous Squamous cell
carcinoma; 4 - Invasive melanoma alone; 5 - Any skin cancer or lesion requiring excision
Table 3. Characteristics of included digital dermoscopy-based CAD (Derm-CAD) systems
Derm-CAD pro-
cessing machine
Role of machine Image analysis Classifier CAD output Studies
MicroDERM (Vi-
siomed AG, Ger-
many)
Dermoscopy unit
with internal cam-
era containing anal-
ysis system
DANAOS software
combines analytical
system
based on ABCD
with database of 21,
000 PSLs
ANN DANAOS score in-
dicating risk of ma-
lignancy
Barzegari 2005;
Serrao 2006;
Boldrick 2007
DB-Dermo MIPS
(Biomips
Engineering, Italy)
Der-
moscopy unit, in-
ternal stereomicro-
scope, internal DB,
pattern analysis sys-
tem
DB-MIPS pattern
analysis system - in-
tegrated database
stores the patient’s
data and the de-
scription of the le-
sion along with the
image icons. 38 fea-
tures anal-
ysed (grouped into
geometries, colours
and Burroni’s is-
lands of colours)
ANN Diagnosis suggested
(e.g. melanoma, be-
nign melanocytic
naevus)
Bauer 2000;
Rubegni 2002a
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Table 3. Characteristics of included digital dermoscopy-based CAD (Derm-CAD) systems (Continued)
Auto-
matic Data Analysis
for Melanoma early
detec-
tion (ADAM) soft-
ware which analy-
ses boundary shape,
texture and colour
distribution
SVM Lowrisk, intermedi-
ate risk or high risk
of melanoma
Stanganelli 2005
DB-MIPS pattern
analysis system
Multivariate dis-
criminant analysis
Graphical output
and
numerical output of
features
provided. Diagno-
sis suggested (e.g.
melanoma, benign
melanocytic naevus)
Seidenari 1998;
Seidenari 1999
DB-MIPS pattern
analysis system
KNN Diagnosis suggested
(e.g. melanoma, be-
nign melanocytic
naevus)
Burroni 2004
DB-MIPS pattern
analysis system
Linear discrimina-
tion
Diagnosis suggested
(e.g. melanoma, be-
nign melanocytic
naevus)
Burroni 2004
DDA software anal-
ysis - analyses 50 pa-
rameters subdivided
into 3 categories, i.e.
geometries, colours,
and textures and
islands of colours
(Burroni islands)
Euclidian distances Not specified Wollina 2007
DEM-MIPS
(Biomips SRL,
Siena, Italy)
Commercially avail-
able software cou-
pled to stereomi-
croscope Wild M-
650 (Leica), video
camera, computer,
colour monitor
DEM-MIPS soft-
ware (Digital Epi
Mi-
croscopyMelanoma
Image Processing
Software; Biomips
SRL, Siena, Italy)
. Evaluates colori-
metric and geomet-
ric features (not re-
ported)
ANN Not specified Piccolo 2002
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Table 3. Characteristics of included digital dermoscopy-based CAD (Derm-CAD) systems (Continued)
Skin View Computerised
image analysis sys-
tem, digital televi-
sion, videocamera.
Connection
with the computer is
through a digitising
board able to pro-
cess colour images
Features of ABCD
system plus clinical
data (anatomic site,
months of growth,
size, shape, colour,
ulceration or regres-
sion)
NR ≥ 2 of 8 binary (on/
off ) indicators in-
dicates malignancy:
1. shape (asymme-
try); 2. clinical data
(changes
through time, re-
gression, ulceration)
; 3. size (mm); 4.
colour (distribution
of hue); 5. darkness
(percent of black
mixed with the hue)
; 6. saturation (per-
cent of white mixed
with the hue); 7.
border (sharpness of
transition between
lesion and healthy
skin; 8. texture
Cascinelli 1992;
Cristofolini 1997
Nevus Doctor Computerised im-
age analysis system
coupled to digital
dermatoscope
ND takes a dermo-
scopic image from
the Canon/
DermLite device as
input and classifies
the lesion
Features not
reported
NR Probability of ma-
lignancy
Mollersen 2015
MoleExpert (Der-
moScan GmbH,
Germany)
(micro Version 3.3.
30.156). Comput-
erised image analysis
with output giving
probability of ma-
lignancy
Features of ABCD
system plus other
features (not listed),
e.g. colour variation
and grey veil
NR Number be-
tween−5.00 and 5.
00, where high val-
ues indicate suspi-
cion of melanoma
Mollersen 2015
Image J (NIH,
Bethesda,
USA)
Image
segmentation, fea-
ture extraction, im-
age analysis coupled
with dermatoscope
MoleMax II
29 features anal-
ysed from 38 ex-
tracted features de-
scribing shape, form
and colour
ANN 2 outputs: 1) Visual
render-
ing of analysis show-
ing coloured areas 2)
Excision vs no ex-
cision decision (sys-
tem considers the
green zone of the
scale as benign (0 to
0.1), the yellow zone
suspicious (0.1 to 0.
Dreiseitl 2009
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Table 3. Characteristics of included digital dermoscopy-based CAD (Derm-CAD) systems (Continued)
4), and the red zone
malignant (0.4 to 1)
)
IBAS 2000
workstation (Zeiss,
Oberkochen, Ger-
many)
Digital image anal-
ysis workstation at-
tached
to Wild binocular
stereomicroscope M
650 (Wild Heer-
brugg AG, Switzer-
land)
Analysis of 16 mor-
phometric parame-
ters from the le-
sion and the bor-
der image: lesion
area and perime-
ter: minimum polar
distance, maximum
polar
distance, aspect ra-
tio, circularity shape
factor, variances of
grey, number differ-
ent colours, range
differ-
ent colours. Border
features and area:
maximum and min-
imumborder width,
ratio of border area
to lesion area, ratio
of border perimeter
to lesion perimeter
ANN Dichotomous deci-
sion: MM vs Benign
(CN or DN)
The network was
trained to yield a
value from 0 to 1
in the output nodes.
The node yielding
the greatest numeri-
cal output was then
used as the classifi-
cation result
Binder 1998
Nevuscreen ®
(Arkè s.a.s., Avez-
zano, Italy)
Dig-
ital database con-
taining image analy-
sis software, coupled
to digital dermato-
scope
Nevuscreen soft-
ware automatically
analyses ABCD fea-
tures
NR TDS score: < 4.75
benign, 4.75 - 5.45
suspicious, > 5.45
highly suggestive of
melanoma
Piccolo 2014
SolarScan
(Polartechnics Lts,
Australia)
Dermoscopy video
unit with internal
algorithm for image
analysis
103 automated im-
age analysis vari-
ables extracted: con-
sisting of various
properties of colour,
pattern, and geom-
etry. Number anal-
ysed not reported
Linear discriminant
analysis
Probability
of melanoma, with
cut-off (not pro-
vided) for benign vs
melanoma
Menzies 2005
Name not reported Computer anal-
ysis of stored images
captured using dif-
ferent dermoscopy/
camera
54 features anal-
ysed, such as bor-
der irregularity, ec-
centricity, length of
major and minor
Digital forest classi-
fier
Severity score (the
fraction of decision
trees (n = 1000) in
which the path ends
in “malignant”. Le-
Ferris 2015
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Table 3. Characteristics of included digital dermoscopy-based CAD (Derm-CAD) systems (Continued)
combinations axes, and colour his-
togram properties
sion classified asma-
lignant if its image
traced a path to a
malignant node in
at least 40% of the
trees)
Name not reported Computer anal-
ysis of stored images
captured using digi-
tal stereomicroscope
Features analysed as
present or ab-
sent (pattern anal-
ysis): Pigment net-
work, brown glob-
ules, radial stream-
ing, pseudopods,
black dots, margin,
pigmentation,
depigmentation
ANN NR Binder 1994
Name not reported Com-
puter analysis of dig-
ital dermoscopy im-
ages (Molemax II)
Fea-
tures corresponding
to the number, size
and asymmetry of
dots: (a) number
of dots, (b) total
number of pixels
in dots, (c) mean
number of pixels in
dots, (d) variance of
num. pixels in dots
(e) fraction of le-
sion area occupied
by dark dots. Asym-
metry: radial, angu-
lar, primary axis
Comparison of 5
classifiers:
Multilayer percep-
tron
KNN
Random forest
SVM polykernel c =
5*
SVM PUK kernel
NR Maglogiannis 2015
Name not reported Computer anal-
ysis of stored images
captured using digi-
tal microscope
14 features investi-
gated: 4 asymme-
try features, colour
variance (red, green,
blue), mean colour
(red, green, blue, in-
tensity)
, range colour (red,
green, blue)
SVM (principal
components analy-
sis)
NR Gilmore 2010
Name not reported Computer anal-
ysis of stored images
captured using digi-
tal microscope
Neg-
ative features: point
and axial symmetry
of pigmentation
Classification and
regression tree
Presence of indica-
tive
features (Melanoma
= 0/2 morpholog-
Menzies 1996
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Table 3. Characteristics of included digital dermoscopy-based CAD (Derm-CAD) systems (Continued)
Presence of only a
single colour.
Pos-
itive features: blue-
white, veil, mul-
tiple brown dots,
pseudopods, radial
stream-
ing, scarlike depig-
mentation, periph-
eral black dots/glob-
ules, multiple (5 -
6) colours, multi-
ple blue/grey dots,
broadened network
ically negative fea-
tures AND at least
1/9 positive mor-
phological features)
Name not reported Computer anal-
ysis of stored images
captured using digi-
tal microscope
Analysis of 64 an-
alytical parameters
including: a large
number of morpho-
logical parameters,
such as
margin, geometric
parameters (surface
area, extent, largest
diameter and largest
orthogonal diame-
ter), invari-
ant moments, sym-
metry, colours (red,
green, blue and grey
value), texture (en-
ergy, entropy, corre-
lation, in-
verse difference mo-
ment and inertia),
number of regions,
focus and difference
of the lesion and its
convex cover
Vision algebra
methods
NR Blum 2004a
*(classifier selected at random for inclusion in review)
Key: ANN - artificial neural network; CN - common naevus; DN - dysplastic naevus; KNN - K-nearest neighbour; NR - not reported;
MM - malignant melanoma; SVM - support vector machine; TDS - total dermoscopic score
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Table 4. Characteristics of included Spectroscopy-based CAD (Spectro-CAD) systems
Spectro-CAD sys-
tem
(spectroscopy
type)
Role of machine Image analysis Classifier CAD Output Studies
SpectroShade
(MHT, Verona
Italy)
(MSI-CAD)
Illumination assem-
bly located inside a
PC and an exter-
nal detection device
placed in a hand-
held probe, with in-
tegrated image anal-
ysis software
Fea-
tures analysed: (i)
reflectance (R); (ii)
variegation (V); (iii)
area (A); (iv) dark
area ratio (DAR);
(v) dark island re-
flectance (DIR); (vi)
dark distribu-
tion factor (DDF)
; (vii) dark perma-
nence (D PER)
ANN (multilayer
perceptron)
NR Tomatis 2005
SpectroShade cou-
pled with a Mole-
Max II dermato-
scope
NR Diag-
nostic category: 1no
melanoma, 2doubt-
ful
melanoma, 3 sus-
pectedmelanoma, 4
probable melanoma
Ascierto 2010
MelaFind (early
predecessor)
(MSI-CAD)
Digital camera and
illumination assem-
bly coupled to a
computer, with sep-
arate image analysis
Features anal-
ysed: Lesion asym-
metry, border, gra-
dient, centroid, tex-
ture, colour
Multiparametric
linear classifier
NR Gutkowicz Krusin
1997
MelaFind
(STRATA
Skin Sciences [for-
merly Mela Sci-
ences Inc], Hor-
sham, PA, USA)
(MSI-CAD)
Multispectral imag-
ing system with in-
tegrated image anal-
ysis software; device
takes images in vivo
MelaFind image
analysis
NR Binary out-
put: (1) positive, (le-
sion should be con-
sidered for biopsy to
rule out melanoma)
; and
(2) negative (lesion
should be consid-
ered for later evalu-
ation)
Monheit 2011
6 constrained linear
classifiers
Binary output: ex-
cise or follow-up
Friedman 2008
NR Monheit 2011 Wells 2012
Logistic regression Monheit 2011 Winkelmann 2016
NR Monheit 2011 Hauschild 2014
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Table 4. Characteristics of included Spectroscopy-based CAD (Spectro-CAD) systems (Continued)
Telespectrophoto-
metric system
(MSI-CAD)
Digital camera cou-
pled with an il-
lumination system
with interference fil-
ters and computer
for storage and anal-
ysis of multispectral
images
From each
spectral image, 3 pa-
rameters, i.e. mean
reflectance, variega-
tion index and le-
sion area, were de-
rived at the corre-
sponding
wavelength
Linear discriminant NR Bono 1996
For each spectral
image, 5 parameters
(lesion descriptors)
based onABCDand
related to colour and
shape of the imaged
lesion were evalu-
ated: mean
reflectance, variega-
tion index, com-
pactness, roughness,
and area
Linear discriminant
vs. ANN*
NR Tomatis 2003
Linear discriminant NR Bono 2002
SIAscopy ™ (As-
tron Clinica, UK)
(MSI-CAD)
Spectrophotomet-
ric imaging system
with hand-held skin
probe (SIAscope II)
and integrated soft-
ware
Analysis of dermal
melanin, erythema-
tous blush, lesion
asymmetry, collagen
’holes’, blood com-
mas, or irregularities
in the collagen
NR SIAgraphs and Bi-
nary output (based
on Australian Scor-
ing System): ‘strong
chance of
melanoma’ or ’low
risk of melanoma’
Glud 2009
Spectrophotomet-
ric imaging system
with hand-held skin
probe (SIAscope V)
and integrated soft-
ware (software Der-
metrics Version 2.0,
Astron Clinica Ltd.,
Great Britain)
NR SIAgraphs (no fur-
ther information)
Terstappen 2013
SIAscope (MedX
Health Corp,
Canada)
(MSI-CAD)
Spectrophoto-
metric imaging sys-
tem with hand-held
skin probe (SIAs-
cope, version NR)
and integrated soft-
ware
NR SIAgraphs and le-
sion score using Pri-
mary Care Scoring
Al-
gorithm (6 or more
points regarded as
suspicious)
Sgouros 2014
SIAscope (MedX
Health Corp,
Canada)
SIAscopy with
MoleMate (software
image management
NR SIAgraphs and le-
sion score using Pri-
mary Care Scoring
Walter 2012
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Table 4. Characteristics of included Spectroscopy-based CAD (Spectro-CAD) systems (Continued)
(MSI-CAD) system) viewing
platform and inte-
grated Primary Care
Scoring Algorithm
Al-
gorithm (6 or more
points regarded as
suspicious)
Oblique Incidence
Diffuse
Reflectance Spec-
troscopy (DRS-
CAD)
Light probe coupled
to imaging spectro-
graph, camera, and
computer to store
images
NR ANN Diagnostic category
(e.g.CN,MM,DN,
BCC, cSCC)
Garcia Uribe 2012
Nevisense (SciBase
III, Sweden)
(EIS-CAD)
Electri-
cal Impedance spec-
troscopy imag-
ing system with in-
tegrated image anal-
ysis software
The system
measures the over-
all electrical resis-
tance and reactance
at 35 different fre-
quencies
SVM (non-proba-
bilistic binary linear
classifier)
The system com-
putes both a score (0
- 10) and a dichoto-
mous output (EIS
negative/positive) at
a fixed cut-off. The
fixed threshold is set
at 4, i.e. scores <
4 are EIS-negative
and scores of≥ 4 are
EIS positive
Mohr 2013
Malvehy 2014
*Classifier excluded at random
Key: ANN - artificial neural network; BCC - basal cell carcinoma; cSCC - cutaneous squamous cell carcinoma; CAD - computer-
assisted diagnosis; CN - common naevus; DN - dysplastic naevus; EIS - electrical impedance spectroscopy; KNN - K-nearest neighbour;
NR - not reported; MM - malignant melanoma; MSI - multispectral imaging; SVM - support vector machine
Table 5. Summary estimates of sensitivity and specificity for CAD according to target condition
Index test, target con-
dition
Studies Cases/Number of partici-
pants
Summary sensitivity (95%
CI) %
Summary specificity (95%
CI) %
Main analyses: Invasive melanoma and atypical intraepidermal melanocytic variants
Derm-CAD 22 1063/8992 90.1 (84.0 to 94.0) 74.3 (63.6 to 82.7)
MSI-CAD 8 286/2401 92.9 (83.7 to 97.1) 43.6 (24.8 to 64.5)
EIS-CAD (Nevisense*) 2 368/2389 97.0 (94.7 to 98.3) 33.6 (31.6 to 35.7)
Individual CAD systems: Invasive melanoma and atypical intraepidermal melanocytic variants
DB-MIPS (Derm-
CAD)
6 502/1903 95.2 (89.5 to 97.9) 89.1 (78.7 to 94.8)
Skin View (Derm-CAD) 2 45/220 80.0 (65.8 to 89.3) 47.4 (40.1 to 54.8)
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Table 5. Summary estimates of sensitivity and specificity for CAD according to target condition (Continued)
MelaFind (MSI-CAD) 5 196/1798 97.1 (91.9 to 98.9) 29.8 (12.3 to 56.3)
Main analyses: Basal cell carcinoma
EIS-CAD (Nevisense*) 2 69/2389 100 (94.7 to 100) 26.3 (24.5 to 28.1)
Secondary target condition: invasive melanoma alone
Derm-CAD 2 120/950 90.8 (84.2 to 94.9) 63.5 (60.2 to 66.7)
MSI-CAD 5 116/386 76.5 (43.0 to 93.3) 60.7 (38.5 to 79.2)
EIS-CAD (Nevisense*) 2 226/2389 98.2 (95.4 to 99.3) 38.0 (36.0 to 40.1)
Secondary target condition: any skin cancer or lesions requiring excision
EIS-CAD (Nevisense*) 2 644/2389 93.5 (91.3 to 95.1) 32.6 (30.4 to 34.8)
*For EIS-CAD the only evidence available was for one system
Key: CAD - computer-assisted diagnosis; CI - confidence interval; Derm-CAD - digital dermoscopy-based computer-assisted diagnosis;
EIS-CAD - electrical impedance spectroscopy-based computer-assisted diagnosis; MSI-CAD - multispectral imaging-based computer-
assisted diagnosis.
Table 6. Comparisons of CAD with dermoscopy for detection of the primary target condition: invasive melanoma and atypical
intraepidermal melanocytic variants
Test Number of studies Number of cases Number of partici-
pants
Pooled sensitivity
(95% CI)
Pooled specificity
(95% CI)
Derm-CAD versus image-based dermoscopy - indirect comparison
Derm-CAD 22 1063 8992 90.1 (84.0 to 94.0) 74.3 (63.6 to 82.7)
Image-based der-
moscopy
5 153 765 93.3 (83.4 to 97.5) 88.5 (57.3 to 97.8)
Difference (95%
CI), P value
- −3.21 (−11.2 to 4.
79), P = 0.43
−14.1 (−34.4 to 6.
06), P = 0.17
Derm-CAD versus image-based dermoscopy - direct comparison
Derm-CAD 5 153 765 94.1 (89.1 to 96.9) 80.8 (68.2 to 89.3)
Image-based der-
moscopy
5 153 765 93.9 (85.1 to 97.7) 88.3 (56.5 to 97.8)
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Table 6. Comparisons of CAD with dermoscopy for detection of the primary target condition: invasive melanoma and atypical
intraepidermal melanocytic variants (Continued)
Difference (95%
CI), P value
- 0.17 (−6.61 to 6.95)
, P = 0.96
−7.44 (−28.4 to 13.
6), P = 0.49
MSI-CAD versus image-based dermoscopy - indirect comparison
MSI-CAD 8 286 2401 92.9 (83.7 to 97.1) 43.6 (24.8 to 64.5)
Image-based der-
moscopy
5 154 371 74.0 (66.5 to 80.3) 58.7 (43.5 to 72.4)
Difference (95%
CI), P value
- 18.9 (9.58 to 28.2),
P = 0.003
−15.0 (−40.7 to 10.
6), P = 0.26
MSI-CAD versus image-based dermoscopy - direct comparison
MSI-CAD 5 154 371 96.8 (92.4 to 98.6) 29.8 (12.4 to 56.1)
Image-based der-
moscopy
5 154 371 74.0 (66.5 to 80.3) 58.7 (43.5 to 72.4)
Difference (95%
CI), P value
- 22.7 (15.2 to 30.2),
P < 0.001
−28.9 (−56.3 to
−1.48), P = 0.039
Melafind (MSI-CAD) versus Image-based dermoscopy - indirect comparison
MelaFind 5 196 1798 97.4 (94.0 to 98.9) 29.3 (12.1 to 55.6)
Image-based der-
moscopy
4 142 288 72.5 (64.6 to 79.2) 50.7 (42.6 to 58.7)
Difference (95%
CI), P value
- 24.5 (16.5 to 32.4),
P < 0.001
−20.9 (−45.5 to 3.
75), P = 0.10
Melafind (MSI-CAD) versus Image-based dermoscopy - direct comparison
MelaFind 4 142 288 96.5 (91.8 to 98.5) 22.8 (8.38 to 48.9)
Image-based der-
moscopy
4 142 288 72.5 (64.6 to 79.2) 50.7 (42.6 to 58.7)
Difference (95%
CI), P value
- 23.9 (16.0 to 31.9),
P < 0.001
−27.9 (−50.1 to -5.
66), P = 0.014
Derm-CAD versus MSI-CAD - indirect comparison
Derm-CAD 22 1063 8992 90.1 (84.0 to 94.0) 74.3 (63.6 to 82.7)
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Table 6. Comparisons of CAD with dermoscopy for detection of the primary target condition: invasive melanoma and atypical
intraepidermal melanocytic variants (Continued)
MSI-CAD 8 286 2401 92.9 (83.7 to 97.1) 43.6 (24.8 to 64.5)
Difference (95%
CI), P value
- 2.83 (−5.04 to 10.7)
,
P = 0.48
−30.7 (−53.8 to
−7.64), P = 0.009
Key:CAD - computer-assisted diagnosis; CI - confidence interval; Derm-CAD - digital dermoscopy- based computer-assisted diagnosis;
MSI-CAD - multispectral imaging-based computer-assisted diagnosis; P - probability.
Table 7. Sensitivity and Specificity of CAD systems in Unreferred Populations
Derm-CAD
CAD
System
Study Target con-
dition
TP FP FN TP Sensitivity (95% CI) Specificity (95% CI)
DB-MIPS Wollina
2007
MEL 17 54 2 284 89.5 (68.6 to 97.1) 84.0 (79.7 to 87.5)
MSI-CAD
CAD
System
Study Target con-
dition
TP FP FN TP Sensitivity (95% CI) Specificity (95% CI)
MoleMate
SIAscope
Walter 2012 MEL 18 209 0 539 100 (82.4 to 100) 72.1 (68.7 to 75.2)
MoleMate
SIAscope
Walter 2012 MM 14 213 0 539 100 (78.5 to 100) 71.7 (68.4 to 74.8)
MoleMate
SIAscope
Walter 2012 Any 23 204 2 537 92.0 (75.0 to 97.8) 72.5 (69.1 to 75.6)
SIAscope Sgouros
2014
Any 26 7 5 6 83.9 (67.4 to 92.9) 46.2 (23.2 to 70.9)
Any - any skin cancer or lesion requiring excision (secondary objective); CI - confidence interval; Derm-CAD - digital dermoscopy-
based computer-assisted diagnosis; FN - false negative; FP - false positive; MEL - invasive melanoma and atypical intraepidermal
melanocytic variants (primary objective);MM-malignant (invasive)melanoma only (secondary objective);MSI-CAD -multispectral
imaging-based computer-assisted diagnosis; TN - true negative; TP - true positive
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Table 8. Direct comparisons of single CAD studies with dermoscopy for diagnosis of melanoma and other types of skin cancer
Study Sensitivity (true positives/cases) % Difference
(95% CI)
Specificity (true negatives/non
cases) %
Difference
(95% CI)
MSI-CAD study comparisons: invasive melanoma and atypical intraepidermal melanocytic variants
MSI-CAD In-person
dermoscopy
MSI-CAD In-person
dermoscopy
Bono 2002 80.3 (53/66) 90.9 (60/66) −10.6 (−22.8 to
1.58)
49.0 (121/247) 74.5 (184/247) −25.5 (−33.5 to
−17.0)
MSI-CAD study comparisons: Invasive melanoma
MSI-CAD In-person
dermoscopy
MSI-CAD In-person
dermoscopy
Ascierto 2010 66.7 (8/12) 100 (12/12) −33.3 (−60.9 to
−2.20)
76.2 (32/42) 45.2 (19/42) 31.0 (10.1 to 48.
4)
MelaFind
(MSI-CAD)
Image-based
dermoscopy
Melafind
(MSI-CAD)
Image-based
dermoscopy
Friedman 2008 100 (21/21) 81.0 (17/21) 19.1 (−0.15 to
40.0)
29.5 (23/78) 44.9 (35/78) −15.4 (−29.6 to
−0.23)
Derm-CAD comparisons: invasive melanoma and atypical intraepidermal melanocytic variants
Derm-CAD In-person
dermoscopy
Derm-CAD In-person
dermoscopy
Bauer 2000 92.9 (39/42) 78.6 (33/42) 14.3 (−1.06 to
29.5)
97.8 (267/273) 96.3 (263/273) 1.47 (−1.55 to
4.64)
Dreiseitl 2009* 88.9 (24/27) 96.3 (26/27) −7.41 (−24.6 to
8.88)
48.0 (207/431) 71.9 (310/431) −23.9 (−30.1 to
−17.4)
Unnamed
system
Derm-CAD
Image-based
dermoscopy
Unnamed
system
Derm-CAD
Image-based
dermoscopy
Menzies 1996 88.9 (40/45) 91.1 (41/45) −2.22 (−15.7 to
11.2)
75.6 (90/119) 70.6 (84/119) 5.04 (−6.21 to
16.1)
DB-MIPS
(Derm-CAD)
In-person
dermoscopy
DB-MIPS
(Derm-CAD)
In-person
dermoscopy
Bauer 2000 92.9 (39/42) 78.6 (33/42) 14.3 (−1.06 to
29.5)
97.8 (267/273) 96.3 (263/273) 1.47 (−1.55 to
4.64)
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Table 8. Direct comparisons of single CAD studies with dermoscopy for diagnosis of melanoma and other types of skin cancer
(Continued)
DB-MIPS
(Derm-CAD)
Image-based
dermoscopy
DB-MIPS
(Derm-CAD)
Image-based
dermoscopy
Seidenari 1998 93.5 (29/31) 80.6 (25/31) 12.9 (−4.62 to
30.5)
94.9 (56/59) 94.9 (56/59) 0.00 (−9.44 to
9.44)
CAD-based diagnosis vs CAD-aided diagnosis: invasive melanoma and atypical intraepidermal melanocytic variants
CAD-based di-
agnosis
CAD-aided di-
agnosis
CAD-based
diagnosis
CAD-aided
diagnosis
Dreiseitl 2009* 88.9 (24/27) 74.1 (20/27) 14.8 (−6.4 to
34.9)
48.0 (207/431) 81.9 (353/431) −33.9 (39.6 to
−27.7)
Hauschild 2014 96.9 (63/65) 78.5 (51/65) 18.5 (7.3 to 30.
1)
9.2 (6/65) 46.2 (30/65) −36.9 (−49.9 to
−22.0)
*Patient-based analysis, unlike other studies in the table which were lesion-based. The Dreiseitl 2009 study did report lesion-based for
the accuracy of CAD-only Derm-CAD, used in the meta-analysis for Derm-CAD accuracy to detect invasive melanoma or atypical
intraepidermal melanocytic variants (data presented in Figure 10).
Key: CAD - computer-assisted diagnosis; CI - confidence interval; Derm-CAD - digital dermoscopy-based computer-assisted diagnosis;
MSI-CAD - multispectral imaging-based computer-assisted diagnosis.
Table 9. Sensitivity and specificity of oblique incidence diffuse reflectance spectrometry CAD (OIDRS-CAD) studies for
primary target condition: invasive melanoma and atypical intraepidermal melanocytic variants
Index test, tar-
get condition
True positives False positives False negatives True negatives Sensitivity (95%
CI) %
Specificity (95%
CI) %
Garcia Uribe
2012
9 13 1 113 90.0 (59.6 to 98.2) 89.7 (83.2 to 93.9)
Table 10. Sensitivity and specificity of electrical impedance spectroscopy CAD (EIS-CAD) studies for each primary target
condition
Index test, tar-
get condition
True positives False positives False negatives True negatives Sensitivity (95%
CI) %
Specificity (95%
CI) %
Invasive melanoma and atypical intraepidermal melanocytic variants
Mohr 2013 101 246 2 97 98.1 (93.2 to 99.5) 28.3 (23.8 to 33.3)
Malvehy 2014 256 1095 9 583 96.6 (93.7 to 98.2) 34.7 (32.5 to 37.1)
Basal cell carcinoma
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Table 10. Sensitivity and specificity of electrical impedance spectroscopy CAD (EIS-CAD) studies for each primary target
condition (Continued)
Mohr 2013 21 351 0 74 100 (84.5 to 100) 17.4 (14.1 to 21.3)
Malvehy 2014 48 1359 0 536 100 (92.6 to 100) 28.3 (26.3 to 30.4)
Cutaneous Squamous cell carcinoma
Malvehy 2014 7 1095 0 841 100 (64.6 to 100) 43.4 (41.3 to 45.7)
A P P E N D I C E S
Appendix 1. Current content and structure of the Programme Grant
LIST OF REVIEWS Number of studies
Diagnosis of melanoma
1 Visual inspection 49
2 Dermoscopy +/- visual inspection 104
3 Teledermatology 22
4 Smartphone applications 2
5a Computer-assisted diagnosis - dermoscopy-based techniques 42
5b Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
6 Reflectance confocal microscopy 18
7 High-frequency ultrasound 5
Diagnosis of keratinocyte skin cancer (BCC and cSCC)
8 Visual inspection +/- Dermoscopy 24
5c Computer-assisted diagnosis - dermoscopy-based techniques Review amalgamated into 5a
5d Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
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(Continued)
9 Optical coherence tomography 5
10 Reflectance confocal microscopy 10
11 Exfoliative cytology 9
Staging of melanoma
12 Imaging tests (ultrasound, CT, MRI, PET-CT) 38
13 Sentinel lymph node biopsy 160
Staging of cSCC
Imaging tests review Review dropped; only one study identified
13 Sentinel lymph node biopsy Review amalgamated into 13 above (n = 15 studies)
Appendix 2. Acronyms
Acronym Definition
µm micrometre
AK actinic keratosis
ANN artificial neural network
BCC basal cell carcinoma
BD Bowen’s disease
BPC between person comparison (of tests)
CAD computer assisted diagnosis
CCS case control study
CS case series
cSCC cutaneous squamous cell carcinoma
D- disease negative
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(Continued)
D+ disease positive
Derm-CAD Digital dermoscopy based computer assisted diagnosis
DF dermatofibroma
DRS diffuse reflectance spectroscopy
DRSi diffuse reflectance spectroscopy imaging
Dx diagnosis
EIS electrical impedance spectroscopy
FN false negative
FP false positive
FU Follow- up
GP general practitioner
H&E haematoxylin and eosin stain
HFUS high-frequency ultrasound
Hz hertz
KHz kilohertz
K-NN k nearest neighbour
MHz megahertz
MiS melanoma in situ (or lentigo maligna)
MM malignant melanoma
mm millimetre
MSI multispectral imaging
N/A not applicable
NC non comparative
nm nanometre
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(Continued)
NPV negative predictive value
NR not reported
P prospective
PPV positive predictive value
PSL pigmented skin lesion
R retrospective
RCM reflectance confocal microscopy
RCT randomised controlled trial
SCC squamous cell carcinoma
SD standard deviation
se sensitivity
sp specificity
spectro-CAD spectroscopy based computer-assisted diagnosis
SK seborrhoeic keratosis
SSM superficial spreading melanoma
SVM Support vector machine
TN true negative
TS Telespectrophotometry System
VI visual inspection
UNREF Unreferred population
WPC within person comparison (of tests)
WPC-algs within person comparison (of algorithms)
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Appendix 3. Proposed sources of heterogeneity
i. Population characteristics
• general versus higher risk populations
• patient population: Primary /secondary / specialist unit
• lesion suspicion: general suspicion/atypical/equivocal/NR
• lesion type: any pigmented; melanocytic
• inclusion of multiple lesions per participant
• ethnicity
ii. Index test characteristics
• the nature of and definition of criteria for test positivity
• observer experience with the index test
• approaches to lesion preparation (e.g., the use of oil or antiseptic gel for dermoscopy)
iii. Reference standard characteristics
• reference standard used
• whether histology-reporting meets pathology-reporting guidelines
• use of excisional versus diagnostic biopsy
• whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
• consecutive or random sample of participants recruited
• index test interpreted blinded to the reference standard result
• index test interpreted blinded to the result of any other index test
• presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by the
reference test or by the same reference test with selection dependent on the index test result)
• use of an adequate reference standard
• overall risk of bias
Appendix 4. Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
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12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer-assisted.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
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64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 “Sensitivity and Specificity”/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
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Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer-assisted.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
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51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
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1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$ or
epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or
epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer-assisted.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
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52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$).mp. or
tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
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104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 “Sensitivity and Specificity”/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 “skin cancer*”
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*)
#6 nmsc
#7 “squamous cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 “basal cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 “visual inspect*”
#20 “visual exam*”
#21 (clinical or physical) next (exam*)
#22 “3 point”
#23 “three point”
#24 “pattern analys*”
#25 ABDC
#26 menzies
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#27 “7 point”
#28 “seven point”
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 “artificial intelligence”
#31 “AI”
#32 “computer assisted”
#33 “computer-assisted”
#34 AI
#35 “neural network*”
#36 MoleMax
#37 “computer diagnosis”
#38 “image process*”
#39 “automatic classif*”
#40 SIAscope
#41 “image analysis”
#42 “optical near/2 scan*”
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 “confocal microscopy”
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 “mitotic index”
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 “Mole Detective”
#60 “Spot Check”
#61 mole* near/2 map*
#62 total near/2 body
#63 “exfoliative cytolog*”
#64 “digital analys*”
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatolog*
#67 “optical coherence” next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or
#47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #
65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
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#76 “CAT SCAN” or “CATSCAN”
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 “magnetic resonance imag*”
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 “positron emission tomograph*”
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or “false negative*” or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 “electrical impedance spectroscopy”
#100 “history taking”
#101 “patient history”
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 “ugly duckling” or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 “clinical accuracy”
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 “diagnostic algorithm*”
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 “virtual image*”
#115 “volatile organic compound*”
#116 dog or dogs
#117 VOC
#118 “gene expression analys*”
#119 “reflex transmission imaging”
#120 “thermal imaging”
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #
112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
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Database : CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH “Melanoma”) OR (MH “Nevi and Melanomas+”)
S2 (MH “Skin Neoplasms+”)
S3 (MH “Carcinoma, Basal Cell+”)
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH “Keratinocytes”)
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or (seven
point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or DermoScan
or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH “Diagnosis, Computer Assisted+”)
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH “Sentinel Lymph Node Biopsy”)
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 “Patient history”
S45 naked eye
S46 skin exam*
S47 physical exam*
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S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR
S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR
S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH “Deoxyglucose+”)
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH “Deoxyglucose+”)
S72 (MH “Tomography, Emission-Computed+”)
S73 (MH “Tomography, X-Ray Computed”)
S74 positron emission tomograph*
S75 (MH “Magnetic Resonance Imaging+”)
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78
OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH “Neoplasm Staging”)
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*))
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#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or “incident light” or “surface microscop*”
or “visual inspect*” or “physical exam*” or 3 point or three point or pattern analy* or ABCDE or menzies or 7 point or seven point
or dermoscop* or dermatoscop* or AI or artificial or computer-assisted or computer assisted or neural network* or Molemax or image
process* or automatic classif* or image analysis or siascope or optical scan* or Aura or melafind or simsys or molemate or solarscan or
vivascope or confocal microscop* or high ultraso* or canine detect* or cellphone* or mobile* or phone* or smartphone or dermoscan
or skinvision or dermlink or spotcheck or spot check or mole detective or mole map* or total body or exfoliative psychology or digital
or image software or optical coherence or teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos*
or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or physical exam*
or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general practice or confocal
microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile organic or VOC or dog* or gene
expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron emission or
computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or sonograph* or ultraso*
or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
Appendix 5. Full text inclusion criteria
Criterion Inclusion Exclusion
Study design For diagnostic and staging reviews
• Any study for which a 2 × 2 contingency table
can be extracted, e.g.
◦ diagnostic case control studies
◦ ’cross-sectional’ test accuracy study with
retrospective or prospective data collection
◦ studies where estimation of test accuracy
was not the primary objective but test results for
both index and reference standard were available
◦ RCTs of tests or testing strategies where
participants were randomised between index tests
and all undergo a reference standard (i.e. accuracy
RCTs)
• < 5 melanoma cases (diagnosis reviews)
• < 10 participants (staging reviews)
• Studies developing new criteria for diagnosis
unless a separate ’test set’ of images were used to
evaluate the criteria (mainly digital dermoscopy)
• Studies using ’normal’ skin as controls
• Letters, editorials, comment papers, narrative
reviews
• Insufficient data to construct a 2 × 2 table
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(Continued)
Target condition • Melanoma
• Keratinocyte skin cancer (or non-melanoma
skin cancer)
◦ BCC or epithelioma
◦ cSCC
• Studies exclusively conducted in children
• Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
• Adults with a skin lesion suspicious for
melanoma, BCC, or cSCC (other terms include
pigmented skin lesion/naevi, melanocytic,
keratinocyte, etc.)
• Adults at high risk of developing melanoma
skin cancer, BCC, or cSCC
For staging reviews
• Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or
distant metastases or both
• People suspected of other forms of skin cancer
• Studies conducted exclusively in children
Index tests For diagnosis
• Visual inspection/clinical examination
• Dermoscopy/dermatoscopy
• Teledermoscopy
• Smartphone/mobile phone applications
• Digital dermoscopy/artificial intelligence
• Confocal microscopy
• Ocular coherence tomography
• Exfoliative cytology
• High-frequency ultrasound
• Canine odour detection
• DNA expression analysis/gene chip analysis
• Other
For staging
• CT
• PET
• PET-CT
• MRI
• Ultrasound +/fine needle aspiration cytology
FNAC
• SLNB +/high-frequency ultrasound
• Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope
used)
• Sentinel lymph biopsy for therapeutic rather
than staging purposes
• Tests to determine melanoma thickness
• Tests to determine surgical margins/lesion
borders
• Tests to improve histopathology diagnose
• LND
Reference standard For diagnostic studies
• Histopathology of the excised lesion
• Clinical follow-up of non-excised/benign
appearing lesions with later histopathology if
For diagnostic studies
• Exclude if any disease positive participants have
diagnosis unconfirmed by histology
• Exclude if > 50% of disease negative
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(Continued)
suspicious
• Expert diagnosis (studies should not be
included if expert diagnosis is the sole reference
standard)
For studies of imaging tests for staging
• Histopathology (via LND or SLMB)
• Clinical/radiological follow-up
• A combination of the above
For studies of SLNB accuracy for staging
• LND of both SLN+ and SLN- participants to
identify all diseased nodes
• LND of SLN+ participants and follow-up of
SLN- participants to identify a subsequent nodal
recurrence in a previously investigated nodal basin
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
• Exclude studies of referral accuracy, i.e.
comparing referral decision with expert diagnosis,
unless evaluations of teledermatology or mobile
phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle aspiration
cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography; PET-CT: positron
emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SLN+: positive
sentinel lymph node; SLN: negative sentinel lymph node; SLNB: sentinel lymph node biopsy
Appendix 6. Quality assessment (based on QUADAS-2)
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues (Whiting 2011).
Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
1) Was a consecutive or random sample of participants or images
enrolled?
Yes - if paper states consecutive or random
No - if paper describes other method of sampling
Unclear - if participant sampling not described
2) Was a case-control design avoided? Yes - if consecutive or random or case-control design clearly not
used
No - if study described as case-control or describes sampling spe-
cific numbers of participants with particular diagnoses
Unclear - if not described
3) Did the study avoid inappropriate exclusions, e.g.,
• ’difficult to diagnose’ lesions not excluded
• lesions not excluded on basis of disagreement between
evaluators
Yes - if inappropriate exclusions were avoided
No - if lesions were excluded that might affect test accuracy, e.
g., ’difficult to diagnose’ lesions, or where disagreement between
evaluators was observed
Unclear - if not clearly reported but there is suspicion that difficult
to diagnose lesions may have been excluded
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4) For between-person comparative studies only (i.e., allocating
different tests to different study participants):
• A) were the same participant selection criteria used for
those allocated to each test?
• B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised sequence?
• C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to assignment?
For A)
• Yes - if same selection criteria were used for each index test,
No - if different selection criteria were used for each index test,
Unclear - if selection criteria per test were not described, N/A -
if only 1 index test was evaluated or all participants received all
tests
For B)
• Yes - if adequate randomisation procedures are described,
No - if inadequate randomisation procedures are described,
Unclear - if the method of allocation to groups is not described
(a description of ’random’ or ’randomised’ is insufficient), N/A -
if only 1 index test was evaluated or all participants received all
tests
For C)
• Yes - if appropriate methods of allocation concealment are
described, No - if appropriate methods of allocation concealment
are not described, Unclear - if the method of allocation
concealment is not described (sufficient detail to allow a definite
judgement is required), N/A - if only 1 index test was evaluated
Could the selection of participants have introduced bias?
For non-comparative and within person-comparative studies
1. If answers to all of questions 1), 2), and 3) ’Yes’:
2. If answers to any 1 of questions 1), 2), or 3) ’No’:
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’:
For between-person comparative studies
1. If answers to all of questions 1), 2), 3), and 4) ’Yes’:
2. If answers to any 1 of questions 1), 2), 3), or 4) ’No’:
3. If answers to any 1 of questions 1), 2), 3), or 4) ’Unclear’:
For non-comparative and within person-comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
For between-person comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
PARTICIPANT SELECTION (1) - CONCERNS REGARDING APPLICABILITY
1) Are the included participants and chosen study setting gen-
eralisable to the patient population who will receive the test in
practice? (Test set)
• This item is not asking whether exclusion of certain
participant groups might bias the study’s results (as in Risk of
Bias above), but is asking whether the chosen study participants
and setting are appropriate to answer our review question.
Because we are looking to establish test accuracy in both primary
presentation and referred participants, a study could be
appropriate for 1 setting and not for the other, or it could be
unclear as to whether the study can appropriately answer either
question
• For each study assessed, please consider whether it is more
relevant for A) participants with a primary presentation of a skin
lesion or B) referred participants, and respond to the questions
in either A) or B) accordingly. If the study gives insufficient
details, please respond Unclear to both parts of the question
A) For studies that will contribute to the analysis of partici-
pants with a primary presentation of a skin lesion (i.e., test
naive)
Yes - if participants included in the study appear to be generally
representative of those who might present in a usual practice set-
ting
No - if study participants appear to be unrepresentative of usual
practice, e.g., in terms of severity of disease, demographic features,
presence of differential diagnosis or comorbidity, setting of the
study, and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
B) For studies that will contribute to the analysis of referred
participants (i.e., who have already undergone some form of
testing)
Yes - if study participants appear to be representative of those who
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might be referred for further investigation. If the study focuses
only on those with equivocal lesions, for example, we would sug-
gest that this is not representative of the wider referred population
No - if study participants appear to be unrepresentative of usual
practice, e.g., if a particularly high proportion of participants have
been self-referred or referred for cosmetic reasons. Other factors
to consider include severity of disease, demographic features, pres-
ence of differential diagnosis or comorbidity, setting of the study,
and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
2) Did the study avoid including participants with multiple le-
sions?
Yes - if the difference between the number of included lesions and
number of included participants is less than 5%
No - if the difference between the number of included lesions and
number of included participants is greater than 5%
Unclear - if it is not possible to assess
3) Was an adequate spectrum of cases used to train the algorithm?
(training set)
For melanoma studies:
Yes - if all PSLs, main types of melanoma all present (nodular,
SSM,Mis), main types of dysplasia present, and a range of benign
diagnoses included
For keratinocyte cancer studies:
Yes - if the main malignant diagnoses are included (BCC, cSCC)
, as well as main types of atypia/dysplasia and a range of benign
differential diagnoses (AK, SK, BD).
No - if study participants appear to be unrepresentative of usual
practice, for example with a specific focus on certain lesions
groups, e.g. melanoma and common nevus only
Unclear - insufficient details to determine generalisability of study
participants
N/A - algorithm trained in a previous study
Is there concern that the included participants do not match the
review question?
1. If the answer to question 1) and 2) and 3) ’Yes’:
2. If the answer to question 1) or 2) or 3) ’No’:
3. If the answer to question 1) or 2) or 3) ’Unclear’
1. Concern is low
2. Concern is high
3. Concern is unclear
INDEX TEST (2) - RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted without
knowledge of the results of the reference standard?
Yes - if index test described as interpreted without knowledge of
reference standard result or, for prospective studies, if index test is
always conducted and interpreted prior to the reference standard
No - if index test described as interpreted in knowledge of reference
standard result
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Unclear - if index test blinding is not described
2) Was the diagnostic threshold at which the test was considered
positive (i.e., melanoma present) prespecified?
Yes - if threshold was prespecified (i.e., prior to analysing study
results)
No - if threshold was not prespecified
Unclear - if not possible to tell whether or not diagnostic threshold
was prespecified
3)Was the CAD classification algorithm evaluated in an indepen-
dent patient population?
Yes - Test set only study (validated in previous study)OR validated
within-study in a test set using in a different group of participants
recruited from a different source (external validation) OR vali-
dated within-study in a test set comprising a randomised subset
of one larger participant population also used for model training
No - Algorithm developed and evaluated within the same study
(internal validation) where training and test sets use the same
population which is not divided randomly
Unclear - The relationship between training and tests sets is not
reported clearly
4) Was model overfitting accounted for? Yes - a shrinkage method was applied, e.g. bootstrapping for cal-
ibration in the large, calibration in the small, overoptimisation,
optimisation, use of a verify set to optimise stopping.
No - study clearly reports that no method was applied
Unclear - overfitting not discussed or corrected
N/A - study does not contain a derivation element
Could the conduct or interpretation of the index test have intro-
duced bias?
1. If answers to questions 1) and 2) and 3) and 4) ’Yes’ or ’N/
A’:
2. If answers to any of questions 1) or 2) or 3) or 4) ’No’:
3. If answers to any of questions 1) or 2) or 3) or 4) ’Unclear’:
1. Risk is low
2. Risk is high
3. Risk is unclear
INDEX TEST (2) - CONCERN ABOUT APPLICABILITY
1) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold is
described in sufficient detail. This item applies equally to studies
using pattern recognition and those using checklists or algorithms
to aid test interpretation
Yes - If the criteria for diagnosis of melanoma were reported in
sufficient detail to allow replication
No - if the criteria for diagnosis of melanoma were not reported
in sufficient detail to allow replication
Unclear - If some but not sufficient information on criteria for
diagnosis to allow replication were provided
2) Was the test interpretation carried out by an experienced ex-
aminer?
Yes - if the test was interpreted by 1 or more speciality-accredited
dermatologists, or by examiners of any clinical background with
special interest in dermatology and with any formal training in
the use of the test
No - if the test was not interpreted by an experienced examiner
(see above)
Unclear - if the experience of the examiner(s) was not reported in
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sufficient detail to judge or if examiners were described as ’Expert’
with no further detail given
N/A - if system-based diagnosis, i.e., no observer interpretation
3) Was the diagnostic threshold to determine presence or absence
of disease established in a previously published study?
E.g., previously evaluated/established
• algorithm/checklist used
• lesion characteristics indicative of melanoma used
• objective (usually numerical) threshold used
Yes - if a previously evaluated/established tool to aid diagnosis
of melanoma was used or if the diagnostic threshold used was
established in a previously published study
No - if an unfamiliar/new tool to aid diagnosis of melanoma
was used, if no particular algorithm was used, or if the objective
threshold reportedwas chosenbased on results in the current study
Unclear - if insufficient information was reported
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
1. If answers to questions 1), 2), and 3) ’Yes’:
2. If answers to questions 1), 2), or 3) ’No’:
3. If answers to questions 1), 2), or 3) ’Unclear’:
1. Concern is low
2. Concern is high
3. Concern is unclear
REFERENCE STANDARD (3) - RISK OF BIAS
1) Is the reference standard likely to correctly classify the target
condition?
A) Disease-positive - 1 or more of the following:
• histological confirmation of melanoma following biopsy or
lesion excision
• clinical follow-up of benign-appearing lesions for at least 3
months following the application of the index test, leading to a
histological diagnosis of melanoma
B) Disease-negative - 1 or more of the following:
• histological confirmation of absence of melanoma
following biopsy or lesion excision in at least 80% of disease-
negative participants
• clinical follow-up of benign-appearing lesions for a
minimum of 3 months following the index test in up to 20% of
disease-negative participants
A) Disease-positive
Yes - if all participants with a final diagnosis of melanoma under-
went 1 of the listed reference standards
No - If a final diagnosis of melanoma for any participant was
reached without histopathology
Unclear - if the method of final diagnosis was not reported for
any participant with a final diagnosis of melanoma or if the length
of clinical follow-up used was not clear or if a clinical follow-up
reference standard was reported in combination with a partici-
pant-based analysis and it was not possible to determine whether
the detection of a malignant lesion during follow-up is the same
lesion that originally tested negative on the index test
B) Disease-negative
Yes - If at least 80% of benign diagnoses were reached by histology
and up to 20% were reached by clinical follow-up for a minimum
of 3 months following the index test
No - ifmore than20%of benigndiagnoseswere reachedby clinical
follow-up for a minimum of 3 months following the index test or
if clinical follow-up period was less than 3 months
Unclear - if the method of final diagnosis was not reported for
any participant with benign or non-melanoma diagnosis
2) Were the reference standard results interpreted without knowl-
edge of the results of the index test?
Please score this item for all studies even though histopathology
interpretation is usually conducted with knowledge of the clinical
diagnosis (from visual inspection or dermoscopy or both).We will
deal with this by not including the response to this item in the
’Risk of bias’ assessment for these tests. For reviews of all other
Yes - if the reference standard diagnosis was reached blinded to
the index test result
No - if the reference standard diagnosis was reached with knowl-
edge of the index test result
Unclear - if blinded reference test interpretation was not clearly
reported
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tests, this item will be retained
Could the reference standard, its conduct, or its interpretation
have introduced bias?
1. If answers to questions 1) and 2) ’Yes’:
2. If answers to questions 1) or 2) ’No’:
3. If answers to questions 1) or 2) ’Unclear’:
1. Risk is low
2. Risk is high
3. Risk is unclear
REFERENCE STANDARD (3) - CONCERN ABOUT APPLICABILITY
1) Expert opinion (with no histological confirmation) was not
used as a reference standard
’Expert opinion’ means diagnosis based on the standard clinical
examination, with no histology or lesion follow-up
Yes - if expert opinion was not used as a reference standard for
any participant
No - if expert opinion was used as a reference standard for any
participant
Unclear - if not clearly reported
2) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes - if histology interpretation was reported to be carried out by
an experienced histopathologist or dermatopathologist
No - if histology interpretation was reported to be carried out by
a less experienced histopathologist
Unclear - if the experience/qualifications of the pathologist were
not reported
Is there concern that the target condition as defined by the refer-
ence standard does not match the review question?
1. If answers to all questions 1) and 2), ’Yes’:
2. If answers to any 1 of questions 1) or 2) ’No’:
3. If answers to any 1 of questions 1) or 2) ’Unclear’:
1. Concern is low
2. Concern is high
3. Concern is unclear
FLOW AND TIMING (4): RISK OF BIAS
1) Was there an appropriate interval between index test and ref-
erence standard?
A) For histopathological reference standard, was the interval be-
tween index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of border-
line/benign-appearing lesions, was there at least 3 months’ follow-
up following application of index test(s)?
A)
Yes - if study reports ≤ 1 month between index and reference
standard
No - if study reports > 1 month between index and reference
standard
Unclear - if study does not report interval between index and
reference standard
B)
Yes - if study reports ≥ 3 months’ follow-up
No - if study reports < 3 months’ follow-up
Unclear - if study does not report the length of clinical follow-up
2) Did all participants receive the same reference standard? Yes - if all participants underwent the same reference standard
No - if more than 1 reference standard was used
Unclear - if not clearly reported
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3) Were all participants included in the analysis? Yes - if all participants were included in the analysis
No - if some participants were excluded from the analysis
Unclear- if not clearly reported
Could the participant flow have introduced bias?
1. If answers to questions 1), 2), and 3) ’Yes’:
2. If answers to any 1 of questions 1), 2), or 3) ’No’:
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’:
1. Risk is low
2. Risk is high
3. Risk is unclear
BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma
Appendix 7. Forest plots for the direct comparison of CAD systems vs. image-based dermoscopy
Figure 22; Figure 23
Figure 22. Forest plot of direct comparisons between image-based dermoscopy diagnosis versus
multispectral imaging CAD systems (MSI-CAD) for the detection of invasive melanoma or atypical
intraepidermal melanocytic variants (invasive melanoma or atypical intraepidermal melanocytic variants)
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Figure 23. Forest plot of direct comparisons between image-based dermoscopy diagnosis versus digital
dermoscopy CAD systems (Derm-CAD) for the detection of invasive melanoma or atypical intraepidermal
melanocytic variants (invasive melanoma or atypical intraepidermal melanocytic variants)
Appendix 8. Results of sensitivity analysis for CAD systems (excludes diagnostic aid studies)
Index test Studies Cases/Number of participants Summary sensitivity (95%CI)% Summary specificity (95%CI)%
Primary target condition: Invasive melanoma and atypical intraepidermal melanocytic variants
MSI-CAD 7 281/2389 93.7 (83.9 to 97.7) 41.7 (22.0 to 64.6)
Derm-CAD 19 955/8403 88.5 (81.3 to 93.1) 71.3 (60.0 to 80.4)
DB-MIPS 4 427/1479 96.4 (84.9 to 99.2) 85.5 (75.7 to 91.7)
MelaFind 4 191/1786 97.9 (94.6 to 99.2) 24.8 (8.82 to 52.9)
Secondary target condition: Invasive melanoma alone
MSI-CAD 4 80/256 83.1 (26.5 to 98.5) 66.9 (41.6 to 85.1)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We could not conduct reviews on the accuracy of gene expression testing and volatile organic compounds as planned, due to an absence
of relevant studies.
For this review, we amended the inclusion criteria to remove inclusion of participants “at high risk of developing melanoma, including
those with a family history or previous history of melanoma skin cancer, atypical or dysplastic naevus syndrome, or genetic cancer
syndromes” and “at high risk of developing BCC or cSCC, including those with a family history or previous history of skin cancer or
genetic cancer syndromes, such as basal cell naevus (Gorlin) syndrome”, as these are not target populations for CAD use.
We have changed one of the primary objectives and primary target conditions from diagnosing “cutaneous invasive melanoma alone”,
to diagnosing “cutaneous invasive melanoma and atypical intraepidermal melanocytic variants”, as the latter is more clinically relevant
to the practising clinician. The diagnosis of the target condition of invasive melanoma alone has instead been included as a secondary
objective.
We amended the text to clarify that studies available only as conference abstracts would be excluded from the review unless full
papers could be identified; studies available only as conference abstracts do not allow a comprehensive assessment of study methods or
methodological quality.
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We excluded rather than included studies using cross-validation, such as ’leave-one-out’ cross-validation, as these methods are not
sufficiently robust and are likely to produce unrealistic estimates of test accuracy. To improve clarity of methods, this text from the
protocol: “We will include studies developing new algorithms or methods of diagnosis (i.e., derivation studies) if they use a separate
independent ’test set’ of participants or images to evaluate the new approach. We will also include studies using other forms of cross
validation, such as ‘leave-one-out’ cross-validation (Efron 1983). We will note for future reference (but not extract) any data on the
accuracy of lesion characteristics individually, e.g., the presence or absence of a pigment network or detection of asymmetry” has been
replaced with:
“Studies developing new algorithms or methods of diagnosis (i.e. derivation studies) wereincluded if they evaluated the new approach
using a separate ’test set’ of participants or images.
Studies were excluded if they:
• evaluated a new statistical model or algorithm in the same participants or images as those used to train the model (i.e. absence of
an independent test set)
• used cross-validation approaches such as ’leave-one-out’ cross-validation (Efron 1983)”
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g. British Association
of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European Academy of Dermatology and
Venereology Meeting, Society for Melanoma Research Congress, World Congress of Dermatology, European Association of Dermato
Oncology); however, due to volume of evidence retrieved from database searches and time restrictions, we were unable to do this.
For quality assessment, we further tailored the QUADAS-2 tool according to the review topic.
Due to lack of data, we could not perform the following analyses: restriction to analysis of per-patient data, or comparison of accuracy
using diagnosis of stored images (image-based) with in-person diagnosis.
Upon closer review of the topic, but before examination of study data, we planned four secondary analyses in addition to those listed in
the protocol: estimation of diagnostic accuracy for individual CAD systems; comparison of the accuracy of CAD to dermoscopy where
both tests have been evaluated in the same studies (direct comparisons); the comparison of CAD-based diagnosis to CAD-assisted
diagnosis (CAD results used by clinicians as a diagnostic aid); and where CAD systems are used as a diagnostic aid, to determine the
effect of observer experience on diagnostic accuracy.
We planned three heterogeneity investigations relating to population characteristics in addition to those listed in the protocol (Patient
population: primary/secondary/specialist unit; Lesion type: any pigmented/melanocytic; Inclusion of multiple lesions per participant),
but we could not perform these investigations due to insufficient data.
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